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Dedifferentiated liposarcoma (DDLPS) is an aggressive malignancy characterized by 
a high rate of recurrence and dismal patient outcome. Minimal improvement in patient survival 
has been made in the last several decades, highlighting the crucial need for improved 
therapeutic strategies. A better understanding of the molecular deregulations underlying 
DDLPS would facilitate the discovery of improved therapeutic approaches. MDM2 is a well 
characterized oncoprotein and the most known negative regulator of p53. MDM2 amplification 
is considered the “hallmark” of DDLPS. Additionally, these tumors are known to harbor wild-
type p53.  We sought to take advantage of this knowledge and evaluate the role of SAR405838, 
a novel small molecule inhibitor of MDM2, as a potential anti-DDLPS therapeutic strategy. 
To facilitate these studies, we first developed a large set of DDLPS experimental tools, 
specifically human cell lines and xenograft mouse models. These cell lines were further 
characterized, confirming the presence of MDM2 amplification and lack of p53 mutations. 
Other liposarcoma cell lines harboring p53 mutations, but no MDM2 amplification, were used 
as controls. Initial experiments demonstrated that SAR405838 was highly active in DDLPS 
 vii 
cells but not in LPS cells that exhibit mutated p53. Cell culture based assays further 
demonstrated that SAR405838 selectively targeted MDM2 and led to p53 activation. In 
DDLPS cells, SAR405838 resulted in exemplary anti-proliferation, with EC50 values in the 
low nanomolar range (0.13 to 0.49 nM), as well as successfully induced cell cycle (G1 and G2 
phase) arrest and apoptosis in a dose-dependent manner. The anti-DDLPS effects of 
SAR405838 were significantly more pronounced when compared to those of the older 
generation MDM2 inhibitors Nutlin-3a and MI-219.  Most importantly, these cell based 
experiments were replicated in vivo where oral administration of SAR405838 resulted in potent 
anti-DDLPS effects in a dose-dependent manner (50-200 mg/kg).  
Finally, to determine the mechanism of action of MDM2 inhibition in DDLPS cells, 
gene expression array experiments on SAR405838-treated cells and xenografts were 
conducted. We identified multiple pathways and genes that can further enhance our 
understanding of the MDM2-p53 pathway and can be studied as biomarkers of therapeutic 
response.  Taken together, this study highlights the ability of SAR405838 to selectively inhibit 
a biologically relevant target, MDM2, and induce potent, anti-DDLPS effects in a pre-clinical 
investigation supporting further evaluation of this compound in the clinical context. 
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 CHAPTER 1. INTRODUCTION AND BACKGROUND 
 
SECTION 1. DEDIFFERENTIATED LIPOSARCOMA: AN AGGRESSIVE HISTOLOGICAL SUBTYPE 
OF LIPOSARCOMA 
Liposarcoma classification  
Soft tissue sarcomas (STS) are a heterogeneous group of malignancies consisting of 
over 50 different histological subgroups all of which show mesenchymal differentiation1. 
Liposarcoma (LPS), as the name suggests, is a malignancy of adipocyte-derived cells1. The 
World Health Organization (WHO) classifies liposarcomas into three distinct subtypes based 
on their unique characteristics and molecular aberrations: (1) Well-
differentiated/dedifferentiated liposarcoma, (2) Myxoid/round cell liposarcoma, and (3) 
Pleomorphic liposarcoma1. Well-differentiated/dedifferentiated liposarcoma is the most 
prevalent histological subtype, accounting for ~65% of all LPS; myxoid/round cell LPS 
account for ~30%; and pleomorphic LPS accounts for <5% of all liposarcomas1,2.  
Pathological and molecular differences in liposarcoma subtypes 
Well-differentiated/dedifferentiated liposarcoma 
Although grouped together, Well-differentiated (WDLPS) and dedifferentiated 
(DDLPS) have very different tumorigenic phenotypes. WDLPS, sometimes referred as 
atypical lipomatous tumor, is classified as low grade tumors due to its local aggressiveness, 
but lack of metastatic potential1. This lesion is pathologically characterized by aberrantly 
enlarged and hyperchromatic nuclei and is comprised of malignant adipocytes and spindle 
cells, the latter thought to show fibroblastic/myofibroblastic differentiation1,2.  
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Originally described by Evans in 1979, DDLPS is a biphasic tumor consisting of high-
grade cellular and non-lipogenic areas with prominent mitoses juxtaposed to a usually more 
adipocyte-rich WDLPS portion3. Although it is a malignant adipocytic neoplasm, the 
adipocytic differentiation of the high grade component is no longer recognizably adipocytic4. 
On gross examination, these tumors show solid, non-lipomatous dedifferentiated areas sharply 
demarcated from the often multi-nodular and yellow mass that constitutes the well 
differentiated portion of the tumor4,5.   
Together, the WD/DDLPS subgroup share a unique and defining molecular aberration, 
namely the presence of supernumerary circular ring and giant rod chromosomes that harbor 
amplification of the 12q13~15 chromosomal region6–8 (Figure 1.1). There are hundreds of 
genes located in this chromosomal region whose amplifications can be punctuated and/or 
discontinuous, and the copy number increase can extend over 100-fold9–11. Unlike other genes 
in this interval that are variably amplified from case to case, amplification of the murine 
double minute 2 (MDM2) gene is seen in virtually 100% of cases and is considered a 
molecular “hallmark” of this subgroup6–8. Further discussion of these genetic aberrations as 
well as other molecular derangements will be discussed later in this introduction. 
Nevertheless, as our understanding of the molecular underpinnings of DDLPS have advanced, 
WDLPS and DDLPS identifiably possess unmistakably different characteristics. It remains 
unclear if WDLPS and DDLPS represent a tumorigenic continuum that accumulates 
additional aberrations over time or if these diseases represent two separate and distinct lesions 
that arise from related yet distinct adipogenic cells of origin whilst sharing common molecular 
aberrations, such as the genetic amplification of the 12q13~15 chromosomal region8,10–13.  
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Figure 1.1 WDLPS and DDLPS share a common genetic aberration:  12q13~15 
amplification. The shared molecular hallmark of WDLPS and DDLPS is the presence of one 
or more supernumerary circular ring and/or giant rod chromosomes containing highly 
amplified DNA sequences localized to the 12q13~15 region. Fluorescence in situ 
hybridization (FISH) shows the amplified copes of this region (red), as well as the 12q 
centromeric probe (green). 
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Myxoid/Round cell liposarcoma 
The second most prevalent subtype of LPS, myxoid/round cell (MLPS/RCLPS), is 
characterized by distinct chicken-wire vasculature, a sparse cellular component consisting of 
spindle or ovoid cells, mature adipocytes, and immature signet ring lipoblasts set in an 
abundant myxoid stroma1,14. The molecular hallmark of  MLPS/RCLPS is the recurrent 
translocation of chromosomes 12 and 16 t(12;16)(q13;p11) that results in the FUS-CHOP 
gene fusion present in over 95% of cases1,2,14. Alternatively, translocation in 
(t12;22)(q13;q12) results in an EWS-CHOP fusion gene14. Both scenarios are thought to 
interfere with adipocytic differentiation14,15. 
Pleomorphic liposarcoma 
Lastly, pleomorphic liposarcoma (PLS) is the rarest subtype of LPS1.  
Morphologically, PLS is a high grade neoplasm that contains varying numbers of multi-
vacuolated lipoblasts and sometimes multi-nucleated giant cells admixed into a high grade 
spindle cell neoplasm1,16. PLS is molecularly displays a complex karyotype characterized by 
aneuploidy and complex chromosomal rearrangements1. The most common genetic aberration 
is deletion of the 13q14.2~14.3 chromosomal region that occurs in over 60% of PLS; however, 
due to the rarity of the disease, molecular studies are limited2. Of note, TP53 mutations have 
been observed in PLS, which rarely occurs in the other two LPS histological subtypes.  
Inactivating mutations in NF1 have also been observed17. 
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TABLE 1.1 IMPORTANT DIFFERENCES ASSOCIATED WITH LIPOSARCOMA SUBTYPES. 
Histology Cytogenetic 
aberrations 
Molecular 
genetics 
Histological 
features 
Well-
differentiated 
LPS 
Ring chromosomes 
and giant markers 
(12q13~15) 
Amplification of 
MDM2, CDK4, 
HMGA2 
Adipocytes with 
aberrant nuclei 
Dedifferentiated 
LPS 
Ring chromosomes 
and giant markers 
(12q13~15) 
Amplification of 
MDM2, CDK4, 
HMGA2 
Highly cellular area 
juxtaposed to a WD 
portion 
Myxoid/Round 
Cell LPS 
Translocation 
(t12;16)(q13;p11) 
(t12;22)(q13;q22) 
FUS-CHOP/DDIT3 
EWS-
CHOP/DDITS 
fusion protein 
Extracellular myxoid 
material; mature 
adipocytes and 
immature lypoblasts, 
round cells  
Pleomorphic 
LPS Complex karyotype 
TP53 mutations in 
60% 
Highly cellular; 
pleopmorphic 
lipoblasts 
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Dedifferentiated liposarcoma 
Although grouped together due to their shared genetic abnormalities, WDLPS and 
DDLPS pursue two very different clinical courses. WDLPS represents the largest subgroup 
of LPS, accounting for nearly 40-45%1. WDLPS has a peak incidence in the 6th decade of life 
and affects males and females equally1. Clinically, WDLPS presents as a deep-seated, painless 
mass often found in the retroperitoneum; however, it can be found in deep soft tissue of the 
thigh, paratesticular area, as well as the mediastinum1. While WDLPS does not metastasize, 
it has a high recurrence rate (up to 90%) following surgical resection and repeated recurrences 
can lead to extreme morbidity and even death. The location of these tumors is an important 
prognostic factor. Tumors found in very deep sites are more capable of recurrence ( >40% in 
the retroperitoneum compared to <2% in the extremities) and, due to uncontrollable local 
effects, can cause serious problems for patients1. This location is also an important factor 
determining mortality; essentially no extremity WDLPS leads to death, whereas 80% of 
retroperitoneal WDLPS leads to disease specific mortality within 10-20 years of initial 
diagnosis. Overall, the five-year disease-specific survival rate for WDLPS is 85%. 
Nevertheless, the most important prognostic characteristic of WDLPS is the risk of 
dedifferentiation upon recurrence (20%)2. The term “dedifferentiation” was first described in 
chondrosarcoma in 1991 to explain a phenomenon in which a relatively well-differentiated 
lesion accumulates a clearly demarcated component of high-grade tumor cells no longer 
showing the same differentiation as the tumor in which it arises18,19. This dedifferentiation 
results in an overall more aggressive phenotype (15% incidence of distant metastasis) and 
poor patient outcome; therefore, given the severity of this tumor, DDLPS is the histological 
LPS subtype that will be the focus of this study. 
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Incidence  
Soft tissue sarcomas are rare malignancies that constitute approximately 1% of all 
adult cancers (10-12,000 new cases per year in the US)1,20; LPS is the most common adult 
histological subtype of STS, accounting for nearly 40%1 of all STS cases. The specific 
incidence of DDLPS is approximately 1/330,000 persons/year21. There are no gender 
predilections, nor are there currently any known risk factors for the development of DDLPS22. 
This disease typically manifests during the sixth to seventh decade of life22. DDLPS most 
frequently occurs in the retroperitoneum; however, it can also occur in the deep soft tissue of 
the extremities, trunk, mediastinum, head and neck region and spermatic cord22.  
Symptoms and diagnosis 
Patients with DDLPS found in the retroperitoneum can often present with very large 
masses (>30cm) because the retroperitoneal space is able to accommodate much larger 
volumes of a symptomatic disease than other areas of the body23. Symptoms are often 
associated with pressure caused by the lesion on the surrounding organs; e.g. abdominal pain, 
and constipation 24.  
The diagnosis of DDLPS is usually confirmed by several techniques. Upon physical 
examination, a firm palpable mass is often detectable. Computed topography (CT) imaging or 
magnetic resonance imaging (MRI) scanning is critical for staging purposes and used to assess 
the size, involved organs and vasculature of the lesion25,26.  
The next step in diagnostic work up consists of biopsy27. Usually, multiple core needle 
biopsies are performed; however, for small (<5 cm) superficial specimens, an excisional 
biopsy may be possible25. Pathologists consider various cytogenetic correlations associated 
with DDLPS specifically along with histological considerations to diagnose the tumor16. The 
genetic amplification of MDM2 has proven to be especially helpful as a diagnostic finding6,28.  
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Therapeutic treatment options for dedifferentiated liposarcoma 
Despite advances in the field, few new treatment options have emerged. Treatment of 
DDLPS is often determined on the basis of certain factors such as age of patient, size and 
location of the lesion, and involvement of surrounding organs22. Consequently, prospective 
multidisciplinary treatment planning is crucial to provide the best possible outcomes.  
Surgical resection 
The current standard of care for DDLPS is surgical removal of the tumor in its 
entirety29. However, surgery can often be difficult due to tumor location and ability of DDLPS 
to invade into surrounding organs. Patients often must undergo multiple surgeries due to tumor 
local recurrence, which can lead to significant post-surgical morbidity.  
Conventional chemotherapy 
Even following complete surgical resection, more than 80% of DDLPS patients will 
develop unresectable recurrences30,31. For patients with unresectable tumors, chemotherapy is 
frequently used in an attempt to shrink the tumor to a resectable size. The most frequently 
used cytotoxic chemotherapeutic agents are doxorubicin (DOX) and ifosfamide, which is 
often used in combination to DOX32,33.  
Doxorubicin-based chemotherapy has been the most commonly used treatment for 
adult STS since the 1970’s and is the standard first-line agent for treatment34. DOX acts by 
inhibiting topoisomerase II, resulting in DNA double-strand breaks35–37. Cells then activate 
the DNA damage response signaling cascade to guide recruitment of the repair machinery to 
address these breaks38. If this fails, the DNA repair program initiates apoptosis. DOX is 
usually administered intravenously for 96 hours once every three weeks; the threshold dose 
for optimal activity can be as high as 120mg/m2 per cycle in selected patients39. 
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A meta-analysis of 18 randomized prospective clinical trials of 1953 patients was 
performed to assess the impact of adjuvant doxorubicin-based chemotherapy. In this study it 
was observed that the odds ratio for local recurrence as well as distant and overall recurrence 
(0.73 and 0.67, respectively) statistically favored chemotherapy; however, this was not 
associated with a significant improvement in survival40.  
In the early 1990s, ifosfamide-based treatment was deployed as a new and possibly 
improved treatment for progressive disease32,41. Ifosfamide is a nitrogen mustard alkylating 
agent that is delivered intravenously; the  threshold for optimal activity 6 g/m2 per cycle42,43; 
however, in selected patients doses as high as 10-14 g/m2/cycle may be feasible.  
In one phase III clinical trial, Lorigan et al. (2007) compared the effects of ifosfamide 
to doxorubicin as a single agent regarding toxicity, response rate, progression-free and overall 
survival.  They concluded that while both drugs exhibited similar anti-tumor effects, single-
agent DOX had a better therapeutic impact than ifosfamide alone due to the comparatively 
increased toxicity in patients receiving ifosfamide44. 
While these chemotherapeutic agents have been considered the front-line treatment 
option when surgery is not an option, DDLPS has proven to be resistant to such conventional 
chemotherapy22. Furthermore, neither single-agent nor combination therapies have proven 
survival benefits in clinical trials45,46.  
Radiation therapy 
Use radiation therapy (RT) has been shown to have an effect on local control but no 
significant effect on the overall patient survival47,48. For patients with deep seated lesions, RT 
in conjunction with surgery appears to improve local control25. 
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RT has been used in combination with chemotherapeutic agents, with minimal 
improvement in recurrence-free and overall survival. In an 83 patient trial (27/83 patients 
diagnosed with DDLPS), Gronchi et al. (2014) administered a combination of ifosfamide 
(three cycles; 14 g/m2) and radiotherapy (total dose up to 50.4Gy) prior to surgery as part of 
a phase I-II study for localized liposarcoma. Most patients were unable to complete the full 
course of pre-operative RT. Gronchi showed that in patients diagnosed with DDLPS, 33% 
had locoregional recurrence, 25.9% had distant recurrence and only one patient (3.7%) had 
both local and distant recurrence. Compared to other soft tissue sarcomas in this study (well-
differentiated liposarcoma, leiomysarcoma, and “others”), DDLPS tumors responded the 
worst overall, with an overall progression-free survival in only 10/83 patients49. Currently, 
there is an on-going phase III clinical trial to study the effects of pre-operative RT followed 
by surgery (clinical trials identifier: NCT01344018) versus surgery alone, comparing 
recurrence-free, metastasis-free, and overall survival of these patient groups.  
Novel systemic therapies  
Novel systemic therapies targeting the unique genetic aberrations specific to DDLPS 
have emerged in the past decade based on disease biology, including genetic and molecular 
aberrations; thereby, increasing the specificity and efficacy of a drug. A list of currently on-
going clinical trials can be found in Table 1.2.  
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TABLE 1.2 OVERVIEW OF CURRENT CLINICAL TRIALS FOR NOVEL SYSTEMIC THERAPIES IN 
LIPOSARCOMA. 
Therapy Author (year) Mechanism of 
action Cohort Study 
Cabazitaxel + 
Prolonged 
infusional 
ifosfamide 
Hayward (2013 - 
NCT01913652) 
interferes with 
microtubules DDLPS Phase II 
Eribulin Schöffski (2011) Anti-microtubule 
agent DDLPS Phase II 
Flavopiridol Luke (2012) pan-CDK inhibitor WDLPS/DDLPS Phase I 
PD0332991 Dickson (2013) CDK4 and CDK6 
inhibitor WDLPS/DDLPS Phase II 
Pazopanib Sleijfer (2009) Tyrosine kinase 
receptor inhibitor 
All histologic 
subtypes of LPS Phase II 
Sorafenib Von Mehren 
(2012) 
Tyrosine kinase 
receptor inhibitor 
All histologic 
subtypes of LPS Phase II 
Sunitinib Mahmood (2011) Tyrosine kinase 
receptor inhibitor 
All histologic 
subtypes of LPS Phase II 
Troglitazone,  Debrock (2003),  PPAR-γ agonist All histologic  Phase I 
 
Inhibition of MDM2  
Targeting a specific molecular aberration in a certain tumor type will hopefully better 
enable physicians to treat patients with drugs that will have improved effects on outcome. The 
amplification of MDM2 in DDLPS has proven to be reliable in clinical diagnosis8,28,50,51. As 
will be explained below, MDM2 as a negative regulator of the tumor protein p53 (p53) tumor 
suppressor gene implies that targeting of MDM2 may be a potential approach for DDLPS 
therapy. Recently, Ray-Coquard et al. (2012) has reported an initial WDLPS/DDLPS patient 
directed clinical trial using the MDM2 inhibitor RG711252. In brief, 20 untreated patients were 
enrolled in a phase 1 proof-of-mechanism study of RG7112. Resected tumors demonstrated 
that RG7112 restored p53 activity and elicited anti-tumorigenic properties52. Clinical trials 
specific to the molecular drivers of DDLPS pave the way for future novel therapeutic options; 
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hence a better understanding of molecular driving forces promoting tumorigenesis is critical 
to develop more effective therapeutic strategies.  
Outcome 
Unfortunately, DDLPS often results in a dismal fate for afflicted patients. DDLPS may 
arise de novo (approximately 90% of cases) or in areas of recurrence from the WD precursor 
lesions (~10% of cases; i.e., secondary DDLPS)23. Various predictors of outcome have been 
investigated; it has been observed that in patients with primary lesions, the median 
progression-free survival and overall survival are 21.1 and 59 months, respectively. However, 
this high recurrence rate is one of the most notorious characteristics of the disease which has 
the propensity to recur locally at rates as high as 90%, most frequently in the retroperitoneum 
(92%) or peritoneal cavity (26%)53. From the presentation of the initial primary lesion, the 
local- and distant recurrence-free survival is approximately 21.5 and 45.8 months53.  
Furthermore, patients diagnosed with primary DDLPS may have as many as three or 
more episodes of local recurrences before metastatic dissemination occurs23. Unlike its 
WDLPS counterpart, DDLPS has the potential to metastasize, observed in >20% of patients, 
typically to the lungs23. In patients with advanced disease, the average elapsed time between 
primary diagnosis and metastasis is 25 months, with a median survival time of 11.5 months 
for metastatic patients. Even worse is the grim five year disease free survival rate of 5.2% for 
advanced disease23.  
The high rate of recurrence and disease progression, coupled with unacceptably low 
survival rates regardless of treatment, renders DDLPS a deadly disease.  
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SECTION 2. MOLECULAR DRIVING FORCES OF DEDIFFERENTIATED LIPOSARCOMAGENESIS 
Genomic aberrations associated with dedifferentiated liposarcoma 
Identifying the molecular underpinnings of DDLPS is a critical step in understanding 
the biology of DDLPS. Advancements with high-throughput techniques in tissue based studies 
have propelled our understandings of the molecular deregulations in DDLPS54–56.  These 
recent developments in genomic studies have provided critical information for genetic 
aberrations driving tumorigenesis, histological characterization, as well as identify new 
biomarkers for targeted drug therapy and treatment response in patients. 
More than 90% of DDLPS tumors contain supernumery ring chromosomes and/or 
giant marker chromosomes derived from the 12q13~15 chromosome segment8,10–13,57. Within 
this amplicon lies the oncogene MDM258. However, because this is a discontinuous 
amplification with several hundred genes, it has been an ongoing challenge to distinguish 
which genes are vital to disease biology59. Two genes, for example, high mobility group AT-
hook 2 (HMGA2), and fibroblast growth factor receptor substrate 2 (FRS2) which are 
amplified and highly expressed are hypothesized as essential regulators for the initiation and 
progression of liposarcomagenesis9,60. Furthermore, overexpression of HMGA2 and FRS2 
have demonstrated important roles in cellular transformation and tumor establishment61. 
HMGA2 has also demonstrated a direct adipogenic neoplastic involvement when spontaneous 
lipomas developed in mice expressing C-terminal truncated HMGA262.  Another gene and 
more popularly studied, cyclin dependent kinase 4 (CDK4) amplification has been observed 
as frequently as 90% in DDLPS and is often used as a diagnostic marker alongside of MDM29–
11,13. Functionally, CDK4 is an important regulator of cell cycle progression in which it 
complexes with cyclin D to enable the G1-S transition by phosphorylating the retinoblastoma 
protein (Rb) and resulting in the activation of E2F target genes63–65. CDK4 is also a target for 
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therapy in an ongoing phase II clinical trial (ClinicalTrials.gov identifier: NCT01209598). 
Genes located in the 12q13~15 chromosomal loci can also serve to differentiate between LPS 
subtypes. For example, differentially expressed genes that are involved in cell cycle control 
(G1-S and G2-M transition) and growth factor receptors have been identified to molecularly 
differentiate between DDLPS and the more aggressive, higher grade PLS subtypes54. These 
examples demonstrate the importance for understanding the role of the genes located in this 
chromosomal amplification.   
The progression from a WDLPS to the highly cellular DDLPS state acquires multiple 
genetic and epigenetic events that influence disease progression. In one recent study, Crago 
et al. (2012) identified genomic aberrations between 55 WDLPS and 52 DDLPS samples in 
an attempt to outline the molecular pathogenesis of liposarcoma. The most commonly 
observed alteration in disease progression was the loss of 11q23~24 chromosomal region in 
which multiple tumor suppressor genes reside. On the other hand, the loss of 19q13 was 
associated with tumor establishment, but did not correlate with tumor progression. To a lesser 
extent, other copy number variations were observed during progression including losses at 
3p14~21, 3q29, 9p22~24, 10p15, 17q21 and gains at 17p11 and 20q119.  Together, these 
amplified and lost regions result in the presumed expression of oncogenes and/or loss of tumor 
suppressor genes enhancing the malignant DDLPS phenotype. 
Additionally, it has been observed that chromosomal aberrations associated with 
prognosis and survival correlated with amplification of 13q21 and loss of 19q139,66. Gain of 
13q21 significantly correlated with poor overall survival (average of 78 months for patients 
without gain versus 35 months with 13q gain)66. Loss of the chromosome segment 19q13 
resulted in a significantly shorter disease specific survival (27 months compared to >90 
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months for diploid retaining specimens) as well as negatively correlated to local recurrence 
rate9. 
Recently, the amplification of chromosome 1p in DDLPS has been observed in 
multiple groups9,67. The JUN gene, located at 1p32~31 encodes the oncoprotein c-Jun. Jun is 
required for progression through the G1 phase of the cell cycle, as well as protects the cells 
from certain induced apoptosis68. Importantly, overexpression of c-Jun results in decreased 
levels of p53.   
While these studies have unveiled new findings, deeper exploration of the associated 
genes within the affected amplicons must be investigated. Indeed, aberrations in DDLPS are 
highly prevalent; however, few are currently being targeted as a novel therapeutic modality.  
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TABLE 1.3 A SUMMARY OF GENOMIC ABERRATIONS AND THEIR FUNCTIONAL CONSEQUENCES IN DDLPS.  
c Imbalance Functional Consequence First Author 
1p21~32 Amplification JUN 
Transcription factor, blocks adipocytic differentiation and increases 
aggressiveness  
(Mariani, 2007)69 
1q21~23 Amplification Gains in this region have been observed in tumor establishment (Szymanska.,1997)70 
6q23~24 Amplification ASK1 Kinase, mediates differentiation and apoptosis signal transduction. (Chibon, 2004)71 
11q23~24 Loss 
This region contains key tumor suppressor genes that are lost in tumor progression  
from WDLPS to DDLPS (ZBTB16,PP2R1B, E124) 
(Crago, 2012)9 
12q13~15 
Amplification 
MDM2 
E3 ubiquitin ligase, targets the tumor suppressor protein p53 for 
proteasomal degradation 
(Momand, 1992)72 
CDK4 
Regulates cell cycle at the G1/S phase, can result in chromosomal instability 
proliferation 
(Segura-Sánchez, 2006)10 
HMGA2 
Transcription factor that regulates cell cycle (G2/M) and role in 
adipogenesis and differentiation 
(Arlotta, 2000)62 
FRS2 
Role in FGR signaling; increases tumor formation, angiogenesis and tumor 
progression 
(Zhang, 2013)61 
Loss HRK 
Activator of apoptosis; interacts with pro-survival proteins BCL2 and 
BCLXL 
(Bjorn Fritz, 2002)73 
13q21 Amplification 
Gains are associated with poor prognosis and worsened overall survival in DDLPS 
patients 
(Schmidt, 2005)66 
19q13 Loss CEBPa 
 lost in tumor progression, regulates cell cycle at G2/M and involved in 
differentiation 
(Y. V Wu et al., 2012)74 
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Other deregulations: receptor tyrosine kinases 
A broad understanding of various deregulated pathways is crucial for understanding 
the pathobiology of DDLPS. With this in mind, we have strived to investigate common 
abnormalities observed in other cancers that are also specific to DDLPS. While there are many 
deregulations in DDLPS that have yet to be explored due to the rarity of this disease, it is 
critical to identify targetable deregulations as a key strategy for therapy. Receptor tyrosine 
kinases (RTKs) are aberrantly overexpressed and active in sarcomas, including DDLPS75,76. 
RTKs are activated through ligand-dependent and ligand-independent mechanisms and, as a 
result, increased activation is able to activate and enhance multiple downstream tumorigenic 
pathways contributing to disease progression77. Of specific interest, we have observed that the 
RTK c-Met is overexpressed and activated in DDLPS75. However, c-Met is but one of many 
targetable deregulations in this disease. Targeting c-Met in DDLPS demonstrated anti-DDLPS 
tumorigenic effects; however, it was not the focus of this dissertation. The results from this 
study can be found in Appendix D.  
 
 
In summary, there are many potential molecular aberrations observed in DDLPS; 
however, amplification and expression of MDM2 is the most prominent deregulation and 
plays a critical role in tumorigenesis and progression of this disease.  
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SECTION 3. THE MDM2:P53 AXIS 
Together, MDM2 and p53 have established one of the most significant axes in all 
human cancers. In order to exemplify the importance of this axis, we must first understand 
their basic properties and functions. 
P53: The guardian of the genome  
The p53 tumor suppressor protein is irrefutably the most heavily studied molecule in 
cancer biology since its identification in 197978,79. Often referred to as “the guardian of the 
genome” for its ability to prevent genome mutations, p53 activities are carefully controlled in 
normal cells. Consequently, p53 activity must be inhibited in order for cancer cells to flourish 
and survive. Therefore, it is no surprise that 50% of all human tumor cells harbor mutations 
or deletions in the TP53 gene, resulting in either partial or complete inactivation of p53 
responses80. In response to cellular stress, p53 protein is stabilized and transformed into its 
active form functioning as a transcription factor to regulate the expression levels of 
downstream transcriptional targets genes which participate in various cellular processes78. In 
normal cells, p53 levels are negatively regulated by MDM2 which binds and targets p53 to 
the cytoplasm for degradation72. A complete review of p53 regulation and function in response 
to all of its various stimuli is beyond the depths of this study; therefore, we will focus on the 
specific functions in the p53 signaling network that relates to this body of work. 
Stabilization and activation of p53 
There are a variety of proteins that influence the stabilization and activation of p53 
constitutively and in response to different stress stimuli. A few of these proteins, which 
include protein kinases, proteins influencing localization, as well as proteins that influence the 
p53-MDM2 interaction are listed in Table 1.4.  
 19 
p53 stabilization occurs in response to DNA damage as well as by deregulated growth 
signals. One well characterized p53 stabilization process involves phosphorylation of p53. 
The two checkpoint kinases, Chk1 and Chk2 are capable of phosphorylating p53 allowing p53 
to deter degradation and be stabilized81. Chk2 phosphorylates p53 on Ser20 and, therefore, 
inhibits p53 degradation from MDM2. Double-stranded breaks in chromosomal DNA caused 
by ionizing radiation, transfer a signal to the ataxia telangiectasia mutated (ATM) kinase 
which passes along its signal to the ataxia telangiectasia and Rad3-related protein (ATR) 
kinase that is capable of directly phosphorylating p53 on Ser15 and deterring it from 
destruction82,83. Chemotherapeutic agents depend on the ability of ATR kinase to transfer its 
signal to casein kinase II which, in turn, phosphorylates p53 in another mechanism for p53 
stabilization83. Lastly, in response to aberrant growth signals of the pRB-E2F cell cycle 
control deregulation, p53 activation can occur84.  
Cells are constantly induced to environmental factors that cause DNA damage such as 
X-rays, ultraviolet radiation, chemotherapeutic drugs, hypoxia, DNA synthesis inhibitors, etc. 
are just a few that cause a rapid increase in p53 protein levels and result in p53 stabilization 
and activation. p53 protects cells from such physiological stresses by activating DNA damage 
responses. In the event that a cell endures DNA damage, p53 will become activated by both 
increased protein expression levels and post-translational modifications that allow 
downstream activation of transcriptional targets. These cellular processes include DNA-
repair, cell cycle arrest, senescence, inhibition of angiogenesis, and apoptosis, etc. (Figure 
1.2)79,85–88. However, not all signals are equal, and in response to stress, p53 must mediate the 
decision of a cell to either repair the damage and resume proliferation or eliminate these 
irreparable cells through cell death mechanisms. 
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Table 1.4 Proteins influencing p53 stabilization and activation. Select proteins and their 
specific effect on p53.  
Protein Effect on p53  
Inhibits or 
activates p53 
activity 
Reference 
MDM2 Tags for ubiquitin degradation Inhibits Kubbutat (1997)89 
P300/CBP 
Acetylates p53 during DNA 
damage response 
Activates 
(Grossman, 2001)90 
ATM Phosphorylates p53 at ser15 Activates (Morgan, 1997)91 
CHK2 Phosphorylates p53 at ser20 Activates (Kastan, 2004)92 
HAUSP 
De-ubiquitinates p53 and 
stabilizes p53 
Activates 
(Li, 2004)93 
DAXX Enhances p53 ubiquitination Inhibits (Kruse, 2009)94 
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Figure 1.2 p53 influences multiple cellular stress pathways. Various physiological 
stresses increase and stabilize p53 levels. In turn, p53 activates a variety of different responses   
 
Functions of p53: Downstream responses to activation 
Structure  
The TP53 gene is localized on the short arm of chromosome 17 (17p13.1) and encodes 
for the 393 amino acid (a.a.) phosphoprotein95. The TP53 gene consists of 11 exons. The first 
exon, is non-coding; there are five highly conserved regions that extend from exons 2 to 8 that 
are essential for p53 function96. Like most transcription factors, p53 protein contains distinct 
domains which correspond to specific functions responsible for sequence-specific DNA 
binding and transcriptional activation. (1) the N-terminal transactivation domain (1-50 a.a.); 
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(2) the central DNA-binding domain (102-292 a.a.); (3) the C-terminal oligomerization 
domain (323-355 a.a.) containing a nuclear export signal; and the (4) regulatory domain (356-
393 a.a.) containing three nuclear localization signals and non-specific DNA binding domain 
that binds to damaged DNA97 (Figure 1.3).  
 
   
    FIGURE 1.3 SCHEMATIC REPRESENTATION OF P53 STRUCTURAL DOMAINS.   
  
 
When stabilized, p53 forms a tetramer composed of two homodimers through the C-
terminal oligomerization domain; tetramerization is required for p53 activity and growth 
suppression98. Within the C-terminal oligomerization domain is a basic region that is 
implicated in recognition of DNA damage, transcription, and apoptosis98. Furthermore, three 
nuclear localization signals which are required for nuclear localization of p5398. 
Once stabilized, p53 is able to regulate gene transcription by binding in a sequence 
specific manner to the consensus sequence in p53 activated gene promoters on target genes99. 
The p53 pathway 
Primarily, p53 initiates and controls a critical signal transduction network known as 
the p53 pathway100. As previously mentioned, upon activation p53 functions as a transcription 
factor to regulate various gene expressions that modulate p53 response pathways; these 
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responses include cell cycle arrest, differentiation, DNA repair, apoptosis, and senescence, 
etc. Importantly, when activated p53 must determine between life (cell cycle arrest) and death 
(apoptosis). This decision is mediated by the ability of p53 to switch on or off certain genes 
through its transcriptional activity. There are over 4,000 putative p53-binding sites identified 
in the human genome; however, a short list of p53 target-genes tabland their associated p53 
responses are listed in Table 1.5.  
 
TABLE 1.5 P53 RESPONSES AND ASSOCIATED TARGET GENES. 
p53 response p53 target genes Reference 
Apoptosis 
APAF1 (Robles, Bemmels, Foraker, & 
Harris, 2001)101 
BAX (Toshiyuki & Reed, 1995)102 
FAS (Owen-Schaub et al., 1995)103 
NOXA (Oda, 2000)104 
PUMA (Nakano & Vousden, 2001)105 
Cell cycle arrest 
CDKN1A (Broude et al., 2007)106 
GADD45 (Hollander et al., 1993)107 
14-3-3-σ (Hermeking et al., 1997)108 
Angiogenesis TSP1 (Dameron, Volpert, Tainsky, & 
Bouck, 1994)109 
Auto-regulation MDM2 (X. Wu, Bayle, Olson, & 
Levine, 1993b)110 
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Cell cycle 
In normal cell biology, cell growth and proliferation is tightly regulated through a 
signal processing circuit known as the “cell cycle clock”. This “clock” decides the fate of a 
cell by integrating signals and choosing to either proliferate and continue through the cell 
cycle, or withdraw into a non-proliferative state. In order to implement this decision, cyclin-
dependent kinases (CDKs) and their associated subunits (cyclin proteins) send signals to other 
molecules that enable and carry out the process of cell cycle111. CDK-cyclin complexes are 
well defined in each period of the cell cycle (Figure 1.4). Importantly, these complexes can 
be regulated by proteins known as CDK inhibitors. The best characterized CDK inhibitor is 
p21WIF/CP1 (p21)112. p21 is a widely acting, pan-CDK inhibitor that can arrest a cell in many 
different stages of the cell cycle and plays an important role in p53-dependent cell cycle 
arrest113. 
 
 
Figure 1.4 Schematic of the cell cycle. The phases of the cell cycle and the major 
cyclin/CDK complexes associated with each phase.  
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p53 is involved in several different aspects of the cell cycle and transactivates or 
inhibits the expression of genes in order to mediate cell cycle progression114. A cell makes the 
decision to proliferate specifically during the G1 phase of the cell cycle, in which it is 
responsive to extracellular signals and mitogenic growth factors; whereas the following 
phases are able to proceed on fixed schedule92. Predominately, p53 influences the G1 phase of 
the cell cycle by inducing the expression of p21. In response to DNA damage, p21 mediates 
p53-dependent cell cycle arrest by binding to and inhibiting cyclin-Cdk complexes115. For 
example, in normal cellular context, pRB is bound to the E2F protein and upon nearing the 
end of the G1 phase, pRB is targeted for phosphorylation by Cyclin E-Cdk2 and disrupts the 
pRB-E2F interaction, thus, signaling the cell to continue to S phase116. However, in situations 
of cellular stress, p53 stimulates the transcription of p21 which inhibits the Cyclin E-Cdk2 
function and holds the cell in the G1 phase until the stress is removed. p21 is active throughout 
the entire cell cycle, exemplifying the ability of p53 to control various points in cell cycle 
progression113. This is an important capability of p53 as inhibition of the G1 cyclin-Cdk 
complexes (cyclin E-Cdk2 and cyclin D-Cdk4/6) by p21 prevents a cell from copying un-
repaired DNA damage in the S phase. However, if a cell has already progressed into S phase, 
p53 induced activation of p21 employs the DNA polymerase machinery at the replication fork 
resulting in inhibition of further replication of DNA template molecules. In addition, at the 
G2/M checkpoint, p53 is able to induce a G2 arrest and inhibit entry into mitosis by decreasing 
cyclin B1 transcription and synthesis117. To do so, p53 induces the expression of other cell 
cycle inhibitors such as Gadd45a and 14-3-3σ. Gadd45a promotes cell cycle arrest by 
disassociation of the  CDC2-cylin B1 complex formation118, while 14-3-3σ binds to and 
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inactivates Cdc25 and Cdc2 by sequestering them to the cytoplasm resulting in G2/M block
108. 
In another method of control, p53 is able to stall the cell cycle by repressing Cdk4 and cyclin 
E118. p53 has also been shown to play a role in the spindle checkpoint and avoid the re-
replication of damaged DNA. Lastly, p53 is able to associate with centrosomes and prevent 
mitotic failure in centrosome duplication119. The ability for p53 to influence a cell at multiple 
checkpoints highlights the importance of its regulation and activity in cell biology. 
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Figure 1.5 p53 cell cycle regulation. Transcriptional activation and repression of target 
genes results in cell cycle arrest 
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Apoptosis  
The cell death mechanism of apoptosis is a fundamental biological response that plays 
a critical role in normal cell development and homeostasis. p53’s role in apoptosis was first 
observed when imposed expression of p53 lead to features associated with apoptotic cell death 
such as DNA fragmentation caused by the cleavage of nuclear DNA in internucleosomal 
regions120. In response to environmental stresses, p53 employs several critical transcription 
targets that are essential for cell death and can trigger apoptosis through extrinsic or intrinsic 
signaling pathways, which, while differing on stimuli, converge at the level caspase activation.  
The extrinsic pathway is initiated by the death receptor family of proteins, and 
activated through ligand-receptor binding on the cell surface. Cell surface receptors, such as 
FAS, are transcriptionally up-regulated by p53 following DNA damage121.  Following 
formation of the death-receptor-signaling-complex (DISC), a chain of events is triggered 
which results in caspase-8 and subsequent caspase activation. Caspsase-8 is the established 
initiator caspase for this specific pathway. p53 participates in this pathway by inducing the 
transcription of these death receptors and ligands. 
In contrast, the intrinsic pathway is regulated by the pro-apoptotic and pro-survival 
Bcl-2 family proteins. The Bcl-2 family is divided into three subclasses: (1) pro-survival 
proteins (BclXL and BCL-2); (2) pro-apoptotic proteins (BAX and BAK); and (3) BH3-only 
pro-apoptotic proteins (PUMA and NOXA)122.  
In response to apoptotic stimuli, activation of the pro-apoptotic proteins bind to the 
pro-survival proteins, resulting in the activation of BAX/BAK. BAX and BAK oligomerize 
at the outer mitochondrial membrane which results in membrane permeabilization and 
promotes the release of cytochrome c and the resulting activation of effector caspases. The 
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pro-survival Bcl-2 family members inhibit this pathway by directly binding to BAX and 
BAK122. However, this interaction is disrupted two other p53 transcriptional targets, PUMA 
and NOXA, which is up-regulated by p53 following cellular stress105,123. Together with 
NOXA, these proteins mediate apoptosis liberating BAX and BAK. p53 is linked to the 
apoptotic pathway by directly inducing the transcription of several genes (PUMA, NOXA, and 
BAX).  
In summary, p53 is capable of inducing apoptosis through three mechanisms: (1) 
transcriptional regulation of apoptotic genes; (2) activating cytosolic BAX; and (3) inhibition 
and activation of apoptotic proteins at the mitochondria. 
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Figure 1.6 Schematic of extrinsic and intrinsic apoptotic pathways. The p53 targets are 
shown in red. 
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Loss of p53 activity in cancer 
p53 mediates critical cellular functions such as cell growth and proliferation; therefore, 
it is no surprise that p53 function is often disrupted in cancer. Various mechanisms contribute 
to the loss of p53 function in tumor cells, such as prevention of p53 activation, mutations in 
the p53 gene, as well as mutations in downstream target genes. The loss of p53 function due 
to mutations occurs in nearly 50% of all human cancers, wherein 90% of all mutations occur 
in the DNA-binding domain which manages the DNA-binding function of p53124,125. Most 
frequently (93% of mutations), the nature of p53 mutations is point-mutated alleles leading to 
amino acid substitutions. Because p53 function is a tetramer formation, the existence of a 
mutant allele could interfere with the function of the tetramer as a whole, giving the cell an 
advantage in compromising p53 function126. As a result, it is of particular interest as to how 
cancer cells are able to discard p53 function, as it appeared to be an anomaly to Knudson’s 
commonly accepted “two-hit hypothesis”127. Briefly, in this hypothesis Knudson described 
that the malignant benefits of silencing a tumor suppressor gene once it has lost both copies 
of the gene, and will only marginally benefit from the inactivation of one copy. Nevertheless, 
in the remaining 50% of cancers, such as DDLPS, the p53 retains its wild type (WT) genotype. 
As a result, these tumors acquire additional defects in other ways that abrogate the stability 
and cellular responses of p53.  
Regulation of p53 function 
p53 is regulated at both the mRNA and protein level through various mechanisms such 
as the control of p53 transcription and translation, modulation of p53s ability to function 
properly, and cellular localization98,128,129.  
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 Cellular localization 
The localization of p53 between the cytoplasm and nucleus is a tightly regulated 
process; in order for p53 to function as a transcription factor it must be present in the nucleus. 
As briefly mentioned, the nuclear localization signals and nuclear export signals control p53 
location and can either import or export p53 to/from the nucleus, respectively129. On the other 
hand, in order for p53 to be degraded, it must be exported from the nucleus; however, the 
nuclear export of p53 also requires the ubiquitin ligase of MDM2129–132. 
The MDM2:p53 negative feedback loop 
It is the p53 transcriptional target, MDM2 that is the best known regulator of p53 
protein stability. MDM2 regulates the basal level and activity of p53 through direct protein-
protein interaction126. Under normal conditions p53 levels are kept low, generally with a half-
life of only 20 minutes; however, in response to physiological signals, p53 degradation is 
inhibited and p53 levels rapidly increased100 and p53 is free to transcriptionally regulate 
downstream target genes, one of which is MDM2. p53 binds to the P2 promoter of MDM2 and 
transcriptionally stimulates MDM2 expression133. In return, as MDM2 protein levels rise it 
binds to p53 and targets it for proteasomal degradation. Together, MDM2 and p53 regulate 
one another via an autoregulatory feedback loop100 (Figure 1.7).   
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Figure 1.7 Schema of the autoregulatory negative feedback loop between MDM2 and 
p53. p53 and MDM2 form an negative feedback loop. When activated, p53 is stabilized and 
binds to the transcriptional domain of MDM2. As MDM2 levels rise, it binds to p53 and tags 
it for degradation via the proteasome.  
 34 
MDM2  
Identification and biological function 
The MDM2 gene was originally identified in a spontaneously transformed BALB/c 
mouse cell line (3T3-DM).  Later, it was found that the overexpression of the gene product 
was responsible for this transformation134,135. Initial experiments demonstrated that MDM2 
binds to p53, thus, inhibiting p53-mediated transactivation136. Furthermore, the amplification 
of the MDM2 gene was observed in over 30% of sarcomas that retained WT p53137. These 
studies suggested that the overexpression of MDM2 was one mechanism in which p53 was 
regulated.  
As previously described, MDM2 and p53 participate in a feedback loop regulating one 
another’s expression level; the physiological relevance of the p53-MDM2 relationship has 
been eloquently shown in mouse models. Two independent groups showed that the loss of 
MDM2 lead to embryonic lethality in very early development; however, this can be rescued 
by simultaneous depletion of TP53138,139. Furthermore, Terzian and colleagues (2007) 
demonstrated that while MDM2 heterozygosity is adequate enough to maintain the level of 
p53 in adult mice under normal conditions, the exposure to even very low doses of ionizing 
radiation is lethal, and is therefore insufficient in response to DNA damage140. Taken together, 
these studies demonstrate the critical nature of MDM2 and p53 regulation and indicate that 
the primary function of MDM2 is to inhibit p53 activity in early development and when 
exposed to DNA damage. 
Structure 
Structurally, MDM2 is a 491 a.a. protein that contains five domains for the basis of its 
oncogenic properties126 (Figure 1.8). Amino acids 1-118 comprise the p53 binding domain of 
the N-terminal portion and plays a critical role for inhibition of p53 transcriptional activity126. 
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The nuclear localization and nuclear export signal are located in the central region and are 
involved with the shuttling of MDM2 from the nucleus and cytoplasm141. The interaction 
between MDM2 and ribosomal proteins is regulated by the acidic and zinc finger 
domains142,143; while the C-terminus contains the RING finger domain responsible for the E3 
ubiquitin ligase activity144,145. 
 
 
FIGURE 1.8 STRUCTURE OF MDM2 PROTEIN.   
 
Master regulator of p53  
Although briefly mentioned, MDM2 is best known for its ability to regulate p53. 
MDM2 inhibits p53 functions and negatively regulates the transcriptional activity and stability 
of p53 in at least three different ways. First, functioning as an E3 ubiquitin ligase, MDM2 
binds to p53 and attaches ubiquitin groups to the carboxy-terminus of p53 resulting in 
ubiquitin-dependent degradation of p53 through the 26S proteasome100,126. Secondly, MDM2 
and p53 also interact through the N-terminal transcription activation domain of p53, thus 
directly interrupting p53 transcriptional activity136,146. Thirdly, via its nuclear export signal 
sequence, MDM2 can promote p53 translocation through nuclear export as MDM2 removes 
p53 from its target genes and degrading the protein in the cytoplasm141,147,148 
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MDM2 functions as an E3 ubiquitin ligase 
The ubiquitin ligase activity of MDM2 is responsible for the attachment of an ubiquitin 
on the p53 protein. Ubiquitin, a 76 a.a. protein, was first identified in 1975 and can be 
covalently attached to proteins in a process called ubiquitinylation149. This is an inducible and 
reversible process in which ubiquitin tags a protein for degradation into its constituent amino 
acids by the 26S proteasome in an ATP dependent mechanism150,151. The sequential process 
for ubiquitinylation of p53 involves three enzymes. First, the ubiquitin activating enzyme (E1) 
binds to ubiquitin, this activated ubiquitin is then transferred to ubiquitin conjugating enzyme 
(E2), and finally, MDM2 bound to p53 acts as an E3 ubiquitin ligase and causes ubiquitin to 
be directly transferred to p53130,131. Until recently, it was believed that p53 requires poly-
ubiquitinylation of four or more ubiquitin subunits for effective degradation152; however, 
recent data reveals that MDM2 mediates monomeric ubiquitinylation on multiple lysine 
residues instead of polymeric ubiquitinylation153.  
It is the E3 ubiquitin ligase that allows specificity in the ubiquitinylation process as 
there are over 100 different E3 ubiquitin ligases and only 20 different E2 ubiquitin ligases and 
only one E1 ubiquitin ligase154. Specifically, MDM2 is a Really Interesting New Gene (RING) 
domain type of E3 ubiquitin ligase154. The RING E3 ubiquitin ligases allow the direct transfer 
of ubiquitin from E2 to the targeted substrate; i.e. p53130,131,154. Furthermore, MDM2 
undergoes self-ubiquitinylation, targeting itself for degradation154. 
MDM2 regulation 
The MDM2 gene is transcriptionally controlled by two promoters: P1, which is located 
upstream of the first exon, and P2, which is located within the first intron. The basal expression 
of MDM2 transcription is regulated by the P1 promoter and is p53-independent. While there 
are few regulators of the P1 promoter, NF-kB and PTEN have been shown to positively and 
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negatively regulate MDM2, respectively.  On the other hand, inducible expression of MDM2 
is regulated by the P2 promoter which contains several response elements accountable for 
either inhibiting of activating MDM2 transcription155.  
Other proteins that interact with MDM2 
Several other proteins that interact with MDM2 either upstream or are specific 
downstream targets have been identified and characterized for their relevance in 
tumorigenesis. Generally, most upstream targets are kinases and phosphatases and can 
regulate MDM2 in one of three ways: (1) these effector proteins can regulate MDM2 
transcriptionally by binding directly to the P1 or P2 promoter; (2) MDM2 can be regulated 
post-transcriptionally when these proteins bind to the MDM2 mRNA; (3) these proteins can 
post-translationally regulate MDM2 through ubiquitination, de-ubiquitination or 
phosphorylation155. On the other hand, because MDM2 functions as an E3 ubiquitin ligase, 
the majority of downstream proteins of MDM2 are targets for proteasomal degradation. A list 
of select proteins is summarized in Table 1.6. 
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TABLE 1.6. PROTEINS THAT INTERACT WITH MDM2 FUNCTION AND REGULATION. 
 Protein 
Effect on MDM2/result of 
interaction 
Reference 
Effector proteins 
of MDM2 
p19
ARF
 
Binds to MDM2 and inhibits 
MDM2:p53 interaction 
(Tao & Levine, 
1999)156 
ATM 
Phosphorylates MDM2 at 
ser395, inhibits its interaction 
with p53 
(Maya et al., 
2001)157 
MDMX Inhibits auto-polyubiquitination 
(Terzian et al., 
2007)140 
P300/CBP 
MDM2 blocks p300/CBP from 
interacting with p53 
(Clegg et 
al.,2012)158 
Affecter proteins 
of MDM2 
E2F1/DP1 
MDM2 activates transcriptional 
activity and antagonize E2F1 
apoptotic activity 
(Loughran & La 
Thangue, 2000)159 
RB RB binding to E2F1 is inhibited 
(Hsieh et al., 
1999)84 
p63 
MDM2 translocates p63 to 
cytoplasm and increases its 
transcriptional activity 
(Su, Chakravarti, 
& Flores, 2013)160 
p73 
MDM2 translocates p73 to 
cytoplasm, P53 activity is 
decreased 
(Zeng et al., 
1999)161 
 
MDM2 overexpression in cancer 
Based on its behavior in human malignancies, MDM2 is classified as an oncogene. 
Over expression of the MDM2 gene has been found in many human malignancies either due 
to the amplification of the chromosomal region, or over expression of the protein without gene 
amplification58. The overall frequency of MDM2 amplification in human tumors is 7%; 
moreover, the highest frequency of MDM2 amplification (20%) is observed in STS58,125. Other 
mechanisms accounting for MDM2 overexpression include increased transcription and 
translation162, as well as a single nucleotide polymorphism (SNP), SNP309, which increases 
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the mRNA expression of MDM2163. Importantly, high expression of MDM2 is associated with 
tumor progression and worse prognosis164. 
 
 As previously mentioned, in DDLPS this high expression can be attributed to 
amplification of the 12q13~15 chromosomal segment. This apparent predilection to MDM2 
amplification merits further investigation in these tumors, and, as a result, DDLPS not only 
provides a unique model for probing of the MDM2:p53 axis, but also an exemplary candidate 
for treatment with inhibitors of the MDM2:p53 complex. 
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SECTION 4. TARGETING THE MDM2:P53 WITH SMALL MOLECULE INHIBITORS AS A 
THERAPEUTIC STRATEGY FOR DDLPS  
Reactivation of the p53 pathway with small molecule MDM2 inhibitors 
Reactivation of p53 as a therapeutic strategy is an attractive therapeutic target due to 
its powerful tumor suppressive functions that can be activated to eradicate tumors. 
Approximately half of all human tumors retain WT p53; however, the p53 function can be 
abrogated by the overexpression of MDM2165. Frequently (~30%), this overexpression is due 
to amplification, such as seen in DDLPS (~90-100%)58. As a result, this therapeutic strategy 
is particularly advantageous for the treatment of DDLPS. MDM2 has proven itself to be a 
promising target for cancer therapies. There are two classes of MDM2 targeted compounds: 
(1) inhibiting the E3 ubiquitin ligase activity of MDM2; (2) inhibits the protein-protein 
interactions between MDM2 and p53. For this study, we have focused on the latter.  
Small molecule inhibitors of the MDM2-p53 protein-protein interaction 
Structural characterization of the p53-MDM2 interface revealed a deep hydrophobic 
cleft on the surface of MDM2 is occupied by the transactivation domain of p53166. Further 
analysis unveiled that deep within this “pocket” are four key hydrophobic residues crucial for 
the interaction between MDM2 and p53. Nevertheless, the ability to disrupt the protein-
protein interactions has proven to be a difficult challenge. In an attempt to target this 
interaction, several classes of small molecule inhibitors have been described. Each inhibitor 
has a distinct chemical structure and includes: analogs of cis-imidazoline, spiro-oxindole, 
benzodiasepinedione, sulfanomide, and many others167. Currently, there are several small-
molecule MDM2 inhibitors in various stages of clinical investigation (Table 1.7). 
Specifically, in this study we investigated the effects of two previously reported small-
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molecule inhibitors (Nutlin-3a and MI-219) and one novel MDM2 antagonist (SAR405838) 
for the treatment of DDLPS. 
 
 
Table 1.7 Small molecule inhibitors of the MDM2-p53 complex. An overview of 
several MDM2 antagonists currently in clinical trials.  
Mechanism Compound Study 
Inhibitor of the p53 binding pocket on 
MDM2 
Nutlin-3 Phase I 
RG7112 Phase I/II 
MI-63 Phase I 
SAR405838 Phase I 
NU8231 Pre-clinical 
PXN-822 Pre-clinical 
RG7388 Phase I 
Inhibitor of the p53 binding pocket to 
both MDM2 and MDMX 
CGM097 Phase I 
MK-8242 Phase I 
RO-5963 Pre-clinical 
p53 inhibitor of MDM2 and MDMX 
binding pockets on the wild type and 
mutant p53 proteins 
RITA Pre-clinical 
 
 
 
Initial peptide-based compounds were designed to target the MDM2 binding pocket 
of MDM2; however, they demonstrated poor cell permeability and were not useful for cell 
based studies. As a result, the pursuit was on to design a compound with enhanced 
permeability, high-affinity, and resulted in marked cellular activity. Chemical library 
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screening, computational three-dimensional database screening, and structure-based design, 
all lead to the discovery and development of lead compounds168.  
Mechanism of action 
While the core structure of MDM2 antagonists varies between each compound class, 
the overall mechanism of action remains the same. Targeting the protein-protein interaction 
of p53 and MDM2 with small molecule inhibitors has presented its challenges due to the large 
hydrophobic interface on MDM2169,170; however, if prevented from interacting, p53 is  
liberated from MDM2 degradation and capable of reactivating various tumor suppressor 
responses171–174. Four key hydrophobic residues are required for the interaction between 
MDM2 and p53: Phe19, Leu22, Trp23 and Leu26. Disrupting the interaction of these amino 
acids inhibits the binding of MDM2 and p53. As a result, the ability to mimic this binding 
through use of selective, small-molecule MDM2 antagonists in cancers retaining WT p53 has 
been highly invested as an important therapeutic option171–174.  
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Figure 1.9 Small molecule inhibitors of MDM2 inhibit the MDM2-p53 complex. 
MDM2 antagonists bind to the p53 binding pocket on the surface of MDM2 and inhibit the 
interaction of MDM2 and p53. As a result, p53 is liberated from MDM2 proteasomal 
degradation and is able to activate the p53 pathway. 
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Nutlins 
 
Discovered by Vassilev and colleagues, the Nutlins 
were the first examples of potent and selective small-
molecule MDM2 antagonists. Experimental screenings of 
synthetic compounds and extensive chemical 
modifications ultimately resulted in the cis-imidazoline 
core structure of the small-molecule MDM2 inhibitors174. 
Nutlin-1, Nutlin-2, and Nutlin-3 displaced p53 from MDM2 with IC50 values of 260nM, 
140nM, and 90nM, respectively
175. However; it was, Nutlin-3a, an active enantiomer isolated 
from Nutlin-3 that provided the most promising therapeutic potential. Vassilev demonstrated 
that Nutlin-3a successfully activated the p53 pathway in cells retaining WT p53 in basic cell 
culture based assays, as well as provided the first in vivo proof-of-concept that the 
pharmacological inhibition of MDM2 and reactivation of WT p53 inhibited tumor-growth. 
This early therapeutic pioneer opened the doors for increased selectivity and potency for 
MDM2 antagonists. 
Recently, the Nutlin-derivative RG7112 exemplified the use of MDM2 inhibition and 
reactivation of p53 in WDLPS and DDLPS52 and is currently in the most advanced stages of 
clinical development (Phase II) for a small-molecule MDM2 inhibitor 174. The importance of 
this study lies in the fact that this traditionally chemotherapeutic-resistant disease responded 
to treatment, as well as provide insight into biomarkers for therapeutic response174.   
The design of small molecule inhibitors using a computational pharmacophore search 
strategy was performed by Galatin and Abraham176. NSC279827 was the one compound 
FIGURE 1.10 THE CHEMICAL 
STRUCTURE NUTLIN-3A. 
Nutlin-3a 
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found to inhibit MDM2-p53 binding; however, it demonstrated a weak affinity with only 20% 
increase in p53 transcriptional activity following 100μM.  
 
MI-219 
Nevertheless, these two screening approaches had 
limitations based on the lead-core design. As a result, a new 
class of compounds were developed using a structure-based de 
novo strategy177. This design is based on the crystal structure of 
the p53:MDM2 complex and heavily weighted on one specific 
residue (Trp23) of p53 that is located in the hydrophobic pocket 
of MDM2177. To inhibit this interaction, the oxindole ring 
system was utilized to mimic this interaction177.  This resulted in the design of a new class of 
inhibitors based on the spiro(oxindole-3,3’-pyrrolidine) core structure. Spiro-oxindoles are 
able to bind to MDM2 with high affinity and activate the p53 pathway in cell lines with WT 
p53177,178. Following structure-based optimization, highly potent inhibitors were developed, 
such as MI-219179.  
MI-219 (MDM2 inhibitor-219) is an optimized analog of MDM2-inihibitor-63 (MI-
63) and has been the leading compound in this class of inhibitors177. MI-219 mimics the four 
key amino acids on the MDM2 binding pocket. MI-219 showed initial pharmacological 
potential due to the oral bioavailability, specificity to MDM2, and disruption of the 
MDM2:p53 complex. Furthermore, MI-219 displayed a high binding affinity and specificity 
for MDM2, disrupting MDM2:p53 binding and inducing stabilization of p53 in cells with WT 
p53177,178. 
MI-219 
FIGURE 1.11 THE 
CHEMICAL STRUCTURE 
MI-219. 
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Anti-tumorigenic responses of MDM2 inhibition 
Small molecule inhibitors have certain desirable properties that are crucial for its 
effectiveness, these include: (1) high binding affinity and specificity to MDM2; (2) potent 
cellular activity in cancer cells with wild-type p53; and (3) a desirable pharmacokinetic (PK) 
profile167. Nutlin-3a and MI-219 provided valuable preliminary evaluations for MDM2 
inhibitors. In studies comparing the therapeutic effects of these drugs, both Nutlin-3a and MI-
219 demonstrated p53 induced anti-tumorigenic results173. It was observed that in normal cells 
that these inhibitors induced cell cycle arrest, but not death; meaning that these inhibitors are 
not toxic to normal cells; therefore, highlighting their potential therapeutic use173. p53 
pathway activation was observed by the G1 and G2 cell cycle arrest, as well as up regulation 
of the p53 transcriptional target, p21, a known mediator in cell cycle arrest. Both drugs 
induced p53-dependent cell cycle arrest and apoptosis; however, MI-219 demonstrated a more 
desirable pharmacokinetic profile than Nutlin-3a167,174,177,178. Together, these two inhibitors 
were important to the development for the rational and evidence of small-molecule MDM2 
inhibitors and are often used as a standard in comparing the efficacy of new drugs.  
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SAR405838: a novel small molecule MDM2 inhibitor 
 
Currently, optimization of spiro-oxindole 
compounds is being heavily pursued; consequently, many 
of these inhibitors have only been disclosed in patents and 
little is known about their cellular activity, pharmacological 
properties and mechanism of action. Towards that end, a 
novel spiro-oxindole small-molecule inhibitor of MDM2 
has been developed by Sanofi-Aventis: SAR405838.  
SAR405838, an analog of MI-219, has shown superior pre-
clinical results. Initial experiments demonstrated p53 stabilization and activation in cancer 
cell lines with WT p53. Osteosarcoma-bearing xenograft models showed anti-tumor dose-
dependent responses following SAR405838 treatment, as well as demonstrated a promising 
pharmacokinetic profile as the plasma concentrations of SAR405838 were similar between a 
single day and 11 day repetitive oral administration.  
Due to the encouraging initial results from SAR405838, we investigated the initial pre-
clinical use of this drug in DDLPS, of whom it would be the most biologically relevant model.   
 
   
SAR405838 
FIGURE 1.12 THE CHEMICAL 
STRUCTURE SAR405838. 
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HYPOTHESIS AND SPECIFIC AIMS 
 
HYPOTHESIS 
 
MDM2 targeted therapy is an effective anti-DDLPS therapeutic strategy. 
SPECIFIC AIMS 
 
Aim 1: To develop and characterize experimental models for DDLPS 
1.1 Develop currently lacking human  DDLPS cell lines and xenograft models 
1.2 Determine MDM2 and p53 status in these cell lines 
1.3 Unravel the molecular characteristics of these cell lines 
 
Aim 2: To investigate MDM2 as a therapeutic target for the treatment of DDLPS 
2.1  Determine the efficacy of the small molecule MDM2 inhibitor SAR405838 in 
vitro 
2.2  Evaluate the efficacy of SAR405838 in vivo 
 
Aim 3: To define the molecular changes in DDLPS in response to MDM2 inhibition  
3.1 Identify gene expression changes in response to SAR405838 treatment in vitro 
3.2 Identify gene expression changes in response to SAR405838 in vivo 
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SIGNIFICANCE 
 
MDM2 amplification in the presence of WT TP53 is a molecular hallmark of DDLPS. 
In this body of work, we inhibited this oncogenic pathway as a node of therapeutic 
vulnerability.  New generation small molecule MDM2 inhibitors, such as SAR405838 are 
highly effective in disinhibiting the p53 pathway in DDLPS cells resulting in significant anti-
tumorigenic effects. These preclinical data strongly support the development of clinical trials 
for patients with this aggressive cancer and perhaps other cancers where MDM2 is pathogenic.  
MDM2 amplification has commonly been observed in other malignancies that retain wild-
type p53. Our findings suggest a basis for the utility of SAR405838 in these clinical contexts. 
From the biological standpoint, MDM2-p53 pathway is of critical importance in both 
normal physiology and disease. The preclinical tools we developed here can be used to further 
unravel the functional consequences of inhibiting this pathway.  
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CHAPTER 2. MATERIALS AND METHODS 
Isolation and establishment of human DDLPS cell lines from solid tumor 
Human DDLPS cell strains and lines were originally isolated and established in our 
lab were obtained from patient consented tumors. Following surgical resection, a 
representative sample was sectioned and placed into our tissue bank, as well as for 
pathological review. The rest of the DDLPS tumor tissue was aseptically placed into 50mL 
conical vials containing sterile PBS and brought over to our facility on dry ice immediately 
following excision. Tumor samples weighing 20-30 grams were removed from PBS and 
transferred to a glass 10cm petri dish. 10-20mL of DMEM media is added to the tumor, or, if 
it is not a human sample, RPMI1640 media is used. The tumor is cut into 1mm pieces with a 
sterile scalpel. The minced tumor pieces are then transferred in DMEM to a 50mL Falcon 
spinner flask and the petri dish is rinsed with DMEM to collect any remaining tissue. DMEM 
is added to the Falcon flask to reach a total volume of 25mL. 2.5mL of 3% collagenase Type 
1 (Sigma), 5.0mL of 0.02% DNAse I Type II (Sigma), and 1.0mL of 1.5mg/mL hyaluronidase 
(Sigma) is added to the vial. The spinner flask is placed on a Bell-Stir at speed of 8 in 37°C 
incubator for 2 hours to digest the tumor. The tumor samples are then strained through a sterile 
wire mesh screen (Fisher) into a new 50mL tube and centrifuged at 1500 rpm at room 
temperature for 5 minutes. The media is aspirated from the tissue and PBS is added to for a 
total volume of 40mL to wash the cell pellet. The cells are then centrifuged again at 1500rpm 
for 10 minutes at room temperature. The PBS is aspirated and the pellet is resuspended in 
20mL of PBS. Histopaque tubes were set up for every 1mL of cell pellet. 10mL of 100% 
Histopaque (Sigma) is added to the 50mL conical vial and carefully overlayed with 15mL of 
75% histopaque in PBS The cell suspension is carefully added to the top of the histopaque so 
that the solutions are not mixed. The tubes were centrifuged at 4°C for 30 minutes at 1800 
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rpm. The first interface, which contains the tumor cells, is carefully pipetted out of the tube 
without disturbing the other layers. 50mL of PBS is added to the extracted cells and 
centrifuged at 1800rpm for 5 minutes at room temperatures. The PBS is aspirated after 
centrifugation and cells are in DMEM with high glucose, 10% FBS and 1% 
penicillin/streptomycin in a cell flask. Cells are incubated at 37°C. 
Cell Culture 
SW872 was obtained from the American Type Culture Collection. LISA2 and LS2B 
were kindly given to us from Dr. Kiki Broccoli (The Curtis and Elizabeth Anderson Cancer 
Institute, Savannah, GA, USA). Dr. Jonathan Fletcher (Brigham and Women’s Hospital, 
Boston, Ma) generously provided us with LPS141 cells. All cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM) and supplemented with 10% fetal bovine serum (FBS), 
100 U/mL penicillin, and 100 U/mL streptomycin. Human mesenchymal stem cells derived 
from adipose tissue (hMSC-AT) were obtained from Zen-Bio and PromoCell and cultured in 
mesenchymal stem cell medium supplemented with manufacturer’s supplemental mix 
(PromoCell). These cells were cultured under normal conditions in a humidified chamber 
delivering 5% CO2 at 37°C. 
Short Tandem Repeat (STR) 
DNA fingerprinting via sequencing of short tandem repeats (STR) was conducted for 
all cell lines prior to use in studies in order to validate the cell line to the original tumor sample 
from which they were derived. DNA from each cell lines was obtained using a Qiagen Blood 
and Cell Culture DNA kit (Qiagen, Valencia, CA, USA) per manufacturer’s instructions. In 
order to amplify DNA for fingerprinting, AmpFISTR Identifier PCR Amplification kit 
(Applied Biosystems) was used. This kit results in amplification of the amelogenin gender 
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determining marker and 15 tetranucleotide repeat loci. Cell strain/line fingerprints were 
compared with the original tumor or the earliest available passage of cells. Known cell line 
fingerprints were compared to those published by the American Type Culture Collection 
(ATCC). 
Fluorescence in situ Hybridization (FISH) 
FISH analysis was used to observe the genomic amplification of 12q13-15 in our panel 
of cells. Cultured cells were harvested, washed 2x in PBS and resuspended in 200μL of 3:1 
Acetic Acid:Methanol. 200μL of cell suspension was then carefully placed onto slides and 
allowed to “age” over-night at RT. The following day, the cellular DNA is denatured by 
placing the slides in a Coplin jar warmed to 75°C containing the denaturing solution of 70% 
formamide/2XSSC for 5 minutes. The slides are then dehydrated by placing them in sequential 
solutions of 70%, 85% and 100% ethanol at room temperature for 2 minutes each. Each slide 
requires 5 µL of probe mix for the 12q15 chromosomal region (RP11-185H13, RP11-450G15, 
RP11-816C9, RP11-630N19, RP11-717F7, RP11-1104N20, and RP11-426B12; probe was 
kindly given to us from Dr. Dolores Lopez-Terrada, Texas Children’s Hospital, Houston, 
Texas)  5μL of probe mix containing centromeric chromosome-12 fluorescence-labeled 
probes (spectrum green; Abbott Molecular, DesPlaines, IL, USA) is applied to each slide and 
carefully covered with a cover slip. Cover-slipped slides are placed into HyBrite incubator to 
hybridize. The hybridization cycle is preset to melt for 5 minutes at 80°C, and then hybridized 
for 16 hours at 37°C. On the third day, the slides are quickly dipped into a wash solution 
containing 2XSSC/0.3% NP-40 to remove the coverslip. Excess probe is washed off by 
placing slides into a Coplin jar for 2 minutes containing 0.4XSSC/0.3% NP-40 at 70° C, and 
a second wash of 2xSSC/0.1% NP-40 for 1 minute at room temperature. Slides are then 
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allowed to air dry in the dark for 20-30 minutes. Once dry, mounting media containing DAPI 
(ProLong Gold Antifade Reagent with DAPI; Life Technologies, Grand Island, NY, USA) is 
applied and slides are cover-slipped. MDM2 amplification was observed and considered at a 
ratio of MDM2/CEP12 ≥ 2.1 per 100 cells.  
gDNA extraction  
gDNA was extracted from DDLPS cell lines using the QIAamp DAN Mini Kit 
(Qiagen) as per manufacturer’s instructions. Briefly, the cell pellet was resuspend in PBS to a 
final volume of 200 µl. 20 µl of proteinase K and 200 µl of lysis buffer were added to the 
sample, mixed by pulse-vortexing for 15 seconds and incubated at 56°C for 10 min. 200 µl 
ethanol (100%) was added to the sample, and mixed again by pulse-vortexing for 15 seconds. 
The mixture was added to the column and centrifuged at 6000 x g for 1 min. The filtrate was 
discarded and 500 µl of buffer AW1 was added (removing any non-specific binding of 
inhibitors to the spin column membrane) and centrifuged at 6000 for 1 min. The filtrate was 
discarded and 500 µl Buffer AW2 was added (in order to wash away any salts that are present) 
and centrifuged at full speed (20,000 x g) for 3 min. The column was placed in the centrifuge 
at full speed for 1 min to eliminate the chance of possible Buffer AW2 carryover. The column 
was placed in 1.5 ml tube, and 200 µl of distilled water was added, incubated at room 
temperature (15–25°C) for 1 min, and then centrifuged at 6000 x g for 1 min. 
RNA extraction and quantitative real-time PCR 
Cells were cultured at 75% confluence. mRNA was extracted from cell pellets using 
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA)  and quantified using a NanoDrop 
2000 instrument. Bio-Rad's iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) was 
used to perform reverse transcription and Light Cycler 480 SYBR Green 1 Master Mix 
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(Roche) was used for quantitative detection of transcripts. Second derivative max values were 
calculated by Roche’s Light Cycler software. Expression levels were normalized to β-2-
microglobulin, and calculated using the 2ΔΔCT method; all experiments were performed in 
triplicate. Primers are detailed in Table 2.1. 
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Table 2.1 qRT-PCR primer sequences. Sequence of primers used in qRT-PCR experiments. 
Primer Strand Sequence 
MDM2 
sense AAAGGGCCAGGTTAAATGGT 
antisense GTGTGCCCCAGAACAAAGAT 
CDKN1A 
sense GGAAGACCATGTGGACCTGT 
antisense GGCGTTTGGAGTGGTAGAAA 
Nup107 
sense TCAAAGCAGGTTTTTGTGGA 
antisense CGAGGAACAAGGAATGGAAA 
YEATS4 
sense GAAGATGGGCACACTCATCA 
antisense TGGATTGCCATAGCTTTCATGT 
GADD45a 
sense ATCACTGTCGGGGTGTACGA 
antisense ATCTCTGTCGTCGTCCTCGT 
BUB1 
sense AGAGCCCAGGAGACTTCACA 
antisense CAAAGTCGCCTGGGTACACT 
GDF15 
sense ACGCTACGAGGACCTGCTAA 
antisense AGAGATACGCAGGTGCAGGT 
P53 
sense GTTCCGAGAGCTGAATGAGG 
antisense TCTGAGTAGGCCCTTCTGT 
BAX 
sense GTGGCAGCTGACATGTTTTC 
antisense GGAGGAAGTCCAATGTCCAG 
PUMA 
sense GACGACCTCAACGCACAGTA 
antisense CACCTAATTGGGCTCCATCT 
B2M 
sense GAATTCACCCCCACTGAAAA 
antisense CCTCCATGATGCTGCTTACA 
AVIL 
sense GTGCAGGTTCGAGTCAGGAT 
antisense TAACTTCCACTGCTTTGGTG 
CYP27B1 
sense TACCCCTCAGCCACTGTTCT 
Antisense TGTCCCACACGAGAATTTCC 
RAB31P 
sense TGCGAGATCAACTTGGACAG 
antisense CTGCTGTTGCCTGCTTGATA 
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Western blotting 
Western blot (WB) analyses were used to evaluate the protein expression. Cells were 
cultured as previously described prior to collection. Cells were then washed with ice-cold 
phosphate buffered saline (PBS), and resuspended in whole cell lysis buffer (0.5M EDTA, 
200mM PMSF, 200mM Na3VO4) that contained phosphatase inhibitors (Sigma-Aldrich), 
then placed on ice for 30 minutes and centrifuged for 15 min and supernatant was collected. 
Lysates were stored at -20°C. A Bradford assay was performed (Bio-Rad, Hercules, CA, 
USA) using bovine serum albumin (BSA) in order to establish a standard curve to determine 
the protein concentration of each sample.  25-50µg of protein and 1x loading buffer in 10% 
β-mercaptoethanol was prepared and loaded into a bis-acrylamide gel. The protein marker to 
determine the protein weight was added to the first well of the gel. The samples were run at 
100 volts for 1.5 hours to separate the proteins. Protein was transferred onto a Nitrocellulose 
membrane and ran at 100 volts for 1 hour. All western blots were blocked with 5% milk in 
PBS-T for 1 hour. Primary antibodies were diluted at 1:1000 in fresh 5% milk/PBS-T and 
applied and incubated overnight at 4°C. The following day, blots were washed 3 times with 
PBS-T for 10 minutes and a secondary antibody, (goat anti-rabbit IgG and goat anti-mouse 
IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Inc))  diluted 1:3000 
in 5% milk/PBS-T was applied for 1 hour at room temperature. Blots were developed using 
Western Lightning ECL kit (Perkin-Elmer, Inc.) 
Antibodies for western blot analyses 
The following commercially available antibodies were used: MDM2, and Nup107, 
were purchased from Abcam (Cambridge, MA); Cleaved caspase 3, and Aurora A were 
purchased from Cell Signaling (Danvers, MA); p53, p21, GADD45a and β-actin antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit IgG and 
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goat anti-mouse IgG antibodies conjugated to horseradish peroxidase (Santa Cruz 
Biotechnology) were used as secondary antibodies for western blot experiments.  
P53 Mutational Analysis 
p53 mutational analysis was conducted on all cell strains/lines as previously described 
by our lab180. In brief, QUIamp DNA Mini Kit (Qiagen, Valencia, CA, USA) was used to 
extract genomic DNA as per manufacturer’s instructions. The integrity and concentration of 
each sample was evaluated using a NanoDrop spectrophotometer and primers recognizing the 
intronic sequences of exons five through nine of p53 were evaluated. PCR amplification was 
performed on genomic DNA for all p53 and the sequence analysis from the PCR product was 
performed with Sequence Scanner (version 1.0, Applied Biosystems). 
Hematoxylin and eosin (H&E) staining 
As previously explained, tissue samples were fixed in 10% phosphate-buffered 
formalin and embedded in paraffin. These formalin-fixed, paraffin-embedded sections were 
cut and mounted onto slides with a poly-l-lysine coat (Sigma Aldrich, St. Louis, MO. USA) 
and then allowed to dry at 37°C. Slides were then heated on a heating block (55-60°C) for 15-
20 minutes. Slides were deparaffanized and hydrated through the xylene and alcohol to water 
sequences and washed with running water 3-4 times. Slides were stained with Harris 
hematoxylin (Fisher Scientific, #SH26-500D) for 3 minutes, followed by 3 washes with water. 
Slides were then quickly dipped in acid alcohol (700mL 95% EtOH + 250mL dH2O + 10mL 
hydrochloric acid) followed by 3 washes with water. Samples were then placed in PBS for 1 
minute and again washed 3 times with water. Slides were dipped quickly 5-6 times in Eosin-
Y solution (Sigma Aldrich, # 046K4365) to stain the cytoplasm. The slides were decolorized 
and dehydrated through alcohols and xylenes: 4 changes in 95% EtOH (10 dips) 2 changes 
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100% EtOH (10 dips) and 1 change in xylene (10 dips). Following the last xylene dip, slides 
were coverslipped and mounted using Permount (Fischer) and observed under the microscope.  
Immunohistochemistry 
The protocol used to perform immunohistochemistry on paraffin sections has been 
obtained and modified from the protocol established by Donna Reynolds (Chief, Histology 
Laboratory, Department of Cancer Biology, The University of Texas as M.D. Anderson 
Cancer Center, Houston, TX, USA) and varies slightly amongst each protein of interest. The 
following protocol is the standard modified protocol performed. Tissue samples were fixed in 
10% phosphate-buffered formalin and embedded in paraffin. These formalin-fixed, paraffin-
embedded sections were cut, mounted onto slides with a poly-l-lysine coat (Sigma Aldrich, 
St. Louis, MO. USA) and then allowed to dry at 37°C. Prior to deparaffinization, sections 
were then placed on a slide warmer for 20 mins (55-60°C) to soften the paraffin and adhere 
the tissue to the slide. Slides were deparaffinized and hydrated to PBS using the following 
series: Xylene for 4 minutes, Xylene for 3 minutes, 2 100% EtOH washes for 2 minutes each, 
2 washes 95% EtOH for 1 minute each, 80% EtOH for 1 minute and 2 washes of 1X PBS for 
2 minutes each. Antigen retrieval was then performed to restore the immunoreactivity of the 
protein of interest after fixation in formalin. The optimal pH of the recovery buffer is a critical 
element of the recovery step and was established specifically to each protein. DIVA Decloaker 
(BioCare Medical) pH 6.0 was diluted and used as the antigen retrieval. The retrieval was 
performed using a steamer (Vegetable Steamer, Black and Decker) for 40 minutes. After 
heating, the slides were cooled for 15 minutes using partial exchanges (4-8) of retrieval 
solution with PBS until reaching room temperature. Slides were then removed from PBS and 
a Pap Pen was used to draw a small circle around the sample. Slides were taped to a slide 
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holder and placed in a humidity chamber. 3% hydrogen peroxide/methanol solution to the 
slides was added for 12 minutes to block the endogenous peroxidase activity in the tissue and 
prevent it from interfering with the activity of the HRP conjugated to the secondary antibody 
that produces the color change when DAB is added. Slides were then washed 3 times in PBS 
(3 minutes each) and protein block (5:1 normal horse serum:normal goat serum was dropped 
onto tissue for 15-20 minutes. Primary antibody was diluted at 1:100 in the protein block and 
50µL of each primary was added to each slide and allowed to incubate overnight at 4°C. The 
following day, slides were washed 3 times with PBS, and 4+Biotinylated Goat Anti-Rabbit 
secondary antibody was added for 10 minutes and then washed again 3 times in PBS for 3 
minutes. HRP conjugated 4+ Streptavidin was added and incubated for 10 minutes, followed 
by 3 PBS washes for 3 minutes. Slides were rinsed once with PBS/Brij (pH 7.6) and then 
incubated with DAB for 5-10 minutes while monitoring the reaction under the microscope for 
optimal color. Samples were then washed for dH2O 3 times for 3 minutes and once with 
dH2O/Brij. Slides were counterstained with Gill’s #3 hematoxylin for 5-15 seconds, followed 
by a drop of PBS for one minute to darken the hematoxylin. Slides were then washed and 
dried and mounted using Universal Mount to preserve the tissue.   
Array CGH 
Genome wide profiling for chromosomal aberrations was investigated using 
Affymetrix Human SNP Assay 6.0. Over 946,000 probes were used to detect the copy number 
variation in our cell panel. The gDNA was extracted as previously described and the array 
was performed as per manufacturer’s instructions. In brief, 500ng of total gDNA with a 
concentration of 50ng/μL was used per sample. DNA was digested with Nsp I and Sty I 
restriction enzymes, ligated to adaptors and a primer that recognizes the adaptor sequence 
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amplified the DNA fragments. PCR was used to amplify fragments in the 200 to 1100bp size 
and the PCR products for each restriction enzyme were combined and purified using activated 
beads. The amplified DNA was then fragmented, labeled and hybridized to the array. This 
array was then scanned by the GeneChip Scanner 3000 7G system. 
Gene expression array 
Total RNA was isolated from DDLPS cell lines and xenograft tumor tissue as 
previously described in RNA isolation and purification. The total RNA was converted into 
cRNA (Illumina TotalPrep Amplification Kit, Ambion). Samples were hybridized to the HT-
12 Version 4.0 Illumina Chip. Gene expression analysis was performed on samples.  
Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, www.ingenuity.com) was 
utilized to analyze the gene expression array results and reveal which pathways were affected 
by SAR405838 on the mRNA of DDLPS cells and DDLPS xenograft models. Only the 
significantly (p < 0.05) up- and down regulated expressed genes compared to controls (Fold 
change 2.0) were selected for consideration and imported into the software for analysis. These 
genes were associated to the canonical pathways in which they enriched. 
Reagents for experimental procedures 
Nutlin-3a, an MDM2 small-molecule inhibitor, was purchased from Caymen 
Biochemicals. Nutlin-3a was suspended in DMSO for a stock solution of 10mM and stored at 
-20°C. MI-219, and SAR405838 were provided by Sanofi-Aventis (Paris, France). For in vitro 
studies, MI-219, and SAR405838 were suspended in DMSO for a stock solution of 10mM 
and stored at -20°C. For in vivo studies, the following calculations and protocol were 
performed to prepare SAR405838: 
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Preparation for 2mL solution at 20mg/mL 
Density: TPGS=0.947-0.951 PEG=1.127 
1. Weigh 40mg of drugs substance 
2. (1960μL) 2208.92mg PEG200 then vortex 30seconds + ultrasonication 1 minute. 
(vortex and sonicate to repeat if needed) 
3. Add (40μL) 37.95mg TPGS (after melting at about 50°C) then vortex 30 seconds 
+ ultra-sonication 1 min (vortex and sonicate to repeat if needed). If TPGS 
becomes solid during mixing, heat the mixture. 
Cell proliferation analysis 
Cell proliferation was measured via MTS assay using the CellTiter96 Aqueous Non-
Radioactive Cell Proliferation Assay Kit (Promega, Madison, WI, USA) per manufacturer’s 
instructions. Cells were seeded in 96-well plates at 1,500 cells per well in 100μL of media and 
allowed to adhere overnight. Media was then replaced in each well and cells were exposed to 
inhibitors as determined per experiment. At the end of each finalized incubation time point, 
20μL of MTS (Sigma Aldrich) was added to each well and incubated for 2-4 hours at 37°C. 
The absorbance of each well was read at 490 nm (Beckman Coulter, Miami, FL, USA).  The 
cell proliferation was calculated by subtracting the absorbance level from the mock or control 
wells containing no drugs or additives from the treated cell wells. The effective concentration 
for which growth was inhibited by 50% by a certain drug (EC50) was determined using BioStat 
Speed software. All experiments were performed at least three times to obtain final values for 
statistics. 
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Cell cycle analysis 
Cells were exposed to variable conditions as determined per experiment for 48 hours. 
Following standard protocol, attached and floating cells in the media were collected and 
centrifuged at 1.2x103 RPM for 3 min. The media was aspirated and cells were washed twice 
with ice-cold PBS and centrifuged for 3 min at 1.5x103 RPM. The cell pellet was resuspended 
and fixed in 70% EtOH at 4°C overnight. The following day, cells were centrifuged at 2500 
RPM for 5 minutes, and excess ethanol was aspirated. Cell pellets were resuspended in 400-
500μL of Propidium Iodide staining containing 10ug/mL RNase for 2 h in the dark prior to 
flow cytometry analysis of DNA content.  The results were read using Flow Cytometry 
(channel FL-2A, and histograms of cell numbers vs. linear integrated red fluorescence were 
recorded for a minimum of 10,000 nuclei at flow rates no greater than 30 to 50 events per 
second. 
Annexin V/ FITC FACs analysis for detection of apoptosis 
Apoptosis was measured using the Apoptosis Detection kit 1 (BD Pharmagen, San 
Diego, CA, USA) per manufacturer’s instructions. Following standard protocol, cells were 
exposed to variable time and dose conditions as indicated experiment for 96 hours. Floating 
and attached cells were harvested and centrifuged at 2x103 RPM for 2 minutes. Cell pellets 
were resuspended in 100μL of 10% binding buffer and fixed with 5 μL Annexin V/FITC (BD 
Pharmagen, San Diego, CA, USA) and 5 μL propidium iodide (Sigma Aldrich Co.) per 
sample. FACScan (Becton Dickinson) was used to analyze samples by emitting excitation 
light at 488 nm. CellQuest software (Becton Dickinson) was used to analyze data.  
siRNA knockdown 
Small-interfering RNA (siRNA) targeting MDM2 (SMARTpool: ON-TARGETplus 
MDM2 siRNA, #L-003279-00-005), p53 (SMARTpool: ON-TARGETplus p53 siRNA, # L-
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003329-00-0005), and non-targeting control (ON-TARGETplus Non-targeting siRNA #1, 
#D-001810-01-20) were purchased from Dharmacon. siRNA was resuspended in 5X siRNA 
Buffer (Dharmacon) to a 20 nmol final concentration and kept at -80°C. In brief, 2.5x105 cells 
per well were seeded in 2mL of media in a 6-well plate and allowed to adhere overnight. The 
next day, the media was aspirated and siRNA was transfected into DDLPS cells using 
Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) according to the manufacturer’s 
instructions. In brief, (described for a 24-well format and scaled per experiment as 
manufacturer describes) each transfection sample was prepared as followed: 20pmol siRNA 
oligomer was diluted in 50µL of Opti-MEM Reduced Serum Medium without serum (Opti) 
(Life Technologies) and mixed gently. 1µL of Lipofectamine2000 was diluted in 50µL of 
Opti and incubated for 5 minutes at room temperature. Following this incubation, the diluted 
Lipofectamine/2000 and siRNA/Opti suspensions were mixed together and incubated for 20 
minutes at room temperature. The final mixture was then added carefully to each well 
containing the cells and medium and incubated at 37°C for knockdown. siRNA knockdown 
was confirmed via western blot analysis.  
Pharmacokinetics 
Groups of 6-week-old female BALB/c nude mice were given 100, or 200 mg/kg body 
weight of SAR405838 orally into Lipo863 tumor bearing xenografts. Blood samples were 
taken at 6, 24, 48 and 72 hours post treatment. Just after sacrifice of the animals with O2/CO2, 
the blood is taken by intraocular puncture and transferred into heparinazed tubes. The plasma 
is collected (BD Pharmagen, San Diego, CA, USA) after 3 minute centrifugation at 7600g at 
4°C. The tubes with plasmas are frozen at -20°C. For each tumor a piece of 50mg is collected 
for the RNA measurements, this piece is sliced thinly and put in an eppendorf tube containing 
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1.5ml RNA later (Qiagen). After 24h at 4°C, these samples are stored at -20°C. The rest of 
the tumor is cut into 100mg pieces and placed into a Precelly’s tube (Precelly’s tubes ref: 
03961-1-007) where they are immediately frozen at -80°C (on dry ice) and then stored at -
80°C. 1 tube was reserved for PK studies. Samples were shipped to Sanofi Aventis at -80°C 
for analysis. Plasma (100 µL) was submitted to an organic extraction with 300 µL ACN 
supplemented with 2H5-SAR405838 as internal standard.  
DDLPS xenograft models 
Female Balb/c nude SCID mice were purchased from Charles River Laboratories 
International, Inc. and housed in pathogen free conditions as per The University of Texas MD 
Anderson Cancer Center and Institutional Animal Care and Use Committee (IACUC) 
regulations. Animals received humane care as per the Animal Welfare Act and the NIH 
“Guide for the Care and Use of Laboratory Animals”.  For tumor growth studies, 2-3.5x106 
cells were injected subcutaneously and tumor size was monitored 2-3 times a week until the 
study was terminated. 5-10 mice per group were used per study. Once palpable tumors formed 
after approximately two weeks, mice were randomized into vehicle control or SAR405838 
treatment arms (concentrations designated per experiment, ranging from 50-200 mg/kg). 
Tumors were resected, weighed, and either snap-frozen in liquid nitrogen or paraffin 
embedded for sectioning and staining once the experiment was terminated. 
Statistical analysis 
Each cell culture assay was performed in triplicate and standard error mean (SEM) 
was calculated.  Statistical analysis was performed using the GraphPad Prism 6.01 Software 
(La Jolla, Ca, USA). Specific tests of significance were detailed in figure legends. When t-
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tests were performed, they were unpaired and two-tailed. Significance for cell culture based 
assays was set at: p<0.05 =*; p<0.005 = **; and p< 0.0001 = ***.  
For in vivo experiments, the average volume (mm3) and SEM for all group variables 
per study were calculated and recorded. A two-sample t-test was used to assess the differences 
of an outcome at a single time point. Xenograft growth was assessed using a two-tailed 
Student’s t-test. Significance was set at p ≤ 0.05. 
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CHAPTER 3. RESULTS: CREATION AND CHARACTERIZATION OF 
DEDIFFERENTIATED LIPOSARCOMA BIORESOURCES 
 
SECTION 1. CREATION OF DEDIFFERENTIATED LIPOSARCOMA EXPERIMENTAL TOOLS 
 
Perhaps the most impeding obstacle in DDLPS research is the lack of commercially 
available bioresources. Due to this limitation, we created stable cell lines and reproducible 
xenograft models in our lab that made the following studies possible.  
Generation of patient derived DDLPS cell lines 
Cell lines that accurately represent DDLPS molecular features have been difficult to 
establish. Currently, there is only one ‘DDLPS’ cell line commercially available through the 
American Type Culture Collection (ATCC): SW872. However, SW872 fails to accurately 
represent established DDLPS characteristics; SW872 lacks MDM2 amplification and has a 
mutated p53 (c.752 T > A). Consequently, our first goal towards studying DDLPS was to 
establish cell based models derived from patient samples that recapitulate clinical features. 
Towards this goal, we have generated a protocol that efficiently generates DDLPS cell 
lines in culture as explained in the materials and methods. To date we have created >50 
primary human DDLPS cell line cultures, of which 10 are successfully passaged beyond 50 
times. It was these 10 cell lines that were used as our cell line panel to represent DDLPS for 
the following studies. The cell lines that make up our DDLPS cell line panel are listed in 
Table 3.1. 
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Table 3.1 Characteristics of DDLPS cell lines frequently used for cell line panel. Cell 
lines created at the UTMDACC Sarcoma Research Center from primary patient tumors.  
Name Histology Primary/Recurrent tumor Tumor location 
Lipo224 DDLPS primary retroperitoneum 
Lipo224B DDLPS recurrent retroperitoneum 
Lipo246 DDLPS recurrent, secondary mesentery 
Lipo863 DDLPS recurrent retroperitoneum 
Lipo573 DDLPS recurrent, secondary mesentery 
Lipo815** DDLPS recurrent retroperitoneum 
Lipo615 DDLPS recurrent groin 
Lipo984 DDLPS recurrent, secondary retroperitoneum 
LipoDL635 DDLPS primary retroperitoneum 
Lipo318 DDLPS recurrent, secondary retroperitoneum 
**Indicates tumors cells believed to be isolated from a well-differentiated component of a 
DDLPS. 
 
Conservation of molecular characteristics  
Once we were successful in growing disaggregated tumor cells in culture, it was 
critical to ensure that the molecular characteristics of the tumor from which the cell line was 
derived were retained. Therefore, prior to experimental use DDLPS cells were confirmed and 
characterized. 
As previously explained, certain unique molecular characteristics are useful to classify 
each subtype of LPS, specifically, it is the MDM2 amplification in DDLPS that serves as the 
biomarker for histological classification13,51. In WD/DDLPS diagnosis, fluorescence in situ 
hybridization (FISH) studies are frequently performed on samples to reveal the amplification 
of the 12q13~15 region51 and, as a result, a differential diagnosis can be made  between 
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WD/DDLPS and benign lipomas, as well as other high-grade sarcomas51. In normal cell 
biology, two red (fluorescent probe for 12q13~15 segment) and two green (fluorescent 12q 
centromeric probe) signals should be seen per cell representing a single copy of MDM2 per 
chromosome, as marked by the centromeric probe. In tumor cells, multiple red signals indicate 
multiple copies of the 12q13~15 chromosomal region and multiple green signals indicate 
cellular polysomy. Therefore, initial studies to confirm MDM2 amplification were performed 
on our primary cell cultures using FISH; MDM2 amplification was defined as a ratio of 
MDM2/CEP12 ≥ 2.1 per 100 tumor cells. FISH images for each cell line in our LPS cell panel 
are represented in Figure 3.1. MDM2 amplification was observed in each of our DDLPS cell 
lines, but was not amplified in the three LPS cell lines SW872 (unclassified LPS), PLS1 (PLS) 
and LISA2 (PLS), deemed “control cells” in this body of work.  
Although FISH was used primarily for conformational purposes, we observed that the 
percent of MDM2 amplified cells corresponded to the potential cell line establishment 
capability of the primary tissue culture. We observed that if a primary culture had >80% 
MDM2 amplification it was able to progress from a primary cell strain to a reproducible cell 
line. While this is trend was not fail-proof, MDM2 amplification is associated with progression 
towards malignant phenotype; therefore, it is possible that this amplification influences a 
cell’s in vitro growth capability.  
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Figure 3.1 Fluorescence in situ hybridization (FISH) for the detection of MDM2 
amplification in cell panel. The MDM2 gene is amplified in each DDLPS patient-derived cell. 
Multiple copies of MDM2 (red probe) are seen compared to the CEP12-(green probe) per cell, 
therefore determined as positive for MDM2 amplification. Amplification is not seen in the 
three control liposarcoma cells SW872, PLS1 and LISA2.  
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Further characterizing these cells, we began with the most obvious molecular 
deregulation: MDM2 amplification and expression in our cell panel. Although MDM2 levels 
can be estimated using the FISH technique, the probe is not MDM2 specific and, instead, 
probes for a portion of the 12q15 chromosomal region that overlaps the MDM2 locus. In order 
to determine the level of MDM2 amplification, we performed qRT-PCR to quantify the 
genomic level of MDM2 in our cells. In this short panel, we compared 10 DDLPS cell lines 
to adipose-derived human mesenchymal stem cells (hMSC-AT) which was used as the 
control. Our data demonstrates that the genomic MDM2 levels, while variable (4.41 to 
194.91), are without a doubt amplified in our DDLPS cell lines (Figure3.2A). Nevertheless, 
amplification does not necessarily mean that the gene will be expressed; therefore, our next 
step was to investigate the level of expression produced by the amplification. qRT-PCR and 
western blot assays were performed to determine the relative MDM2 expression levels at 
mRNA and protein level, respectively. As demonstrated in Figure 3.2B/C, MDM2 was not 
only amplified, but also highly expressed in our DDLPS cell lines. Interestingly, while the 
degree of amplification and expression varied in our panel, we observed a trend between the 
level of amplification and expression.  
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Figure 3.2 MDM2 is amplified and overexpressed in human DDLPS. A) qRT-PCR 
analysis of the genomic levels of MDM2 in DDLPS. B) MDM2 mRNA expression in LPS 
cell panel. C) Western blot of MDM2 protein expression in LPS panel.  
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TP53 mutational analysis 
DDLPS is a disease that retains WT p53; therefore, it was critical to determine the p53 
status in our DDLPS cell line panel and confirm that p53 was not mutated. Sequencing was 
performed to examine mutations in exons 5-9 of the p53 gene. From the sequencing results, 
no mutations were found and; therefore, were deemed p53 WT. The LPS cell line SW872 was 
confirmed for p53 mutations; PLS1 was determined p53 null, and LISA2, retained a WT p53 
status but lacked MDM2 amplification. These three non-DDLPS adipogenic-derived tumor 
cells (SW872, PLS1, and LISA2) were used concurrently throughout or studies to compare 
the results to cell lines with varying p53 and MDM2 status. 
 
 
Figure 3.3 MDM2 and p53 protein expression in LPS panel. Western blot analysis of 
MDM2 and p53 in our LPS panel. 
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Development of DDLPS xenograft models 
Developing xenograft models that faithfully recapitulate the clinical and molecular 
characteristics of DDLPS have proven to be a challenge; however, the ability to grow patient-
derived cells in a xenograft model system offers a multitude of advantages to cell culture based 
assays. To that end, we generated a protocol to create DDLPS xenograft models to determine 
the tumor forming competence of our patient derived cell lines, which is well described in the 
materials and methods. To date, we have not successfully developed a WDLPS cell line 
derived xenograft model; however, while it was not relevant to this body of work, there have 
been reports that a WDLPS model is possible181.  
For each cell line, we observed the latency period required to establish a palpable 
tumor. The two most reproducible DDLPS tumor-establishing cell lines are Lipo246 and 
Lipo863. While all of our DDLPS cell lines successfully established tumors in mice, they 
grew much slower and did not generate consistent tumors as dependably as Lipo246 and 
Lipo863. The latency of Lipo246 (14 days) and Lipo863 (24 days) allowed us the ability to 
estimate when an established tumor will be ready for further investigation, such as for 
evaluation of therapeutic response. The importance of establishing this type of model allowed 
us to determine which cells were able to be utilized as reproducible in vivo models providing 
us the ability for enhanced investigations to test tumor progression as well as test the efficacy 
of novel drugs. 
Preservation of DDLPS histopathology in xenograft models 
It is important that our xenograft models preserved the histopathology of DDLPS; 
therefore, tumors were resected once they reached a size of 1.5cm in dimension in order to 
evaluate the morphology. From our resected tumor samples we found that our mouse models 
retained DDLPS features observed in patient sample (amplification of MDM2; Figure 3.4).  
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Figure 3.4 Histological analysis of DDLPS tumors from patients and mouse 
xenografts. This histology of patient tumors (Patient) is recapitulated in the xenograft tumors 
(Xenografts). H&E staining representing the tumor morphology as well as 
immunohistological staining using antibodies against MDM2 demonstrate that the model 
represents the clinical features. (DDLPS tumor picture courtesy of Dr. Kristelle Lusby; 
University of California, Irvine Medical Center. 
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SECTION 2. CHARACTERIZATION OF DEDIFFERENTIATED LIPOSARCOMA CELL LINES  
Genomic profiling by array CGH analysis of DDLPS cell lines 
In order to investigate patterns of genomic aberrations in our DDLPS cell line panel, 
a genome wide, high resolution analysis of copy number variations (CNVs) was performed 
using array comparative genomic hybridization (aCGH:SNP Array 6.0 – Affymetrix 
platform). More than 946,000 probes were used for the detection of CNVs, thus, providing 
maximum panel power and the highest physical coverage of the genome. Our goal was to 
observe the CNVs acquired in order to enhance our understanding of genomic alterations 
associated with dedifferentiated liposarcomagenesis.  
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Figure 3.5 Copy number variations in DDLPS cell lines. The heatmap represents a 
genome wide, high-resolution analysis of CNV. More than 946,000 probes for the 
detection of CNV were utilized to provide maximum power and the highest physical 
coverage of the genome. Significant differences have been determined for DNA copy 
number fold changes between mesenchymal stem cells and 10 DDLPS cell lines. 95 
genes where CNV is significantly different in >50% of DDLPS cell lines compared 
with mesenchymal stem cell controls. The blue coloring represents genes that are lost, 
while the red coloring represents genes that are amplified.  
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CNVs were analyzed in 10 DDLPS cell lines (Lipo224A, Lipo224B, Lipo246, 
Lipo815, Lipo863, LPS141, Lipo318, Lipo573B, Lipo615, and Lipo984) and compared to 
two human adipocyte derived mesenchymal stem cells (hMSC-AT) from two different 
patients as controls. CNV changes were observed across the whole genome and the circos plot 
(Figure 3.5) visualizes the chromosomal location of the amplified/deleted genes; for example, 
the amplifications seen in chromosome 12q are made obvious by the red coloration displayed 
on the plot. We then wanted to know which genes are the most significantly altered due to 
these genetic aberrations. In order to assess these differences numerically we assigned each 
gene a score. This score corresponds to the largest absolute copy number difference between 
a liposarcoma cell line and he mean of the two mesenchymal samples per gene. To identify 
genes with significant copy number differences, we implemented a two-sample t-test per 
genes. The heatmap in Figure 3.6 visually represents the copy numbers of the top 95 genes 
significantly differentiated in >50% of DDLPS cells compared to controls. Of these 
significantly up-regulated genes 39% of these were located in the 12q13~15 loci. The 12q21 
loci harbored 17% of up-regulated genes, followed by the 5p chromosomal loci that harbored 
13% of the most statistically significant genes. The most significant regions of CNVs lost 
were located at 11q23~24 (26%) and 11p15 (15%) (1.5 fold-change in at least 50% of cells). 
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Figure 3.6 Circos plot depicting copy number in the genome. Circos plot 
summarizes all CNV regions detected in our DDLPS cell lines and control samples; 
plot runs clockwise from chromosome 1 to X. The plot represents several tracks; 
the two innermost tracks represent the two hMSC-AT controls, while the following 
represent DDLPS samples. CNV regions are visualized by color, red representing 
multiple copies.  
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Significant gains in the chromosomal 12q13~15 loci were to be expected. The 
cumulative copy number plot in Figure 3.7 provides visualization of the physical location (x-
axis) and copy number (y-axis) of the amplifications (green color) and deletions (red color) in 
chromosome 12 for all combined DDLPS cell lines. However, this is a discontinuous 
amplification in which the specific gene amplification frequency varies. The graph in Figure 
3.7 represents genes located in chromosome 12q13~15 and their amplification frequency 
observed. MDM2, which is highlighted, is up-regulated in 100% our cells.  The top 95 genes 
where CNV is significantly different in >50% of DDLPS cell lines compared with 
mesenchymal cell lines is listed in Appendix A. 
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Figure 3.7 The 12q13~15 amplification in DDLPS cell lines.  The top panel 
demonstrates the frequency of amplified genes in chromosome bands 12q13~15 loci. The 
amplifications are distinguished by color as green represents amplification and red represents 
deletion in copy numbers. The bottom panel graphically visualizes the amplification 
frequency of genes located in the 12q13~15 loci detected in DDLPS cells. MDM2 has been 
highlighted.  
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While the focus of this body of work is mainly concerned with the amplification and 
expression of MDM2, this analysis suggests additional genomic regions that might be 
important for DDLPS tumor biology. 
Identifying differential gene expression patterns in DDLPS cell lines 
The goal of this analysis was to detect differentially expressed mRNA in DDLPS cell 
lines compared to control cells. Data was acquired using the Illumina HT-12 v4 BeadChip 
assay from 10 DDLPS cells lines and 6 controls (2 hMSC-AT, 2 pre-adipocyte cell lines, and 
2 adipocyte cell lines).  
To identify differentially expressed genes between these two groups, modified 2-
sample t-tests were performed. The obvious segregation of the differentially expressed genes 
between our panel of DDLPS cell lines and controls is visualized by the heatmap in Figure 
3.8. This heatmap represents the 602 significantly differentially expressed genes (FDR 0.05, 
fold change >2.0, ± 2 STD). The red coloring represents genes that are over-expressed in 
DDLPS cell lines, while the blue color represents the genes that are under-expressed. These 
results demonstrate that the differential probes can clearly differentiate between the two 
groups, as well as demonstrate consistency within each group. The differential genes with the 
strongest statistical significance between DDLPS and controls are listed in Appendix B. 
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Figure 3.8 Differentially expressed genes between DDLPS cell lines and controls. 
Heatmap of the 602 most differentially expressed genes selected at a FDR 0.05 and fold 
change > 2.0. The expression values shown on the heatmap have been standardized ± 2 STD. 
Red color represents genes over-expressed; blue color represents genes under-expressed in 
DDLPS cell lines compared to controls.   
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We then wanted to investigate what pathways these gene expression profiles were 
modulating. To answer this question, Ingenuity Pathway Analysis (IPA; www.ingenuity.com) 
was utilized to analyze the up- and down-differentially expressed genes from our microarray. 
Our results revealed that these genes enriched many signaling pathways involved in 
chromosomal instability, cell cycle control and proliferation. Figure 3.9 graphs the top 15 
canonical pathways with the highest estimated probability of involvement from our gene set. 
The red bars represent the percent of genes that are up-regulated in our cells in that specific 
pathway, while the green bars represent the percent of down-regulated genes.  
Figure 3.9 Canonical signaling pathways modulated in DDLPS. The graph represents the 
pathways that were significantly different between DDLPS cell and controls. X axis, the name 
of the pathway; Y axis, the negative logarithm of the P value (-logP). The graph is 
distinguished by color; red represents genes in pathway that are up-regulated, green represents 
genes down-regulated 
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CHAPTER 4. RESULTS: THE MDM2:P53 AXIS IS A TARGETABLE 
THERAPEUTIC STRATEGY IN DEDIFFERENTIATED 
LIPOSARCOMA 
 
The main goal of my study herein was to evaluate the potential anti-DDLPS effects of 
SAR405838 in the pre-clinical context. 
 
SECTION 1.  TARGETING THE MDM2:P53 AXIS IN VITRO 
SAR405838 inhibition stabilizes p53 and activates downstream targets 
Prior to determining the effects on DDLPS tumor growth and survival, we first 
confirmed that SAR405838 truly activated the p53 pathway and gave forth to formerly 
observed results. In previous studies, the small-molecule MDM2 antagonists Nutlin-3a and 
MI-219 were successful in activating the p53 pathway in tumor cells that retain WT p53, but 
not in cells which the transcriptional properties of p53 have been mutated167. Therefore, these 
drugs were used to anticipate and confirm expected results elicited by SAR405838 in our LPS 
cell panel. Our cell panel consisted of 8 LPS cell lines: five DDLPS cells that exemplified 
MDM2 amplification and WT p53 (Lipo224, Lipo246, Lipo863, LPS141, and Lipo815), and 
three PLS cell lines which had either WT p53, but lacked MDM2 amplification (LISA2), 
mutated p53 (SW872) or p53 null (PLS1). The latter three cell lines were deemed “controls” 
for this study. 
To confirm that SAR405838 in fact hit its target (i.e. activated p53) we tested our cell 
panel first with Nutlin-3a and MI-219; DDLPS cells were incubated with incremental drug 
doses (0-10µM) of these for 24h. As shown by western blot analysis (Figure 4.1), p53 was 
stabilized and activated in a dose-dependent manner following incubation with these MDM2 
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inhibitors. Two p53 transcriptional targets, p21 and MDM2, confirmed the transcriptional 
activity induced by p53 stabilization in DDLPS cell lines (Figure 4.1). Following suit, we 
evaluated the activation of p53 when incubated with SAR405838. Again, we treated our cell 
panel with incremental doses (0-10µM) for 24h (Figure 4.2). Similar to our previous results, 
SAR405838 treatment resulted in a dose-dependent effect on p53 and downstream targets; 
however, no effect was seen in the control cell lines, as expected. Compared to Nutlin-3a and 
MI-219, SAR405838 induced p53 activity at lower doses (0.1nM versus 5µM and 1µM, 
respectively), as demonstrated in the increase in MDM2 and p21. Together, these results 
confirmed the initial evidence that SAR405838 induced p53 activity in DDLPS cell lines. 
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Figure 4.1 MDM2 antagonists stabilize p53 and induce the p53 pathway in DDLPS 
cells. Treatment of cultured LPS cells with MDM2 antagonists lead to concentration-
dependent accumulation of p53 protein and its transcriptional targets, MDM2 and p21. Protein 
levels were analyzed by western blot analyses following 24h incubation with the indicated 
MDM2 antagonist. 
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Figure 4.2 SAR405838 stabilizes p53 and induces the p53 pathway in WT p53 DDLPS 
cells. Treatment of cultured LPS cells with SAR405838 led to concentration-dependent 
accumulation of p53 protein and its transcriptional targets, MDM2 and p21. A) p53 activation 
was observed all DDLPS cell lines. B) No effect was seen in control cell lines SW872 or 
PLS1. Protein levels were analyzed following 24 hour incubation with SAR405838. 
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SAR405838 inhibits DDLPS cell growth 
Further investigating the biological implications of SAR405838 in the cellular context 
of DDLPS, we evaluated the effects of MDM2 inhibition on cell growth. First, we incubated 
two exponentially proliferating DDLPS cells, Lipo246 and Lipo863, with each MDM2 
inhibitor for 96 hours and evaluated the consequential effect on cell growth via MTS assay. 
In order to institute the effective dose in which 50% of cell proliferation was abrogated (EC50), 
values of each inhibitor were calculated (Table 4.1). We found that while all drugs were 
capable of inhibiting cell proliferation, SAR405838 more potently abrogated cell growth as 
demonstrated by the lower EC50 values following SAR405838 compared to Nutlin-3a and MI-
219 in both cell lines (Figure 4.3).  
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Figure 4.3 Small molecule MDM2 inhibitors produce anti-proliferative effects. 
MDM2 antagonists Nutlin-3a, MI-219, and SAR405838 result in a dose-dependent inhibition 
of cell growth and viability. Lipo246 (left panel) and Lipo863 (right panel) were treated with 
each inhibitor for 96 hours and cell viability was measured via MTS assay. (Graphs represent 
n=3 ± SEM). 
 
 
TABLE 4.1 EC50 VALUES FOLLOWING TREATMENT WITH MDM2 
Mean EC
50 
(µM) 
Inhibitor Lipo246 Lipo863 
Nutlin-3a 2.90 2.75 
MI-219 2.34 3.03 
SAR405838 0.31 0.49 
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SAR405838 was then tested in each cell line of our cell panel. Following 96 hour 
incubation with SAR405838, each DDLPS cell line exhibited a dose-dependent, anti-
proliferative response; however, there was no effect on proliferation in the control cell lines 
at the concentrations tested (Figure 4.4). For each cell line, the EC50 value in response to 
SAR405838 treatment at 96 hours was calculated (Table 4.2). Also from these results, we 
inferred that SAR405838 not only required functional, WT p53, but also amplified MDM2 
expression as LISA2, which retains WT p53 but lacks MDM2 over-expression, was not 
affected by the inhibitor. 
 
 
Figure 4.4 SAR405838 elicits anti-proliferative effects in DDLPS cell line panel. The 
cytotoxicity of SAR405838 depends on the p53 status and MDM2 amplification. Cell lines 
were incubated with SAR405838 for 96h to determine the anti-proliferative effects. Cellular 
viability was measured by MTS assay. (Graphs represent n=3 ± SEM). 
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Mean EC
50
 
Cell line SAR405838 (µM) 
Lipo246 0.31 
Lipo224 0.31 
LPS141 0.13 
Lipo863 0.49 
Lipo815 0.37 
SW872 >10 
LISA2 >10 
PLS1 >10 
Table 4.2 EC50 values following SAR405838 treatment. Table representing the EC50 values 
of each cell line in our panel following 96h incubation with SAR405838 calculated with 
BiostatSpeed software. Control cell lines had an unmeasurable EC50 value with the 
concentrations tested. 
 
Wild type p53 is required for effective anti-DDLPS SAR405838 effects 
 Following these initial experiments, we wanted to validate that WT p53 was 
mandatory for the effects induced by SAR405838. Thus far, our results revealed that 
SAR405838 was not effective in inducing p53 activity effects in our cells with mutated/null 
p53 or when MDM2 was not amplified; therefore, to address this question, we used siRNA to 
transiently knockdown p53 in Lipo246 cells. Lipo246 parental mock and a non-targeting 
siRNA were used as controls. Following transient deletion (24h), Lipo246 cells were 
incubated with DMSO, SAR405383 (3µM) and Nutlin-3a (5µM) for 24 hours and protein 
expression level was evaluated. Compared to Lipo246 controls, the depletion of p53 resulted 
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in complete ablation of both MDM2 antagonists’ abilities to activate p53 and transcribe 
downstream targets, as seen in the western blot (Figure 4.5A). We then tested the anti-
proliferative effects of SAR405838 in response of p53 silencing. Our results confirmed that 
when p53 is eliminated, SAR405838 is unable to induce the anti-proliferative effects (Figure 
4.5B). 
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Figure 4.5 SAR405838 efficacy is dependent on the presence of WT p53. siRNA p53 
knock out in Lipo246 depleted the ability for SAR405838 to stabilize p53 and activate p53 
pathway functions. A) Western blot analysis confirmed p53 knockdown and showed that the 
expression of downstream p53 transcription targets, MDM2 and p21, was not increased when 
treated with MDM2 antagonists. B) p53 knock out eliminated the anti-proliferation effects of 
SAR405838.  
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Activation of the p53 pathway halts cell cycle progression 
One of the main functions of p53 is to regulate cell cycle progression and protect cells 
from advancing through cell division. p21 is a transcriptional target of p53 and one of the 
main proteins responsible for inducing cell-cycle arrest. As previously observed (Figure 4.2), 
p21 was increased following SAR405838 treatment in DDLPS cells, suggesting that p53 is 
active and inducing target genes in the p53 pathway. Additionally, we observed that in all 8 
DDLPS cells, p21 was highly expressed following incubation with 1µM of SAR405838. 
Therefore, utilizing these results, we chose two concentrations for cell cycle analysis: 1µM 
and 3µM.   
Exponentially proliferating cells were incubated for 48 hours with each inhibitor 
(Figure 4.6) and the cell cycle distribution was assessed by flow cytometry. Our results 
revealed that SAR405838 successfully induced cell cycle arrest in all DDLPS cell lines. While 
the G1 and G2 arrest varied amongst cell lines, the average G1 fraction reduced from 57.29% 
to 53.28% and the G2 fraction increased from 16.55% to 33.55%. Also, the S-phase fraction 
decreased from an average of 26.15% to 13.15%. The variation observed between cells is 
likely due each cell’s innate proliferation rate and cycling time. Furthermore, there was a 
significant and sub-G1 fraction observed in DDLPS cells following SAR40838 treatment 
indicating possible apoptosis. Again, there was no effect on cell cycle progression in the 
control cell lines (Figure 4.7).  
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Figure 4.6 Inhibition of the MDM2:p53 complex induces cell cycle arrest. Treatment 
with Nutlin-3a (2.5, 5μM), MI-219 (1, 3μM), and SAR405838 (1, 3μM) for 48h resulted in 
G1/G2 cell cycle arrest in DDLPS cells. Graphs represent the average of triplicate experiments 
± SEM. 
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Figure 4.7 SAR405838 induces cell-cycle arrest. Treatment with SAR405838 (1, 
3μM) for 48h resulted in G1/G2 cell cycle arrest in DDLPS cells. No change in the different 
cell cycle phases was seen in control cells (SW872 and PLS1). Graphs represent the average 
of triplicate experiments ± SEM. 
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SAR405838 induces p53 apoptotic response  
While the transcriptional activity of p53 controls both cell cycle arrest and induction 
of apoptosis, they are regulated by different downstream pathways and in certain 
circumstances p53 may opt to trigger apoptosis. Therefore, we wanted to see if SAR405838 
potently induced apoptosis in DDLPS cells.  
First, we evaluated the ability of SAR405838 to mimic Nutlin-3a and MI-219 induced 
apoptotic effects in Lipo246 and Lipo863 cell lines. We observed that SAR405838 was 
successful in penetrating cells and inducing cell cycle arrest at 1 and 3µM; however, due to 
the increase of MDM2 expression observed at previously with lower doses, as well as the 
EC50 values previously established, we chose two lower concentrations (0.1 and 0.3µM) to 
determine the apoptotic response following SAR405838 (Figure 4.8). We treated 
exponentially proliferating cells with each inhibitor for 96 hours (SAR405838: 0, 0.1, 0.3µM; 
Nutlin-3a: 0, 1, 2.5µM; and MI-219: 0, 0.1, 0.3µM). Coinciding with our results from the 
MTS assay and EC50 vales, SAR405838 induced marked, dose-dependent apoptosis after 96 
hour incubation and to a much higher degree than Nutlin-3a and MI-219 after the same amount 
of time as determined via Annexin V/PI staining FACS analyses. In Lipo246 cells, Nutlin-3a 
induced significant apoptosis (27.19%) after incubation with 2.5µM treatment; however, after 
only 0.3µM, SAR405838 induced 30.88% apoptosis (p<0.05). Lipo863 cells resulted in 
28.99%, 11.92% and 24.12% apoptosis with the highest dose each drug of Nutlin-3a, MI-219 
and SAR405838, respectively. Interestingly, we found that in both cell lines, MI-219 did not 
induce apoptosis, neither between control treatment and MI-219 treatment, nor between each 
dose (Figure 4.8). 
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Figure 4.8 Inhibition of the MDM2:p53 complex induces apoptosis. Treatment with 
Nutlin-3a (1.0, 2.5μM), MI-219 (0.1, 0.3μM), and SAR405838 (0.1, 0.3μM)  for 96h resulted 
in a dose-dependent increase in apoptosis following incubation with small molecule  MDM2 
inhibitors compared to control treatment (DMSO) in DDLPS cells. Apoptosis was measured 
via Annexin V/PI staining and FACS analysis. Graphs represent the average of triplicate 
experiments ± SEM; * denotes statistically significant effects (p<0.05) 
 
 
We then investigated the apoptotic response in the rest of our cell panel. We incubated 
cells with DMSO, 0.1 or 0.3µM of SAR405838 for 96 hours and the percentage of apoptotic 
cells (Annexin V-positive portion) was determined via flow cytometry. Following 96 hours, 
all DDLPS cell lines displayed a dose-dependent apoptotic response as determined by the 
Annexin V-positive cells. Although Annexin V staining is generally regarded as an indicator 
for early apoptosis, 96 hours of treatment proved to be an adequate time for cells to commit 
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to apoptosis and account for the possible delayed response in cells. To further confirm that 
these results are due to p53-induced apoptosis, cleaved caspase-3 expression was evaluated 
following 96 hours with SAR405838 treatment observed via western blot (Figure 4.9).  
Taken together, these results demonstrate that MDM2 inhibition abrogated DDLPS 
cell proliferation through the induction of two p53 driven mechanisms: cell cycle arrest and 
apoptosis. 
 
 
 
Figure 4.9 Apoptotic response of DDLPS cells to SAR405838. A) DDLPS cells were 
treated with 0 (DMSO control), 0.1 or 0.3 µM of SAR405838 for 96 hours. Graph represents 
the average number of Annexin V –positive cells (n=3, ± SEM, *=p < 0.05).  
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Amplification of MDM2 corresponds to therapeutic response 
Based on our results from these initial experiments, we observed that when subjected 
to MDM2 antagonists, our p53 WT DDLPS cells varied in response. Although all cells 
showed marked anti-proliferation, cell cycle arrest and apoptosis following treatment with 
SAR405838, we wanted to further understand what might be the reason for these varied 
results. So, we looked into which cells had the strongest therapeutic response in each assay in 
an effort to find a common trend. We characterized these cells for MDM2 amplification and 
p53 mutational status (Table 4.3) and found that while each cell had amplified MDM2, the 
amplification varied between cell lines. Therefore we asked whether there was a potential 
correlation between MDM2 expression levels and therapeutic response. To address this 
question, we categorized our cell panel by their relative MDM2 expression level into two 
groups, MDM2HI or MDM2LO, and took a deeper look into our previous results. This analysis 
revealed that DDLPS cell lines expressing relatively higher amounts of MDM2 (Lipo246, 
Lipo224, LPS141) had a lower overall EC50 compared to the relatively low MDM2 cell lines 
(Lipo863, Lipo815) after 96h incubation with SAR405838 (0.25μM versus 0.43μM). 
Furthermore, MDM2HI cells induced a higher percent of apoptosis than that of the MDM2LO 
group (30.88% versus 24.12%) following 0.3µM SAR405838.  
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TABLE 4.3 RELATIVE MDM2 AMPLIFICATION; MDM2HI AND MDM2LO.  
Cell line p53 Status 
MDM2 copy 
number 
MDM2 mRNA 
level MDM2HI/LO 
Lipo246 TP53WT  194.10 106.6 MDM2HI 
Lipo224 TP53WT  65.25 44.81 MDM2HI 
LPS141 TP53WT 131.22 112.7 MDM2HI 
Lipo863 TP53WT  42.16 12.35 MDM2LO 
Lipo815 TP53WT 50.15 14.23 MDM2LO 
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SECTION 2. TARGETING THE MDM2:P53 AXIS IN VIVO  
Pharmacokinetics of SAR405838  
To study the tumor penetration and stability of SAR405838, we performed a 
pharmacokinetics (PK) study in Lipo863 tumor bearing mice. Plasma concentrations were 
measured from 0 to 72 hours in mice following a single oral dose of 100 or 200 mg/kg of 
SAR405838. The concentration-time data of SAR405838 is plotted (Figure 4.10); following 
administration, SAR405838 concentrations rapidly reached a maximum value (Cmax) at 
approximately 6 hours measuring 8200 ng/ML (at 100mg/kg) and 1630 ng/mL (at 200mg/kg) 
(Table 4.4). After 72 hours, all data were below the lower limit of quantitation (LLOQ) 
(5ng/mL) of the assay. The data demonstrates that drug accumulation was dose-dependent and 
at 200 mg/kg was almost 2-fold to 100 mg/kg administration. The AUC0-72 increased in a dose-
dependent manner was approximately twice as high with 200mg/kg dose versus the 100mg/kg 
dose. These results suggest that the Cmax and AUClast increase proportionally with the dose 
(Table 4.5). 
 
 
 
 
 
 
 
 
 
 
 103 
 
 
 
 Figure 4.10 Time-concentration profiles. Mean plasma concentration profiles 
following a single oral dose administration of SAR405838 (100 or 200 mg/kg).  
 
TABLE 4.4 SUMMARY OF PK PARAMETERS. 
 
 
TABLE 4.5 PK PARAMETERS RATIO VERSUS DOSE. 
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In order to better understand the concentration-effect relationship the relative gene and 
protein expression levels at each time point were assessed. Compared to vehicle, MDM2, p21 
and PUMA mRNA all peaked following 6 hours of SAR405838 treatment; minimal difference 
between the 100 and 200 mg/kg treatment was observed at 6 hours. The MDM2 protein 
expression peaked for both 100 and 200 mg/kg at 6 hours after dose and continued to persist 
at 48 hours at the 200mg/kg dose whereas the levels for 100 mg/kg quickly dissipated. p21 
followed a similar trend, between doses and retained its levels in 200mg/kg for 48 hours. 
proteolytic activation of caspase-3  increased in a dose and time dependent manner. Taken 
together, the effects of SAR405838 lead to p53 pathway activation in a as observed by the 
expression of p53 transcriptional targets (Figure 4.11).  
 
 105 
 
Figure 4.11 Expression levels from DDLPS xenograft models following SAR405838 
treatment. A) mRNA and B) protein expression levels of selected genes in response to time 
(6-72 h) and a single dose (vehicle, 100 and 200 mg/kg, p.o.) of SAR405838. Data represents 
mean ± STD, n=3.    
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SAR405838 elicits potent anti-DDLPS tumor growth effects in xenograft models 
In response to our cell-culture based results, we sought to evaluate whether the anti-
DDLPS effects of SAR405838 could be replicated in vivo. Towards that end, multiple 
therapeutic experiments were performed. In all therapeutic experiments, two DDLPS cell 
lines, Lipo246 (2.5 x 106 cells injected s.c.) and Lipo863 (3.5 x 106 cells injected s.c.), were 
utilized and injected subcutaneously into female Balb/c nude SCID mice.  
In our first therapeutic experiment we sought to evaluate the dose response following 
SAR405838 treatment. DDLPS tumor bearing mice received either vehicle control 
(TPGS/PEG200) or SAR405838 once a tumor was established (~5mm3). For Lipo863-tumor 
bearing mice, mice were grouped into four treatment arms and received oral administration of 
vehicle or bi-weekly (BIW) (100mg/kg) and weekly (100mg/kg and 200mg/kg) doses of 
SAR405838. However, due to the unexpected death of two mice in the bi-weekly group, the 
dose was reduced to 50mg/kg BIW for the remainder of the experiment. Vehicle and 50 
mg/kg/BIW treatment groups received a total of 7 weeks of treatment prior to termination, 
while the other two treatment groups continued dosage for an additional two weeks prior to 
termination as the tumor volume in these groups was very small. Upon termination, the tumor 
volume of each group was calculated. The average tumor volume of the vehicle group was 
1932.84 mm3 whereas the average tumor volume of the 50mg/kg/BIW, 100mg/kg/wk and 
200mg/kg/wk treatment groups were 137.66mm3, 2.55mm3 and 0.57mm3, respectively 
(Figure 4.12).  
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Figure 4.12. Therapeutic effects of SAR405838 in vivo.   
TABLE 4.6 TUMOR VOLUME OF LIPO863 TUMOR BEARING MICE. 
* Dose changed from 100mg/kg/BIW to 50mg/kg/BIW after first week  
**One mouse died of unknown cause 
 
 
 
  
 
First day of treatment Control mice sacrificed 
Last day of 
measurement 
# of mice 
with 
tumor 
Avg. 
tumor 
volume 
(±SEM) 
# of mice with 
tumor 
Avg. tumor 
volume 
(±SEM) 
# of 
mice 
with 
tumor 
Avg. tumor 
volume 
(±SEM) 
Vehicle 8/8 
83.70  
± 10.71 
6/6 
1932.84 
± 460.08 
6/6 
1932.84 
± 460.08 
50mg/kg/BIW* 8/8 
84.91  
± 4.01 
4/6 
137.66 
± 80.77 
4/6 
137.66 
± 80.77 
100mg/kg/wk 8/8 
84.65  
± 10.12 
1/8 
4.29 
± 4.29 
1/8 
2.55 
± 2.55 
200mg/kg/wk 8/8 
86.57 
± 10.18 
1/7** 
0.51 
± 0.51 
1/7 
0.57 
± 0.57 
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In a similar manner and to provide an additional model for SAR405838 therapeutic 
response, Lipo246 tumor bearing mice were separated into four treatment groups and received 
oral administration of either vehicle, 50mg/kg, 100mg/kg or 200mg/kg once a week. On day 
15, three mice from both vehicle and 50mg/kg treatment were terminated due to large tumor 
burden; the remaining mice from these two groups were terminated one week later and the 
mean tumor volume was calculated (vehicle: 2722.35 mm3; 50mg/kg: 1821.65 mm3).  Mice 
receiving 100 and 200mg/kg doses continued treatment for an additional two weeks due to the 
anti-tumor response and small tumor sizes. Upon termination, there was a measurable tumor 
in 5/7 mice receiving 100mg/kg with an average tumor volume of 1047.80 mm3. More 
impressively, 0/8 mice that received the 200mg/kg dose had any measureable tumor when the 
experiment was terminated (Figure 4.13).  
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Figure 4.13 Therapeutic effects of SAR405838 in vivo.   
 
Table 4.7 Tumor volume of Lipo246 tumor bearing mice.  
 
 
Tables 4.6 and 4.7 list the tumor volume of each group on day one of treatment, the 
day the vehicle control group was sacrificed, as well as the last day of measurement in both 
Lipo863 and Lipo246, respectively. Taken together, our data demonstrates that SAR405838 
effectively inhibits the growth of DDLPS tumors in a dose-dependent manner in xenograft 
models.  
 
First day of treatment Control mice sacrificed Last day of measurement 
# of mice 
with 
tumor 
Avg. tumor 
volume 
(±SEM) 
# of mice 
with 
tumor 
Avg. tumor 
volume 
(±SEM) 
# of mice 
with 
tumor 
Avg. tumor 
volume 
(±SEM) 
Vehicle 7/7 
137.36  
± 22.75 
7/7 
2722.35 
± 203.38 
7/7 
2722.35 
± 203.38 
50mg/kg/wk 7/7 
137.13  
± 27.21 
7/7 
1821.65 
± 377.11 
7/7 
1821.65 
± 377.11 
100mg/kg/wk 7/7 
140.83  
± 23.07 
6/7 
126.13 
± 75.83 
5/7 
1047.80 
± 464.37 
200mg/kg/wk 8/8 
140.69 
± 26.73 
3/8 
5.43 
± 3.18 
0/8 
0.00 
± 0.00 
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Therapeutic effects of SAR405838 in large DDLPS tumor burden  
Patients with DDLPS often have very large, deep-seated, and invasive tumors that 
make complete surgical difficult; therefore, in an effort to recapitulate the large tumor burdens 
presented in patients, we allowed for DDLPS tumor bearing mice (n=5, Balb/c nude SCID 
mice) to form very large tumors (~400mm3) prior to treatment with SAR405838 
(200mg/kg/wk p.o.) in our two xenograft models.  
These results exemplified the anti-DDLPS effects of SAR405838 as treatment 
significantly abrogated the tumor growth in Lipo246 tumor bearing mice, showing a complete 
regression of tumor growth after only two treatments (412.48mm3 ± 47.9 average tumor 
volume prior to treatment, 0.00mm3 ± 0.00 after 14 days and termination on day 43) (Figure 
4.14A).  On the other hand, Lipo863 tumor bearing mice did not respond with such anti-
tumorigenic enthusiasm. Following the first 3 doses, all tumors showed an initial regression, 
including one mouse with complete tumor burden elimination; however, tumors in the other 
mice began to show tumor regrowth and continued until termination of the experiment. The 
average tumor volume following six weeks of SAR405838 treatment was 492.56mm3 ± 
171.95, these tumors began at a volume of 369.13mm3 ± 84.56 (Figure 4.14B). 
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Figure 4.14 The in vivo effects of SAR405838 on established large tumor burdens. 
Therapeutic effects of SAR405838 in DDLPS xenografts. Mice were administered 
200mg/kg/wk p.o.  The effects on two different DDLPS models were observed. A) Lipo246 
tumor bearing mice. B) Lipo863 tumor bearing mice.  (n=5 per group) 
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CHAPTER 5. RESULTS: GENE EXPRESSION PROFILING 
IDENTIFIES IMPORTANT GENES MODULATED BY SAR405838 
 
SECTION 1. IDENTIFYING MOLECULAR CHANGES INDUCED BY SAR405838 FOR POTENTIAL 
BIOMARKERS OF THERAPEUTIC RESPONSE 
 
The goal of the studies within this chapter was to determine the SAR405838 induced 
effects on downstream targets in both cell culture and in xenograft models. This knowledge 
can potentially highlight and/or unravel novel p53 targets not previously known in the 
MDM2-p53 regulatory pathway, as well as give insight into biomarkers of therapeutic 
response that can potentially be used clinically. To address this goal, we performed two 
microarray analyses using an Illumina Human ref-12 v4.0 bead chip and compared global 
gene expression. The first array investigated the differentially expressed genes following 
SAR405838 treatment in four DDLPS cells in vitro; the second array investigated the 
modulated genes in vivo. In order to ensure consistency and significance of these expression 
changes, the two arrays were combined for a final analysis. 
Identifying molecular deregulations induced by SAR405838 in dedifferentiated 
liposarcoma in vitro  
In the first stage, we performed a gene expression array based on in vitro results; the 
goal of this study was to detect mRNAs that are differentially expressed before and after 
treatment with SAR405838. As the schematic in Figure 5.1 shows, two independent 
biological replicates of four DDLPS cell lines (Lipo224, Lipo815, Lipo246 and Lipo863) were 
treated with 0.003% DMSO (control), 1µM, and 3µM of SAR405838 for 24 hours. Following 
24 hours, cells were harvested and RNA was extracted.  
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Figure 5.1 Schema of the experimental outline. Schema of the experiments performed 
to investigate differentially expressed genes before and after SAR05838 treatment. 
 
 
The dataset was acquired using the Illumina HT-12 v4 Bead Chip and for each cell 
line, the p-value and fold change for treatment (1µM + 3µM) profiles versus the DMSO 
control profiles were computed using the log-transformed data. Genes were selected that 
obtained a significant p-value (p<0.05) and a fold change >1.4 or <1/1.4 (treatment profiles 
(1µM + 3µM) versus the DMSO profiles) for any three out of the four cell lines investigated; 
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a total of 858 probes were found to lay within these parameters for these profiles. Results 
showed that the expression patterns were quite similar from between cell lines. Furthermore, 
1µM versus 3µM patterns were largely similar as well, although the gene patterns appeared 
to be slightly stronger in the 3µM group, as might be expected. Of these differentially 
expressed genes found, a total of 381 up-regulated and 477 down-regulated genes compared 
to DMSO controls in at least three out of four cell lines (p<0.05, FC>1.4 or <1/1.4). 
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Figure 5.2 Gene expression profiling in DDLPS cells in response to SAR405838. The 
heatmap of untreated and SAR405838-treated DDLPS cells demonstrates the 472 most 
differentially expressed significantly up- and down-regulated gene in DDLPS cells. Red 
indicates significantly up-regulated genes, and blue indicates down-regulated genes selected 
at FDR 0.05 and a fold change >2.0. The expression values shown on the heatmap have been 
standardized and at ± 3 STD.  
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Gene ontologies (GOs) of the differential expression genes were analyzed. The bar 
plot in Figure 5.3 represents the number of genes that were down-regulated in our microarray 
that enrich the top 20 GOs. These results show that the top down regulated are heavily 
involved in mitosis and cell cycle regulation. Cell cycle processes, kinetochore, spindle, 
regulation of mitosis, etc. are all processes that relate to cell division and mitosis, implying 
that if the genes enriching these processes are significantly down-regulated, it is likely that 
the process of proliferation is being slowed.  
 
 
Figure 5.3 Gene Ontology Enrichment in DDLPS with SAR405838 treatment. Bar 
plot of the number of genes in the top 20 gene ontology groups.   
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Identifying molecular deregulations induced by SAR405838 in dedifferentiated 
liposarcoma in vivo  
In our second microarray, we wanted to perform a similar experiment identifying 
which genes are being modulated following SAR405838 treatment in vivo. Lipo246 tumor 
bearing xenografts were utilized to investigate the changes in gene expression. Once palpable 
tumors were established, mice (n=5) were given a single dose of either vehicle 
(TPGS/PEG200) or SAR405838 (200mg/kg); following 24 hours, mice were sacrificed and 
tumors were extracted for RNA and protein evaluation.  RNA was extracted from tumor 
samples of each group (n=3) for microarray analysis (Illumina Platform, HT v12).   
From our microarray data, we detected 1074 (586 up-regulated, 488 down-regulated) 
genes to be significantly different following SAR405838 treatment (fold change >2.0, 
p<0.01). The differential gene expressions are clearly delineated by the heatmap in Figure 
5.4. Gene expression was normalized to the controls and then separated between up-regulated 
(yellow) and down-regulated (blue) following SAR405838 treatment.   
Appendix C lists of the top 50 significantly affected genes following SAR405838 
treatment in vitro and in vivo.   
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Figure 5.4 Gene expression profiles in response to SAR405838 treatment in vivo. The 
heatmap represents the 1074 most significant differentially expressed up- and down-regulated 
gene in DDLPS cells. Yellow indicates significantly up-regulated genes, and blue indicates 
down-regulated genes selected at FDR 0.05 and a fold change >2.0 or <0.5 and p<0.01.  
 
 
 
 
 119 
SECTION 2. CANONICAL PATHWAYS ENRICHED BY GENES DIFFERENTIALLY EXPRESSED 
FOLLOWING TREATMENT WITH SAR405838 
In an effort to determine which enriched pathways held significant biological 
relevance, we crossed our two independent microarray datasets. Intersecting these gene lists 
revealed that 237 genes were significant in both analyses, of which 115 were down-regulated 
in both analyses and 122 were up-regulated in both analyses. These differentially expressed 
genes were then selected for subsequent analysis in order to determine commonly affected 
pathways in DDLPS following SAR405838 treatment. We used Ingenuity Pathway Analysis 
to determine which signaling pathways were enriched from the differentially expressed genes 
of our microarray results (Figure 5.5). 
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Figure 5.5 Canonical pathways modulated by differentially expressed genes. Venn diagrams 
represent the matching differentially expressed genes that are up-regulated (left panel) and 
down-regulated (right panel) following SAR405838 treatment between in vitro and in vivo 
gene expression microarrays. These combined 237 genes (122 up- and 115 down-regulated) 
enrich multiple pathways determined by IPA; select genes are listed next to the associated 
pathway.   
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 Our results demonstrated that the expressed genes enriched 171 canonical pathways; 
Table 5.1 lists the top 3 canonical pathways with the highest estimated probability 
involvement. This analysis revealed that the p53 signaling pathway was the most affected 
pathway modified by both up and down-regulated genes from our two microarrays. Other 
pathways that were affected included pathways important in genomic stability such as cell 
cycle and checkpoint regulation (p53 signaling, G2/M and G1/S checkpoint regulation), and 
response to DNA damage (role of BRCA1 in DNA damage response, ATM signaling). In 
order to confirm these results, qRT-PCR was performed on select genes with RNA used in 
each microarray. 
 
TABLE 5.1 TOP THREE INGENUITY CANONICAL PATHWAYS.  
Ingenuity canonical 
pathway Overexpressed genes in pathway P-value 
p53 Signaling 
BCL2L1, TP53INP1, GADD45A, ADCK3, 
CDKN1A, CCNK, TNFRSF10B, RRM2B, 
MDM2, BAX, FAS, DRAM1 
1.17E-09 
Cell Cycle Control of 
Chromosomal Replication MCM5, MCM3, MCM2, CDC7, MCM7 1.21E-05 
Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 
GADD45A, CDKN1A, TOP2A, MDM2, 
CCNB1 1.24E-04 
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Microarray gene profiling in DDLPS cells treated with SAR405838 demonstrated up- 
and down-regulated genes in a p53-dependent manner 
Among the affected genes, we detected several p53-regulated targets. IPA 
transcription factor analysis revealed that p53 was the most significantly activated 
transcription factor (z-score of 5.643). qRT-PCR analysis validated several of these genes. 
The data from the qRT-PCR was very similar to the microarray analyses. Together, 
SAR405838 reactivated p53 activity and affected many p53 target genes in a p53-dependent 
manner. 
One of the main cellular functions of p53 is regulation of the cell cycle control by 
preventing cell progression in G1/S and G2/M phases; we observed that treatment with 
SAR405838 induced cell cycle arrest in DDLPS cells. As a transcription factor, p53 
transcriptionally regulates the expression of multiple genes involved in this pathway. From 
our two arrays, our results revealed that pathways involved in cell cycle progression and 
genomic instability were significantly affected following SAR405838 treatment. To validate 
the induced effects of SAR405838 on cell cycle regulation we performed qRT-PCR (Figure 
5.6). The selected genes are all involved in different checkpoint regulations of the cell cycle 
and were used to for confirmation purposes of the arrays (Table 5.2).  
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Figure 5.6 Differentially expressed genes following SAR405838 treatment involved in cell 
cycle control. qRT-PCR was used to confirm mRNA expression of differentially expressed 
genes . (*=p<0.05; student’s t-test compared to vehicle control; n=3 ± SEM). 
 
Table 5.2 Genes identified by both microarray analyses involved in cell cycle regulation. 
Select genes from our two microarrays and their protein function. 
Gene symbol Function 
CDKN1A 
Pan cyclin-dependent kinase inhibitor; regulates cell cycle 
progression 
GADD45a DNA damage repair and promotes growth arrest at G2/M  
BUB1 
Kinase involved in spindle checkpoint function, inhibits 
activation of the anaphase 
CDC20 
Microtubule-dependent processes: nuclear movement prior 
to anaphase and chromosome separation. 
PBK Mitotic  kinase, regulates cell cycle progression at G2/M 
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To gain further insight into the connection between p53 signaling and the mitotic 
pathway, we studied p53-induced genes from the expression arrays analyses. The increased 
expression of Aurora Kinase A, Aurora Kinase B and PLK1 was observed and the connection 
to p53 is demonstrated in Figure 5.7A.  So our question became: does p53 regulate the aurora 
pathway? To answer this, we investigated our top down regulated gene list and crossed it with 
potential interactions using IPA and found that there were potential direct and indirect 
pathway interactions that deserved further exploration. We further confirmed these results 
with WB analysis (Figure 5.7B). Lipo863 cells were treated with increasing concentrations 
of SAR405838 for 48 hours and our results show that there is a decrease in Aurora A when 
treated with SAR405838.   
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Figure 5.7 Connections between p53 signaling and the mitotic pathway. A) The 
shortest connection between p53 and the mitotic pathway; red represents p53 affected genes. 
Solid arrows represent direct transcriptional regulation. B) Western blot analysis of 
SAR405838 treatment (48 h) and its effect on the expression of Aurora Kinase A.  
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While cell cycle arrest and the induction of apoptosis are both p53 driven processes, 
they involve very different downstream target genes. Ideally, the desired result of p53 based 
therapies is the induction of apoptosis. Therefore, to gain a better understanding of 
SAR405838 induced apoptosis in DDLPS, we investigated the apoptotic genes modified from 
our expression arrays. Activation of p53 following SAR405838 displayed mutual apoptotic 
profiles in both arrays; increase in two p53 dependent apoptotic genes, BAX and PUMA were 
observed in both arrays and confirmed with qRT-PCR (Figure 5.9).  
 
  
 127 
 
Figure 5.8 SAR405838 induces apoptotic gene profiles in DDLPS. Increase of apoptotic gene 
expressions from microarray analyses were confirmed with qRT-PCR. (n=3 ± SEM). 
 
 
 
Table 5.3 Genes identified by both microarray analyses involved in apoptosis. Select genes 
from our two microarrays and their protein function. 
Gene symbol Function 
BCL2L1  Inhibits activation of caspases in apoptosis 
BAX Antagonizes BCL2, promotes activation of caspase-3 
FAS Cell surface death receptor, recruits caspase-8 to activated receptor 
PUMA Induces mitochondrial dysfunction and caspase activation 
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SAR405838 modulates the expression of genes in the 12q13~15 chromosomal loci 
Given that the 12q13~15 chromosomal region is amplified in DDLPS, we wanted to 
take a deeper look into which genes were being modulated in this amplicon following 
SAR405838 treatment. To do this, we utilized all three of our microarray analyses. Genes that 
were over-expressed in DDLPS cells compared to controls (Figure 3.7) were then further 
analyzed following SAR405838 treatment. From this analysis we found 3 genes that were up-
regulated and 5 that were down-regulated following MDM2 inhibition (Table 5.4). qRT-PCR 
was performed to validate the expression following (Figure 5.9). 
 
 
Figure 5.9 Genes modulated in the 12q13~15 amplicon following SAR405838 treatment. 
qRT-PCR was performed to confirm (A) genes up-regulated and (B) down-regulated  
following SAR405838 treatment. (n=3 ± SEM). 
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Table 5.4 Genes identified by both microarray analyses located within the 12q13~15 
chromosomal interval.  Select genes from our two microarrays and their protein function. 
 Gene symbol Function 
Up-regulated 
AVIL Formation of actin-containing structure 
CYP27B1 Role in metabolism and tissue 
differentiation 
MDM2 E3 ubiquitin ligase activity 
Down-regulated 
NUP107 Nuclear pore complex assembly and/or 
maintenance 
PRIM1 Polymerase, synthesizes RNA primers 
made during DNA replication 
XRCC6BP1 DNA dependent protein kinase activity 
YEATS4 
Structural constituent of cytoskeleton and 
sequence-specific DNA binding 
transcription factor 
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CHAPTER 6. DISCUSSION 
Dedifferentiated liposarcoma is a devastating disease with very few treatment options. 
More than 90% of DDLPS patients will suffer recurrent disease and, disturbingly, a mere 
5.2% of patients with advanced stage disease will ultimately survive23. In this body of work 
we sought to create and characterize DDLPS bioresources as well as target MDM2 as a 
potential therapeutic strategy for the treatment of DDLPS.  
 
Establishment and characterization of novel DDLPS models 
One of the major limitations to achieve an enhanced molecular understanding, as in 
many rare cancers, is the lack of experimental models that can be used to investigate this 
disease which hinders pre-clinical and clinical advances75. Consequently, creating a model 
system that mimics the human disease is a vital first step. The most common model system 
used in cancer research involves cell lines; however, there is only one commercially available 
cell line for the study of DDLPS (SW872)181. Cell lines are an effective way to initially study 
the molecular aberrations and mechanisms in DDLPS and for pre-clinical testing of potential 
therapeutic agents. For these reasons, we first developed novel DDLPS bioresources to pave 
the way for many future experiments. The DDLPS cell line panel used in these studies 
represents our 10 most successful and reproducible cell lines generated in our lab. Evaluation 
of DDLPS in vitro enables pre-clinical investigations, as well as enhances our understanding 
of the molecular underpinnings. However, this is complicated by the lack of relevant baseline 
or control cell lines in which to make comparative conclusions of significance. In an attempt 
to overcome these issues we have created an in depth DDLPS “encyclopedia” with our cell 
line model to understand the baseline properties that can be used to compare results and make 
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more meaningful conclusions. This initial characterization also provided information on the 
molecular phenotypes of each cell line that could then be used to predict responses, thereby 
making even better use of these rare resources. 
Another common way to study cancer biology uses animal models. Animal models for 
well-differentiated liposarcoma have been recently developed. One group reported a mouse 
model that spontaneously developed a WDLPS when fed a high fat diet in the presence of IL-
22 over expression182 while another developed a zebrafish model that expressed a 
transactivation mutation in p53 and constitutively active AKT leading to WDLPS tumors183. 
Nonetheless, no such animal model exists for the spontaneous development of DDLPS. The 
most common animal-based model to study to DDLPS is a xenograft system. Xenograft 
models are able to grow human tissue from tissue samples or cell cultures in an immune 
compromised mouse. We were able to generate xenografts from all 10 of our cell lines, and 
the molecular and morphological features in our xenografts mimic those of the tumors from 
which they were derived. With the development of this system, we were able to identify 
molecular aberrations as well as test the pre-clinical responses to therapeutic drugs.  
Another limitation for studying DDLPS is the relatively small patient cohort in each 
LPS histological subgroup; consequently, LPS is frequently lumped together as though it were 
one single disease. This broad and potentially misleading categorization has slowly dissipated 
over the years as subtype-specific therapies, based on in depth characterizations, have been 
developed67,184. However, minimal therapeutic advances and overall low success rates of these 
newer therapies highlight the urgent need for the development of new drugs based on specific 
molecular abnormalities and molecular driving forces unique to each subtype. With this in 
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mind, we characterized our panel of DDLPS cell lines to establish genomic- and expression-
based profiles. 
Cytogenetic studies are perhaps the most comprehensive investigative tool available 
to learn about the genomic alterations influencing dedifferentiated liposarcomagenesis. While 
limited, tissue-based aCGH and gene expression profiling studies have been performed to 
investigate the molecular differences regarding tumor establishment and progression as well 
as histological classification7,54,57,61,66,185,186. We hypothesized that these genetic aberrations 
were reproducible and consistent as per specific malignant phenotypes. To test this hypothesis, 
we used aCGH analysis to determine genomic aberrations acquired by DDLPS, perhaps from 
their mesenchymal stem cell precursors. DDLPS cell lines, as a group, clustered and 
segregated together compared to controls. The results suggest that although cancer is 
heterogeneous, DDLPS acquires certain common and reproducible genetic changes that 
distinguish it from other mesenchymal cells. 
With this in mind, the genomic loci alterations and the associated gene expression in 
our DDLPS cell panel were further assessed. Our analyses revealed patterns of genomic 
imbalances, specifically gains in the chromosomal regions 12q13~15, 12q21 and 5p, as well 
as losses in 11q23~24 and 11p15. 
FISH and aCGH studies have clearly visualized and demonstrated amplification of 
12q13~15 material located within the ring and giant chromosomes of DDLPS. Therefore, 
amplification of 12q13~15 was expected and confirmed by our data. The delineated 
amplification of 12q13~15 corresponds to variable amplification of oncogenes involved in 
tumorigenesis. The most important amplification in the 12q13~15 region is MDM2. MDM2 
amplification was observed in our cells via FISH as a common finding in our cells and used 
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to confirm diagnosis of a primary tumor tissue as well as to confirm that molecular 
characteristics were retained in subsequent passages of our cell lines.  
The ability to efficiently and effectively diagnose the tumor histology provides 
valuable information relevant to treatment. In one study, Weaver and colleagues (2010) 
investigated the use of core needle biopsies as a reliable tool for diagnosis for WDLPS 
compared to benign lipomas28. Their results showed that FISH had higher sensitivity (100%) 
and specificity (100%) compared to the immunohistochemistry analysis of core needle 
biopsies (65% and 89%, respectively). However; in a recent study assessing the accuracy of 
biopsy techniques and resection specimen of 257 patients, the diagnostic accuracy of a core 
biopsy was only accurate in 78% of patient tumors187. These results vary from center to center, 
but the ability to confirm MDM2 amplification via a core needle biopsy can only be as accurate 
as the biopsy itself, mandating that tumor rather than normal tissues is sampled. Nevertheless, 
not only were we able to confirm the genomic amplification as relevant to histological 
purposes, but the percent of MDM2 amplification in our primary cell cultures also gave us 
insight into the ability of these cells to grow in vitro.  
Genetic changes provide insight into the establishment and progression of DDLPS; 
the relationship between disease progression and amplification of chromosomal loci has been 
linked in previous studies. For example, it has been suggested that the initial amplification of 
chromosome 12q13~15 gives rise to the morphological appearance of WDLPS from an 
adipogenic cell56,188. While the 12q13~15 amplicon is amplified in the WDLPS/DDLPS 
subtype, the progression from a WDLPS to a DDLPS phenotype requires additional specific 
genetic changes. 
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Amplification of 1p31~32 and 6q23~24 amplicons have been reported to be mutually 
exclusive, resulting in the up-regulation of JUN or MAP3K5 which correspond to each loci, 
respectively. However, in our study, we did not observe significant amplification at these loci. 
Additionally, gains within 13q have recently been shown to correlate with worse prognosis in 
DDLPS patient samples66; however, there were no striking amplifications observed in our 
array studies.  
It is critical to distinguish which aberrations are driving DDLPS transformation; 
therefore, by developing and characterizing novel model systems we were able to acquire new 
information about the biology of DDLPS that can be used to not only better understand the 
disease but also serve as a target for potential therapies. 
 
SAR405838 restores the p53 pathway in DDLPS cells 
Small molecule MDM2 inhibitors have provided researchers with the opportunity to 
scrutinize the molecular mechanisms of p53 due to their potency and specificity.  Inhibition 
of MDM2 leads to the canonical cellular responses attributable to p53 activation; as a result 
MDM2 inhibition is an exciting possibility for DDLPS treatment. Two of these processes, 
(cell cycle and apoptosis) were therefore investigated for their response to SAR405838 
treatment. 
The cell cycle is regulated by cyclin-CDK complexes that prevent transition through 
the cell cycle in a well-organized check and balances scenario: G1 progression is regulated by 
cyclin D-CDK4/6; cyclin E-CDK2 regulates the G1-S transition; S-phase progression is 
regulated by cyclin A-CDK2; cyclin A/B-CDK1 regulates the entry into M phase78,79. We 
observed that SAR405838 modulated the cell cycle profile in DDLPS cells in a dose-
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dependent manner (0 to 3μmol/L) and induced cell-cycle arrest in both G1 and G2 phases, 
depending on the cell line. In a similar study using Nutlin-3a, this differential phase response 
was also observed depending on the cell line studied. It was observed that cell arrest in G1 was 
due to suppressed phosphorylation of the retinoblastoma protein (Rb), while G2 arrest was 
achieved following suppression of CDC2 and cyclin B189.  Therefore, it is possible that 
suppression of Rb phosphorylation is greater in cells manifesting in G1 phase arrest, while cell 
arrest in G2 may be due to suppression of the CDC2/cyclin B complex. 
p53 regulates cell cycle largely through transcriptional activation of CDKN1A (p21). 
Indeed, the p53-dependent increase of p21 expression following MDM2 inhibition is well 
documented106,167,171,173,190–196. In agreement, we observed increased p21 expression 
throughout our experiments, and p21 levels were used as a standard to represent p53 activation 
in our studies. CCNB1 encodes an important regulator of the G2/M DNA damage checkpoint, 
cyclin-B1, and was down-regulated following SAR405838 treatment compared to controls as 
demonstrated in our microarrays. High expression levels of cyclin B1 provides not only 
evidence of unregulated cell cycle progression but is also associated with tumor progression 
and a worse prognosis197. Cyclin B1 forms a complex with Cdk1 and is predominately 
expressed during the early G2/M phase of the cell cycle. Following SAR405838 treatment, 
CCNB1 expression was decreased (FC -2.14) and provides futher evidence for p53-induced 
cell cycle arrest.  
Identifying which cell cycle-regulated genes are being modulated is important when 
investigating the proliferation signature that may be drug-induced. However, when 
investigating the genes involved in cell-cycle following treatment it is possible that the 
decrease in cell proliferation is due to cells are not entering the cell cycle. Consequently, these 
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genes may not be directly affected by SAR405838 and are not expressed because the cells are 
not proliferating at that particular time. In order to effectively identify cell-cycle-regulated 
genes, synchronization of the cells is important; while we did not synchronize the cells prior 
to our investigations, SAR405838 produced a strong cell cycle expression profile as the 
modulation of multiple cell cycle regulating genes were observed in our gene expression 
arrays.  
Taken together, MDM2 antagonist drugs have shown to induce cell cycle arrest 
through reactivation of the p53 pathway; therefore, by identifying genes that are directly 
affected by MDM2 antagonists, this can potentially predict if a tumor is experiencing a cell 
cycle arrest, which often leads to cytostatic response, or is due to an effect on proliferation 
and therefore a possible more desirable cytotoxic response. 
 
Apoptosis is an orchestrated and programmed process of cell-death. The cleavage of 
caspases in the cytoplasm and nucleus produces a proteolytic caspase cascade that triggers 
cell death198. This evolutionarily conserved process is characterized from other forms of cell 
death (i.e., necrosis) by morphological features observed including membrane blebbing, DNA 
fragmentation, as well as the formation of distinct apoptotic bodies198.  
The cytotoxic effects of MDM2 inhibitors rely on the innate ability of p53 to induce 
apoptosis. Partly by promoting the specific downstream target genes, and partly by repressing 
the expression of anti-apoptotic proteins, p53 is able to initiate components of apoptosis. In 
our studies we have demonstrated the induction of apoptosis in multiple experiments. We 
observed a dose-dependent correlation of apoptosis following SAR405838 treatment in cell 
culture-based assays, including Annexin V/FITC, as well as by the increased expression of 
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apoptotic genes and proteins via qRT-PCR and western blot assays, respectively. 
Additionally, the resistance to apoptosis correlated with either p53 mutations or a lack of 
MDM2 amplification.  In comparison to cell cycle arrest, apoptosis is a more desirable 
therapeutic response; therefore, it is gratifying that SAR405838 was capable of inducing these 
cytotoxic results more effectively than both Nutlin-3a and MI-219 as a means if gaining 
therapeutic leverage.  
Following SAR405838 treatment, an apoptotic expression profile was observed in our 
microarray analyses. Specifically, the expression of two genes (PUMA and BAX) was 
increased in response to MDM2 inhibition. The pro-apoptotic protein PUMA interacts with 
anti-apoptotic Bcl-2 family members, thus inhibiting their interaction with Bax and Bak and 
as a result, Bax activates mitochondrial dysfunction leading to caspase activation and cell 
death86,105,199. PUMA is capable of inducing apoptosis rapidly200; however, at the earliest time 
point we examined its expression was following 24 hours of treatment; therefore, SAR405838 
may be capable of inducing apoptosis at much earlier time points. It is very plausible that 
these genes have been selectively modulated due to their involvement in tumor development. 
Additionally, SAR405838 could assist in identifying which of these aberrations are most 
prevalent in the p53 pathway and potentially aid in the prediction of patient selection and 
response.   
Malignant progression and chemo-resistance are frequently seen when tumor cells no 
longer exhibit an apoptotic response; therefore, a better understanding of p53-induced 
apoptotic genes may be relevant to therapeutic advancements. Because p53 apoptotic targets 
frequently retain a WT status201, it suggests the possibility of targeted therapies that are not 
dependent on the status and activation of p53. 
 138 
 
P53; a choice between cell life and death 
While the mechanisms of cell cycle and apoptosis have been well characterized, the 
question remains how does p53 determine a cell's fate and participate in either life (cell cycle 
arrest) or death (apoptosis), a process that is based on a multitude of different factors. 
Depending on the physiologically relevant circumstance, p53 induces different genes that 
mediate different p53 functions.  
It has been suggested that a p53 “affinity model” is feasible in which the low or high 
expression level of p53 is able to induce transcriptional targets involved in either cell cycle 
arrest or apoptosis, respectively. Recently, Kracikova and colleagues challenged this model 
by showing that p53 is able to induce apoptotic responses even at very low p53 expression 
levels202. Most importantly, they demonstrated that lowering the ‘apoptotic threshold’ by 
inhibiting the anti-apoptotic BCL2 gene sensitized the cells to apoptosis. In our results we 
have demonstrated that both MDM2 and p53 levels vary. MDM2 levels have been suggested 
as a possible biomarker for therapeutic efficacy; consistently, cells expressing high MDM2 
levels had a more potent response to MDM2 inhibition, whereas ‘low’ MDM2 expressing 
cells did not elicit as strong a response. Our results also demonstrate that very low doses of 
SAR405838 (0.1nM) induced the expression of the cell cycle-arrest associated gene p21; 
however, although not significant, we did notice apoptosis at this low concentration. As a 
result, it is a possible that by lowering the apoptotic threshold to switch from cell cycle arrest 
to apoptosis by concomitant BCL2 inhibition with an inhibitor of apoptosis, such as ABT-263 
(an inhibitor of the BCL2 family genes), apoptosis could be triggered at extremely low doses 
in cells that would not otherwise do so. This not only highlights the use of MDM2 as a 
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biomarker of response, but also suggests a way to induce a more potent response. In support 
of this hypothesis, results from our differentially expressed gene arrays showed that the major 
pathways affected by SAR405838 treatment were p53 signaling, cell cycle: G2/M DNA 
damage checkpoint, and ATM signaling for which the associated genes were pro-arrest and 
pro-survival, such as CDKN1A, GADD45a, and BCL2.  While this can be tested in vitro, the 
more pertinent results would be an in vivo model. Lipo863, which has a low MDM2 
expression, would provide an excellent construct with which to test this hypothesis.    
Another possibility that might influence p53 effects is due to the basal level and 
expression of certain proteins that modulate different downstream pathways of p53. It is an 
interesting and therapeutically applicable observation that in response to p53, tumor cells 
seem to have a greater propensity for death as opposed to normal tissues. Malignant 
transformation is supplemented with uncontrolled proliferation, and loss of normal cellular 
environment as well as stress can render cancer cells more sensitive to apoptotic signals203. 
Alternatively, normal cells are not subject to the same conditions and their intact survival 
mechanisms may be better suited to override the death signals instituted by p53. The basal 
levels of p53 are constitutively expressed in normal cells, and as a result, p53 is able to 
transiently activate cellular responses in normal or stress situations. This activation is not 
sufficient to elicit apoptosis possibly because either the specific stimuli induce different 
transcriptional processes or perhaps the nature of the response is only temporary. 
Nevertheless, this transient activation of p53 can possibly be enough to deter early 
tumorigenic events. 
How p53 contributes to reversible cell cycle arrest versus irreversible apoptotic 
responses is of great relevance to cancer therapies. As we continue to investigate the biology 
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underlying these mechanisms, we may be able to develop enhanced therapeutics that 
selectively lead to a desired process.  
 
Anti-tumor response of SAR405838 in xenograft models 
Although cellular-based assays are efficient to assess the anti-proliferative effects of a 
drug, the results from an animal model are more often considered as representative of clinical 
behavior. The effects of MDM2 inhibition in xenograft models have been considered using 
Nutlin-3a and MI-219. Despite initial pharmacodynamic experiments demonstrating p53 
activation; both drugs failed to achieve complete tumor regression173. Throughout our studies, 
we demonstrated that SAR405838 had exemplary results and induced the anticipated 
favorable effects of an MDM2 inhibitor better than either Nutin-3a or MI-219. As a result, we 
had hoped that in vivo SAR405838 treatment would result in strong anti-tumorigenic 
responses. Indeed, after a single oral dose of SAR405838, we did observe activation of p53 in 
our pharmacodynamic studies, as suggested by the accumulation of p53 downstream targets 
(MDM2 and p21), and a dose-dependent response in these initial therapeutic experiments. 
Interestingly, we observed two completely different responses between our two cell lines in 
large tumor burden studies. Mice that were injected with Lipo246 maintained complete 
responses following two weeks of treatment (200mg/kg), whereas Lipo863 appeared to have 
an initial response after only one week of treatment, but were no longer affected by treatment 
in that the tumors continued to grow. One possible explanation for this is that the MDM2 
levels in Lipo863 are not expressed highly enough for SAR405838 to have sustained 
therapeutic effects after this treatment span. We noticed in the LISA2 cell line which retains 
WT MDM2 and TP53 that SAR405838 did not induce anti-tumor responses, and a similar 
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situation may hold true for Lipo863. Although SAR405838 was able to elicit anti-tumorigenic 
effects when the tumor is very small, these may not be enough in a larger tumor setting where 
additional abrogations independent of MDM2 and p53 may be the primary driving force.  
 
Predictors and biomarkers of therapeutic response  
Predictors of response to MDM2 inhibitors have been studied using Nutlin-3 and MI-
219 where it was shown that the major determinant of MDM2 inhibitor antitumor activity  is 
the WT p53 status178. Nutlin-3a and MI-219 target the MDM2-p53 interaction with high 
specificity and as a result they elicit promising anti-tumorigenic responses in cancer cell lines 
in which MDM2 overexpression remains the dominant regulator inhibiting p53173. MDM2 
overexpression may be due to several different mechanisms, including amplification, 
increased transcription and translation, and single-nucleotide polymorphism (SNP) of the 
MDM2 gene204. This recently identified SNP is a T to G mutation at nucleotide 309 (SNP309); 
importantly, this mutation has been shown to correlate with poor overall survival as well as 
therapeutic resistance163. Interestingly, it has been suggested that the cohort of patients bearing 
this molecular signature may benefit from the use of MDM2 antagonists205.  
There is inconclusive evidence regarding the relevance of MDM2 amplification as a 
benchmark biomarker of therapeutic response196,206–208. In a recent study, Pishas et al. reported 
that neither amplification nor expression correlated with apoptotic response following Nutlin-
3a as shown in a broad screening of sarcomas, perhaps due to the hypermethylation of 
GADD45A as observed in cell lines that did not respond to treatment209. Nevertheless, they 
did observe effective cytostatic results in all cell lines and therefore might have possibly seen 
stronger apoptotic responses in these cells if the time utilized to assess apoptosis was longer 
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than 24 hours209. In light of this possibility, throughout our studies we evaluated the toxicity 
of SAR405838 in our panel of cells as based on the relative MDM2 amplification status 
assigned (MDM2HI and MDM2LO). Our results showed that SAR405838 successfully 
stabilized p53 and activated downstream transcriptional targets, effectively inhibited cell 
proliferation, induced cell-cycle arrest as well as induced apoptosis, all in a dose-dependent 
manner. MDM2HI cells were able to show these responses more consistently and at lower 
concentrations than MDM2LO cells.   
Nonetheless, there is contradictory evidence regarding the clinical relevance of 
MDM2 amplification which may possibly be due to several confounding factors. One 
possibility is that the particular antibody used to detect the MDM2 might only assess the total 
MDM2 protein level and not take into account mutant or alternatively spliced MDM2. 
However, the question still remains whether or not MDM2 amplification correlates with 
therapeutic outcome and if it can serve as a potential biomarker for patients receiving MDM2 
antagonist therapies. 
 
So the question remains, which processes controlled by p53 are critical for tumor 
suppression? To answer this question, we performed multiple high-throughput experiments to 
analyze the therapeutic responses evoked by p53 reactivation. The purpose of these high 
throughput screens was to identify molecular aberrations induced by inhibition of the MDM2-
p53 complex that can either serve as biomarkers for therapeutic response, or can be potentially 
targeted in a combinational drug setting. We identified expression profiles associated with 
p53 pathway signaling, cell cycle deregulation, and apoptosis; however, it is the interpretation 
of these expression patterns and their associated functional deregulation that remains a 
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challenge. Because gene expression analyses are more objective and quantitative than cellular-
based assays, their results can possibly be more directly translated to clinical use.  For 
example, the first critically utilized gene expression array, performed only a few years ago, 
was used to predict the recurrence of tamoxifen-treated, node negative breast cancer210. 
Studies like this may be even more crucial for rare cancers such as DDLPS current therapeutic 
options are much more limited. 
 
SAR405838 is an MDM2 inhibitor whose antitumor effects depend on the activation 
of p53. As a result, the biomarkers of response of this compound must be specific indicators 
of p53 activation, as well as demonstrate specificity for the tumor and not a component of the 
surrounding normal tissue. This criterion can be difficult to establish as p53 has numerous 
downstream transcriptional targets. Therefore, we utilized a multi-microarray approach to 
analyze candidate target genes with hopes of identifying the most therapeutically and 
biologically relevant markers of response. By crossing the significantly expressed (both 
significantly up- or down-regulated) genes in both of our gene expression microarrays, we 
identified which signaling pathways were significantly enriched to ensure that only the genes 
detected in the representing pathways were significantly up or down regulated in both arrays. 
Expression profiles showed enrichment in the canonical pathways that were involved in cell 
cycle regulation, DNA damage response, and apoptosis. As expected, p53 pathway signaling 
was the most up-regulated following treatment. Expression levels of the genes located in this 
pathway correlated mostly with cell cycle control and apoptosis. The genomic instability 
observed provides promising results from this MDM2 inhibitor.  
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From our data we identified growth differentiation factor-15 (GDF-15) to be the most 
statistically significant expressed gene. GDF-15 is a distant member of the transforming 
growth factor-β (TGF-β) family, regulates tissue differentiation and maintenance and is 
expressed at high levels in the placenta, prostate and skin, but at very low levels in other 
tissues211. Basal expression levels of GDF-15 are generally low until a stress stimuli induces 
its expression212 and functions as a growth factor most commonly in the P13K/AKT signaling 
pathway. This cytokine is induced during cellular stress, and high expression is associated 
with cancer progression213. Furthermore, studies have demonstrated that GDF-expression can 
be induced by p53 activation-mediated cell cycle arrest and apoptosis213. As a result, this 
cytokine could plausibly serve as a secreted biomarker of SAR450838 activation in DDLPS.  
Identification of novel biomarkers, such as GDF-15, can progress our understanding 
of molecular underpinnings driving liposarcomagenesis, and provide insight into new 
therapeutic targets. Identifying genes that are altered following treatment with SAR405838 
provides valuable information regarding the effects of this specific inhibitor in DDLPS. Our 
data supports further investigation of the clinical applicability of GDF-15 as a biomarker for 
therapeutic response.  
Therapeutic resistance 
It is important to understand how apoptosis is induced in cells as a therapeutic 
response; it is equally important to understand how a tumor cell might become resistant to 
apoptotic stimuli. Perhaps the most common mechanism of therapeutic resistance is 
inactivation of the p53 pathway. Small molecule inhibitors of the MDM2-p53 interaction are 
based almost entirely on the anti-tumoral responses induced by p53. Consequently, 
therapeutically resistant clones may emerge from p53 mutant cells in a tumor or from an 
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acquired p53 mutation thereby rendering such therapeutic strategies as useless. It has recently 
been observed that repeated exposure of Nutlin-3a in SJSA-1 cells leads to somatic mutations 
in p53214, rendering these cells as no longer responsive to Nutlin treatment.  This important 
study provided the initial demonstration of in vitro drug resistance to Nutlin-3a. One 
possibility to overcome such resistance would be to combine MDM2 antagonists with a drug 
that is capable of targeting p53 mutated cells.   
Other mechanisms of resistance have been documented, including therapy-induced 
autophagy215. The concept of autophagic cell death remains controversial. Nevertheless, this 
dynamic process is fundamental in maintaining cellular homeostasis through degradation and 
recycling of cellular components via the lysosomal system198,216.  
Identified by Crighton and colleagues (2006), DRAM1 is a direct transcriptional target 
of p53217. DRAM1 is located in the 12q13~15 chromosomal loci217.  It has been demonstrated 
that DRAM1 is induced by genotoxic stress (DOX; 24h) in a p53-dependent manner in cancer 
cells217. Importantly, a role for DRAM1 in p53-mediated cell death has been suggested as 
siRNA knockdown of DRAM1 decreased the amount of cell death observed. It has been 
reported that DRAM1 is down-regulated in tumor cells, and although not capable of inducing 
apoptosis alone, it is a key factor in p53-dependent apoptosis. Furthermore, the relationship 
between DRAM1 expression and p53 corresponds to a WT p53 status217.  
The increase of DRAM1 observed in our gene expression arrays following MDM2 
inhibition is an interesting observation for several reasons. First, our data agrees with the 
observation that DRAM1 and WT p53 demonstrate a mutually exclusive relationship, 
supporting an additional form of p53-mediated cell control. Second, the location of DRAM1 
is within the 12q13~15 chromosomal region of DDLPS. The discontinuous amplification of 
 146 
this chromosomal loci suggests plausible evidence as to why certain genes are not amplified. 
Thirdly, although the role of autophagy in cell death or survival remains controversial, this 
gene offers an interesting insight into DDLPS biology. The increase in DRAM1 (FC of 3.46) 
following SAR405838 was observed in our gene expression arrays. This amplification status 
of could possibly be working in the context of a cell survival mechanism of autophagy, or 
specifically, ‘productive autophagy’ as certain cell lines did not induce apoptosis as potently 
following SAR405838 treatment218. However, the addition of a stressor such as SAR405838 
activates p53 and might thereby induce a switch from productive autophagy to autophagic cell 
death. While this hypothesis has yet to be investigated, it provides an interesting potential 
therapeutic target. If DRAM1 is increased in certain cell lines, targeting DRAM1 could 
potentially be capable of transitioning a cell from survival to apoptosis, especially if used in 
combination with an MDM2 inhibitor.  
Enhancing the therapeutic efficacy of MDM2 inhibitors with a combination setting 
The hope of developing a singular “magic bullet” for cancer treatments is pervasive 
even if unrealistic. At one time it was proposed that Nutlin-3 would be an efficacious as a 
single-agent therapy due to the possibility of complete reactivation of p53 and its tumor 
suppression function208. Likewise, SAR405838 exhibits many highly desirable properties of 
a small-molecule inhibitor. However, the utility of SAR405838 as a single agent, while 
hopeful, is probably not realistic in the clinical setting. For example, we observed variable 
anti-tumor responses in our large tumor burden xenograft study when SAR405838 was used 
as a single agent, suggesting the possibility that SAR405838 combination regimens might 
offer enhanced results. Frequently, anticancer drugs are used in combination to produce more 
potent antitumor effects while sparing normal cells. MDM2 inhibitors, such as SAR405838, 
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are non-genotoxic drugs that result in the activation of p53 without causing normal cell 
damage, unlike many traditional genotoxic agents.  
DOX is the current first-line chemotherapeutic agent in DDLPS therapy and is 
included in most DDLPS treatment regimens22. DOX activates p53, inducing G2/M cell cycle 
arrest and apoptosis219. In other cancer types, it has been demonstrated that the combination 
of DOX and Nutlin-3a results in synergistic apoptotic effects in wild-type p53 tumor cells 
while sparing normal cells220. We observed that SAR405838 arrested the cell cycle in G1-S 
and G2-M phases and significantly reduced the S-phase fraction of cells. Perhaps the use of 
S-phase- and M-phase-targeted drugs (taxanes and gemcitabine, respectively) may provide 
protection to normal cells when used in combination and/or as a pre-treatment with 
SAR405838221,222. Combination therapies generally involve either synergistic effects on a 
single pathway or target multiple pathways simultaneously; the combination of SAR405838 
with traditional agents may reduce chemotoxicity or is possible that SAR405838 could be 
combined with standard chemotherapeutic agents to induce apoptosis in cancer cells, thereby 
creating a novel therapeutic option for DDLPS treatment. 
 
Other deregulations contributing to dedifferentiated liposarcomagenesis 
While there are many deregulations in dedifferentiated liposarcoma that have yet to be 
investigated, we sought to identify therapeutically advantageous and targetable abnormalities 
that could positively impact patient outcome. One such study was the identification of the 
overexpression of the RTK c-MET.  Identification of unique deregulations underlying the 
pathobiology and tumorigenesis has been useful in multiple sarcoma histologies. 
Gastrointestinal stromal tumor (GIST) provides a useful example of identifying biologically 
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relevant and targetable genetic mutations and applying this knowledge in a clinically useful 
manner. In 1998, Hirota et al. identified the gain-of-function mutation of the KIT gene, which 
in turn encodes the proto-oncogenic receptor tyrosine kinas (RTK)223. This discovery led to 
the initial awareness of GIST as an entity separate from leiomyosarcoma while simultaneously 
providing a biologically relevant and targetable therapeutic option. Imatinib mesylate, an RTK 
inhibitor, has shown significant utility as a single-agent therapy,  in combination with surgery 
for control of local and metastatic GIST224,225. The promising use of RTK inhibitors have 
gained much attention in the past decade76,226. Therefore, following identification of c-MET 
amplification in a previous study75 in our lab, we have investigated how inhibition of this 
receptor might prove to be therapeutically relevant (Appendix D). While only one example, 
it represents one small step toward developing novel therapeutic strategies for patients 
suffering from DDLPS. 
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CHAPTER 7. SUMMARY 
This body of work encompassed multiple studies investigating dedifferentiated 
liposarcoma including molecular and cytogenetic aberrations in DDLPS tumor cells and the 
pre-clinical effects of a novel small-molecule inhibitor, SAR405838. In doing so, the 
following results were found: 
1. DDLPS is a rare disease with limited experimental resources. The establishment of 
cell lines and xenograft models was a critical first step in studying this disease. 
Importantly, these models accurately represent the tumorigenic phenotype and 
molecular alterations observed in patients. 
2. DDLPS accumulates multiple cytogenetic aberrations; notably, amplification of the 
12q13~15 chromosomal region. 
3. DDLPS cell lines express genetic profiles associated with disease progression.  
4. MDM2 amplification occurred in 100% of all DDLPS cell lines, albeit, to varying 
levels; this genomic amplification demonstrated a linear mRNA and protein 
expression. Furthermore, our results suggest that the amplification of MDM2 provides 
possible therapeutic relevance as a biomarker for therapeutic efficacy. 
5. DDLPS retains a functional and wild-type p53 genomic status which can be 
reactivated, as proven by the re-activation of the p53 pathway following MDM2 
inhibition. 
6. MDM2 antagonists successfully activate the p53 pathway; SAR405838 possessed the 
most effective results in comparison to Nutlin-3a and MI-219. 
7. SAR405838 elicits a dose-dependent anti-DDLPS tumor growth response in vivo. 
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8. The modulated gene expressions following SAR405838 enriched p53 pathways 
involved in genomic stability, cell-cycle arrest and apoptosis.   
 
Taken together, our data highlights the significant contribution of the deregulated 
MDM2:p53 axis in DDLPS tumorigenesis. We have shown that targeting MDM2 with the 
small molecule inhibitor SAR405838 activates the p53 pathway and elicits anti-DDLPS 
effects in vitro and in vivo. We have investigated pathway enrichment following MDM2 
inhibition and suggested possible targetable therapeutic nodes as well as known biomarkers 
associated with p53 activation. Lastly, our data demonstrates that MDM2 in a critical 
manipulator in DDLPS tumorigenesis and targeting MDM2 is a highly effective therapeutic 
option for patients suffering from this disease.  
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 CHAPTER 8. FUTURE DIRECTIONS 
In this body of work we have shown the therapeutic efficacy of a novel small-molecule 
MDM2 inhibitor for the treatment of DDLPS. While there are many deregulations in DDLPS 
that have yet to be investigated, we aimed at targeting the most therapeutically advantageous 
abnormality, MDM2. MDM2 is genomically amplified and highly expressed in DDLPS, 
establishing the biological relevance of MDM2 as a therapeutic target.  
 Following MDM2 inhibition, DDLPS cell lines exhibited variable p53-
dependent responses, notably the level of apoptosis. Cell lines that elicited only minimal 
apoptosis may allude to a defective apoptotic pathway in these cells as a means of survival. 
Cell lines that demonstrated a higher degree of MDM2 amplification responded with stronger 
apoptotic responses, and provide plausible evidence that MDM2 amplification in DDLPS is 
not just an initial tumorigenic driver, but continues to play an important role in cell survival. 
Further analysis of the SAR405838-induced gene expression profiles may reveal differential 
patterns in apoptosis between the cells lines, as well as elucidate potential defective or 
hyperactive molecules that are implicated in apoptosis. Although only a very small panel of 
cells were used to perform this experiment, this can be expanded to other STS histologies that 
do not respond to p53-activating therapies as MDM2 amplification is a common aberration in 
many different tumor types. Additionally, the unique therapeutic responses to SAR405838 in 
our DDLPS model emphasizes the need to further dissect this distinction based on the level 
of MDM2 amplification. Our data implies that MDM2 amplification positively correlates with 
the efficacy of MDM2 inhibition. Future studies determining the level of MDM2 amplification 
in patient biopsies prior to treatment will possibly distinguish a correlation between MDM2 
amplification and therapeutic response. 
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In addition, two very different responses were observed from the large tumor burden 
therapeutic experiment. Previously we observed that SAR405838 successfully penetrated the 
tumor in Lipo863 tumor-bearing mice and initiated p53 responses as demonstrated in our 
pharmacokinetics/pharmacodynamics studies. However, Lipo863 tumors did not respond to 
SAR405838 when treatment began with large initial tumor burdens. This may be due to a 
defective apoptotic pathway in these cells in which an alternative pathway bears more 
influence than p53 does. These cells may have also acquired therapeutic resistance towards 
MDM2 inhibition. Additional therapeutic experiments repeating this large tumor burden 
model with DDLPS cell lines that also demonstrate weak apoptotic responses should be 
performed. This knowledge can potentially demonstrate additional MDM2-p53 independent 
pathways that are dysregulated. Therapeutic resistance due to p53 mutations acquired from 
certain clones in a tumor population should also be investigated and mutational analysis 
should be performed to determine p53 status. Gene expression arrays on these tumors can 
further unravel pathways and processes that are enriched from such oncogenic genes. 
Additionally, combination of SAR405838 with traditional therapies, such as with the 
topoisomerase-2 inhibitor DOX, should result in a stronger anti-tumorigenic response and 
may be more effective in tumors that do not respond with single-agent treatment and should 
be evaluated.  
Consequences from p53 pathway reactivation were examined, mainly cell cycle arrest 
and apoptosis; however, there are many other outcomes that should be explored. Senescence 
is another result of p53 pathway activation and may be an alternative outcome of MDM2 
inhibition. In DDLPS cells it was observed that the most enriched pathways from the gene 
expression arrays involved different cell cycle processes and spindle and mitotic instability. 
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Detection of SA-beta-Gal following SAR405838 in cells will determine if the tumor 
suppressive mechanism is senescence. 
There are multiple regulators of MDM2 that were not evaluated in our studies that may 
impact this oncogene in liposarcomagenesis. For example, MDMX, a close homolog of 
MDM2, is another negative regulator of p53. MDMX is capable of modulating the levels of 
MDM2, thus, regulating the level of p53 protein and function. Nevertheless, this is just one of 
many alternative regulators of MDM2 function that might influence the effectiveness of 
MDM2 inhibitors. 
In order for p53 to be degraded, the nuclear export signal (NES) must export MDM2 
and p53 to the cytosol where MDM2 will inhibit p53 function in at least two ways, by binding 
to the transactivation domain of p53 and inhibiting its transcriptional properties or targeting 
p53 for degradation by its E3 ubiquitination properties. Further investigation into the ability 
of MDM2 to bind to the transactivational domain of p53 should be confirmed through in vitro 
experiments involving the fusion of MDM2 to the DNA-binding domain of p53 to that the 
region is leading to inhibition of p53.  Alternatively, MDM2 ubiquitination function may not 
be fully functional or sufficient to degrade p53 in DDLPS; therefore, the detection of p53 
protein ubiquitination in DDLPS cells should be investigated. The high expression of p53 
observed in DDLPS cells might also be due to the MDM2-p53 complex being held together. 
Performing a pulse-chase experiment to track the localization of these proteins and expression 
levels. If MDM2 is bound to p53, levels will remain high as p53 will continue to increase 
MDM2 levels, but neither will be degraded.  
Within these studies multiple molecular aberrations in DDLPS were identified that 
warrant further evaluation. As a result, these proteins may reveal potential prognosticators, 
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biomarkers and therapeutic targets. For example, growth differentiation factor 15 (GDF-15) 
is a p53 transcriptional target and was the most up-regulated gene following SAR405838 
treatment in the microarrays. GDF-15 protein is a cytokine that can be easily evaluated in 
patient blood samples. Translationally, this can not only reveal p53 activation in patient 
tumors, but potentially can be used to caliber the minimum dose of SAR405838 required for 
efficacy. 
Hopefully in the very near future, the combined knowledgebase of specific histological 
characteristics and the unique genetic and molecular aberrations will lay the foundation 
clinical decisions. It is without any doubt that as we continue to increase our understandings 
of the molecular underpinnings of DDLPS, development of enhanced therapeutic strategies 
will certainly follow. The potential studies mentioned can further unveil the significant impact 
of the MDM2-p53 axis in DDLPS preclinical models and lead to more personalized, 
therapeutically relevant strategies and future DDLPS preclinical trials. 
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 APPENDIX 
 
 
APPENDIX A. ACGH DATA FOR DEDIFFERENTIATED LIPOSARCOMA CELL LINES.  
Symbol Cytoband p-values FDR 
Tspan31 15q24.3 0.0001475 1.4E-06 
Cdk4 12q14.1 1.637E-10 1.4E-06 
March9 9q33.1 2.328E-10 1.4E-06 
LOC100128056 7q34 1.512E-09 5.4E-06 
MIR26A2 13q31.3 1.375E-09 5.4E-06 
CYP27B1 12q14.1 2.381E-09 7.1E-06 
MDM2 12q15 9.858E-09 2.3E-05 
slc35e3 12q15 1.012E-08 2.3E-05 
NUP107 12q15 2.218E-06 0.00332 
BEST3 12q15 0.0005657 0.12971 
LRRC10 12q15 0.0005657 0.12971 
CCT2 12q15 0.0004703 0.12971 
RAB3IP 12q15 0.000279 0.09584 
FRS2 12q15 0.0001338 0.09584 
CNOT2 12q15 0.0007495 0.12971 
KCNMB4 12q15 0.0006077 0.12971 
CPM 12q15 6.149E-08 0.00011 
Agap2 12q14.1 2.258E-08 4.5E-05 
OS9 12q14.1 1.749E-05 0.01846 
Yeats4 12q15 0.0013939 0.12971 
LYZ 12q15 0.0013939 0.12971 
Cpsf6 12q15 0.0015365 0.12971 
ELK3 12q23.1 0.0019154 0.12971 
C12orf28 12q24.31 0.0019378 0.12971 
B4GALNT1 12q14.1 0.0013466 0.12971 
GEFT 12q13.3 0.0013466 0.12971 
TSFM 12q14.1 1.659E-05 0.01846 
FAM119B 12q14.1 1.659E-05 0.01846 
mettl1 Xp21.3 1.659E-05 0.01846 
AVIL 12q14.1 1.659E-05 0.01846 
xrcc6bp1 12q14.1 0.0013009 0.12971 
MYF5 12q21.31 0.0310806 0.19857 
MYF6 12q21.31 0.0310806 0.19857 
ptprq 12q21.31 0.0296756 0.19658 
Lin7a 12q21.31 0.0397626 0.19981 
LOC552889 12q21.1 0.0461876 0.20616 
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TBC1D15 12q21.1 0.0188899 0.16909 
rab21 12q21.1 0.0267993 0.19119 
TPH2 12q21.1 0.0308744 0.19857 
ACSS3 12q21.31 0.0131279 0.1609 
alx1 12q21.31 0.0147234 0.16432 
HMGA2 12q14.3 8.42E-08 0.00014 
TRBV4-3 3q13.13 2.997E-05 0.0283 
LOC100129940 19q13.2 0.0005047 0.12971 
dyrk2 12q15 0.0046173 0.12971 
TRHDE 12q21.1 0.002387 0.12971 
Rap1b 12q15 0.065157 0.23022 
CEP72 5p15.33 0.0117281 0.16065 
EXOC3 5p15.33 0.0117281 0.16065 
C5orf55 5p15.33 0.0117281 0.16065 
LOC25845 5p15.33 0.0117281 0.16065 
SLC9A3 5p15.33 0.0117281 0.16065 
NKD2 5p15.33 0.0177186 0.16565 
Trip13 5p15.33 0.0177186 0.16565 
BRD9 5p15.33 0.0177186 0.16565 
SLC12A7 5p15.33 0.0177186 0.16565 
ZDHHC11 5p15.33 0.0148858 0.16432 
TERT 5p15.33 0.0078586 0.16065 
SLC6A19 5p15.33 0.0089416 0.16065 
SLC6A18 5p15.33 0.006575 0.14813 
Syt1 12q21.2 0.0226519 0.1845 
PPFIA2 12q21.31 0.028728 0.19526 
TRBV6-5 3q13.13 0.0010668 0.12971 
TRBV6-1 3q13.13 0.0010668 0.12971 
Trbv28 3q13.13 0.000136 0.09584 
CFHR3 1q31.3 2.01E-05 0.02004 
Fam19a2 12q14.1 0.0233896 0.18739 
Tmbim4 12q14.3 0.2408784 0.44891 
CDCA7L 7p15.3 0.2736632 0.49554 
SNTG1 8q11.21 0.404485 0.61203 
GBP3 1p22.2 0.3998699 0.60692 
ADAM3A 8p11.23 0.2956098 0.52211 
SNRPF 12q22 0.0226315 0.1845 
LTA4H 12q23.1 0.0227504 0.18488 
CCDC38 12q22 0.0223633 0.1845 
amdhd1 12q23.1 0.0240796 0.18739 
hal 12q23.1 0.027481 0.19231 
PIP4K2C 12q13.3 0.0091986 0.16065 
DTX3 12q13.3 0.0280448 0.19421 
Cdk17 16q24.3 0.0038873 0.12971 
C12orf55 12q24.13 0.0557562 0.21983 
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TMTC3 12q21.32 0.0457105 0.20484 
PTPRB 12q15 0.0081241 0.16065 
ptprr 12q15 0.0061592 0.14716 
Kif5a 12q13.3 0.0193486 0.16962 
Tspan8 12q15 0.009377 0.16065 
RASSF9 12q21.31 0.0451902 0.20332 
MGAT4C 12q21.31 0.0674155 0.23022 
ITGA5 12q13.13 0.0250062 0.18739 
TRBV24-1 3q13.13 0.7151719 0.86551 
WWOX 16q23.1 0.6041573 0.77455 
IGHV3-11 11q13.2 0.0156944 0.16432 
gstm1 1p13.3 0.5434609 0.7201 
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APPENDIX B: DIFFERENTIAL GENE EXPRESSION PATTERNS IN DEDIFFERENTIATED LIPOSARCOMA 
Name Lipo224 Lipo224B Lipo246 Lipo863 LPS141 Lipo573 Lipo815 Lipo615 Lipo984 Control diff.group foldchange p.value t.stat 
NUP107 12.126 13.515 12.673 10.758 14.357 13.689 13.077 12.290 12.496 8.781 3.995 15.939 9.39E-08 9.6302 
CDC20 11.690 12.413 11.964 12.471 11.896 11.087 12.165 10.047 11.187 7.988 3.670 12.729 6.27E-07 8.282677 
METTL1 12.129 12.022 12.354 11.761 8.048 12.434 11.377 11.591 11.096 7.924 3.499 11.308 7.99E-06 6.678477 
TOP2A 10.135 11.751 11.490 12.506 11.502 11.376 12.402 11.680 11.449 8.162 3.426 10.746 2.74E-06 7.328429 
TRIP13 13.341 10.578 12.779 12.211 9.890 10.412 10.956 9.808 10.105 7.763 3.357 10.248 4.34E-05 5.716167 
UBE2C 10.763 11.014 11.400 10.815 10.219 10.301 10.981 10.275 10.087 7.414 3.236 9.423 4.01E-07 8.586087 
ANLN 9.705 11.040 10.720 10.521 12.126 10.335 10.885 9.612 10.185 7.352 3.218 9.307 1.25E-06 7.827341 
CDCA5 11.327 10.979 10.770 11.306 11.217 10.829 11.426 10.561 10.249 7.749 3.214 9.278 1.29E-08 11.20808 
AURKB 9.760 10.280 10.414 9.965 10.006 9.985 9.939 9.158 9.282 6.705 3.161 8.944 5.82E-09 11.89527 
CDC45L 10.497 10.625 10.995 9.657 10.414 10.232 10.356 8.773 9.260 7.039 3.051 8.285 7.31E-07 8.178961 
CDK4 14.275 14.055 14.090 14.306 14.195 14.183 14.252 14.256 14.306 11.208 3.005 8.030 1.97E-14 29.00825 
TSFM 10.975 10.234 11.950 10.304 7.019 11.486 10.583 10.780 8.571 7.256 2.955 7.756 0.000176 4.968256 
UHRF1 10.816 10.945 10.347 10.687 10.859 10.440 10.340 9.427 9.334 7.430 2.925 7.594 3.73E-07 8.637617 
PBK 9.759 10.822 10.060 10.999 8.996 9.696 10.429 9.371 9.581 7.063 2.905 7.492 4.09E-07 8.573916 
SLC35E3 11.186 12.508 12.203 12.183 13.790 13.016 12.085 12.363 12.567 9.531 2.903 7.479 4.56E-08 10.18325 
PRC1 11.248 11.556 11.365 11.460 11.389 11.240 11.491 10.945 11.633 8.479 2.891 7.417 5.05E-07 8.42825 
DUSP1 10.848 12.112 11.567 11.108 11.257 12.730 11.464 11.631 11.467 8.730 2.846 7.191 0.013816 2.792843 
RAD51AP1 10.346 10.527 10.900 10.342 9.831 10.064 10.111 8.973 11.153 7.405 2.845 7.183 2.74E-07 8.852177 
CKAP2L 9.524 10.587 10.389 10.267 9.916 9.643 9.728 8.651 9.000 6.919 2.826 7.090 2.86E-07 8.821365 
NCAPG 10.047 10.972 10.555 11.230 10.909 10.625 10.391 9.623 10.353 7.739 2.784 6.889 1.65E-06 7.648092 
PTTG3P 11.209 11.950 11.277 11.392 9.832 10.674 11.623 10.637 10.873 8.270 2.782 6.877 6.77E-06 6.776799 
TK1 9.618 10.418 9.899 10.102 10.294 9.511 10.999 8.950 9.715 7.191 2.754 6.748 4.22E-07 8.551707 
B4GALNT1 10.244 9.400 8.458 9.452 7.513 7.363 10.460 8.559 10.844 6.396 2.747 6.715 6.08E-05 5.533025 
AURKA 10.717 10.903 11.004 11.214 10.381 10.207 10.640 10.262 10.011 7.849 2.744 6.699 2.17E-07 9.016679 
UBE2T 10.765 10.453 11.590 10.311 9.558 10.825 10.730 11.048 9.821 7.838 2.728 6.626 6.67E-07 8.240765 
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FAM119B 11.717 11.325 12.265 10.879 7.395 11.817 10.001 12.124 10.635 8.191 2.716 6.570 0.000348 4.618887 
PTTG1 11.133 12.010 11.313 11.720 10.325 11.136 11.880 11.009 11.064 8.602 2.686 6.434 4.29E-06 7.051833 
TYMS 11.390 12.039 11.591 11.067 12.106 11.971 12.341 10.456 11.233 8.904 2.673 6.376 2.85E-05 5.948184 
CCNB2 10.028 10.883 9.897 10.499 9.981 9.859 10.411 9.573 9.634 7.428 2.657 6.307 5.69E-07 8.348144 
BUB1 9.288 10.282 10.444 10.670 9.574 9.048 9.559 8.628 8.973 6.953 2.655 6.297 1.16E-06 7.877226 
CDCA3 9.114 10.198 10.199 9.656 8.424 9.170 10.337 9.500 9.083 6.868 2.652 6.284 3.52E-07 8.676438 
CDKN3 9.649 10.637 10.764 9.875 9.781 9.286 11.023 9.593 9.781 7.395 2.648 6.267 1.05E-06 7.938021 
KIF20A 9.296 10.716 9.491 10.580 9.898 9.054 10.357 9.730 9.702 7.242 2.627 6.178 6.28E-07 8.280724 
ASF1B 8.968 9.430 9.576 8.409 9.284 8.759 9.892 9.124 8.474 6.489 2.613 6.117 5.59E-09 11.93064 
CDC2 9.571 10.385 9.726 10.301 9.110 9.845 9.525 9.164 8.980 7.017 2.606 6.087 9.85E-08 9.594813 
CD24 10.909 11.923 8.972 6.604 7.068 11.832 11.941 9.744 7.384 6.995 2.603 6.074 0.009647 2.971166 
NUSAP1 9.496 10.476 9.924 9.680 10.410 10.014 10.139 9.632 9.789 7.356 2.595 6.041 6.91E-08 9.861983 
CEP55 9.918 10.236 10.393 10.325 9.305 10.132 11.002 9.707 10.333 7.557 2.593 6.035 5.99E-06 6.849507 
FEN1 11.067 10.360 10.222 11.605 10.946 10.612 10.993 10.130 9.990 8.084 2.574 5.956 3.86E-07 8.613625 
FAM83D 9.231 9.851 10.094 10.378 9.453 9.102 9.280 8.983 8.853 6.898 2.572 5.945 5.12E-08 10.09362 
CD70 10.802 9.808 8.639 9.944 11.574 6.417 8.184 8.423 8.838 6.636 2.545 5.835 0.000806 4.195397 
CCT2 14.357 14.275 14.131 14.357 14.446 11.571 14.146 11.003 10.804 10.694 2.538 5.807 0.001936 3.760962 
KIFC1 8.885 9.873 9.246 9.517 9.113 9.536 9.895 8.711 8.752 6.761 2.520 5.734 5.22E-08 10.07862 
TTK 9.475 10.018 9.825 9.727 9.201 9.052 10.014 8.918 9.366 7.011 2.500 5.656 3.38E-08 10.41813 
ASPM 9.896 10.441 10.426 11.274 10.804 10.112 10.191 9.311 10.834 7.870 2.496 5.641 9.8E-06 6.55864 
TPX2 9.272 10.150 9.820 10.989 9.987 9.411 10.378 9.559 9.404 7.393 2.493 5.630 5.01E-07 8.433756 
DLGAP5 8.839 9.783 9.898 9.996 9.953 9.218 10.002 8.736 9.336 7.043 2.486 5.601 6.72E-07 8.235632 
CDK2 9.449 9.528 9.944 9.280 8.220 9.345 12.448 8.512 12.012 7.400 2.459 5.500 0.000632 4.317029 
LOC390557 10.279 9.105 9.992 11.228 9.977 7.453 8.321 9.652 8.152 6.897 2.454 5.480 0.000108 5.227146 
NTF3 7.273 9.708 11.133 9.335 8.683 8.200 10.079 7.424 8.332 6.470 2.437 5.417 0.00022 4.853493 
PLAU 11.832 11.618 13.910 12.810 12.545 11.613 11.720 9.143 12.278 9.534 2.407 5.303 0.001328 3.946847 
MELK 10.348 11.416 10.603 10.325 10.990 10.543 10.148 9.696 10.233 8.078 2.400 5.279 2.22E-06 7.459821 
CCNB1 9.562 10.248 9.714 10.591 9.236 8.868 9.643 9.362 9.424 7.229 2.399 5.274 2.16E-07 9.021686 
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MCM7 10.545 10.723 11.168 10.758 10.430 10.689 10.477 9.576 9.902 8.088 2.387 5.230 1.17E-07 9.464971 
BIRC5 9.085 9.921 8.482 9.617 9.004 8.598 9.502 8.746 8.742 6.709 2.368 5.162 1.93E-07 9.10363 
CCNA2 9.796 10.499 10.357 9.921 9.991 10.119 10.010 9.752 9.714 7.663 2.354 5.113 9.27E-08 9.640476 
MCM4 9.356 9.976 9.989 10.580 11.142 10.282 10.161 8.869 9.419 7.635 2.340 5.062 4.13E-06 7.074286 
HJURP 9.029 9.383 9.170 9.310 9.649 8.996 9.151 8.947 9.598 6.924 2.324 5.007 1.28E-08 11.21253 
PRIM1 9.879 9.717 9.997 10.332 9.003 9.637 9.930 8.181 8.547 7.157 2.313 4.968 1.4E-06 7.754261 
GINS2 9.711 10.684 9.737 8.947 9.117 10.110 9.642 9.136 9.783 7.356 2.296 4.911 1.65E-06 7.646397 
CDCA8 9.251 9.502 9.610 9.841 9.147 8.944 9.695 7.991 8.694 6.893 2.293 4.902 3.58E-07 8.664526 
CKS1B 11.529 11.883 11.612 11.956 10.445 11.166 11.452 11.436 10.606 9.051 2.292 4.897 2.55E-07 8.903431 
KIF11 9.228 9.420 9.503 10.014 8.708 9.592 9.633 8.990 9.163 7.082 2.279 4.853 7.25E-08 9.825896 
YEATS4 10.886 12.632 13.573 12.350 8.350 9.610 11.849 8.800 8.445 8.446 2.276 4.842 0.010528 2.927912 
FBXO5 9.676 10.082 9.858 9.058 9.233 9.623 9.559 9.009 9.987 7.295 2.271 4.825 9.16E-08 9.648927 
TACC3 9.510 9.649 9.028 9.802 9.028 9.176 9.507 9.149 9.219 7.072 2.269 4.819 3.04E-08 10.50249 
XRCC6BP1 11.064 10.934 12.278 9.089 8.209 13.270 11.907 8.281 7.746 8.061 2.248 4.750 0.013008 2.822851 
MAD2L1 9.938 10.186 9.776 9.708 9.606 10.124 9.803 9.183 8.853 7.450 2.237 4.713 1.64E-06 7.653115 
MCM10 9.192 9.368 10.715 9.386 8.617 8.319 8.233 7.249 7.852 6.544 2.226 4.677 7.8E-05 5.398945 
OIP5 9.145 9.333 9.299 9.018 9.313 9.366 9.453 8.402 8.916 6.925 2.214 4.639 3.99E-09 12.23267 
ATAD2 9.664 9.541 9.782 9.873 11.116 9.478 8.979 8.676 8.910 7.345 2.213 4.635 6.58E-06 6.793873 
RRM2 8.379 9.491 10.238 8.007 9.588 9.655 9.168 6.842 8.026 6.609 2.212 4.634 0.000152 5.044431 
KIF2C 8.997 9.451 9.483 9.989 9.594 8.495 9.261 7.191 8.348 6.772 2.207 4.616 1.62E-05 6.266329 
HMMR 9.484 10.239 10.606 10.128 10.145 9.392 10.034 9.430 9.485 7.687 2.196 4.581 1.33E-07 9.373581 
APOBEC3B 8.492 9.836 9.134 8.122 8.963 8.087 9.450 8.127 7.031 6.389 2.193 4.574 1.31E-05 6.388713 
KRT81 6.276 8.103 6.622 13.157 8.599 6.391 11.576 8.661 6.142 6.215 2.177 4.522 0.040208 2.249207 
CENPM 8.730 9.190 9.222 8.178 9.034 8.472 9.160 8.332 8.591 6.593 2.175 4.515 5.95E-09 11.87552 
E2F2 9.721 10.042 8.387 7.975 9.736 7.843 8.766 7.499 8.112 6.513 2.162 4.477 3.44E-05 5.84425 
MCM5 10.536 10.175 9.881 8.971 9.411 9.369 9.779 8.611 9.174 7.396 2.150 4.437 2.71E-06 7.33487 
TSPAN31 11.615 10.867 11.216 11.454 13.361 12.503 9.849 11.228 12.211 9.458 2.131 4.381 0.000148 5.061573 
TSPAN8 10.735 8.877 6.255 10.350 11.565 6.323 10.766 6.770 8.340 6.765 2.122 4.354 0.021288 2.575827 
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CCNE2 7.665 8.957 8.736 8.862 9.922 8.821 8.649 7.738 7.398 6.411 2.117 4.337 9.98E-06 6.547631 
NUF2 7.666 8.161 8.160 8.610 11.517 7.563 8.480 7.634 8.968 6.428 2.101 4.291 0.000577 4.362385 
TROAP 8.869 8.868 8.462 8.839 8.243 8.409 9.322 9.043 8.320 6.623 2.085 4.244 1.38E-08 11.14824 
CPA4 9.217 10.411 6.424 9.497 9.196 8.125 10.756 9.316 8.444 6.960 2.083 4.236 0.001746 3.811787 
LOC399942 11.937 11.847 11.832 10.848 9.882 11.332 12.284 11.243 10.472 9.216 2.081 4.232 0.000736 4.240247 
CENPF 8.792 9.110 8.646 10.281 9.495 8.573 9.339 8.452 9.472 7.058 2.071 4.203 1.72E-06 7.619297 
LOC651816 10.787 11.874 11.294 10.943 9.718 10.894 11.703 10.771 10.460 8.873 2.065 4.185 6.94E-06 6.761898 
DTL 9.370 9.532 8.181 8.708 8.701 9.337 9.152 7.664 8.429 6.736 2.050 4.140 2.43E-06 7.403018 
CENPK 9.130 9.629 9.635 9.459 9.593 9.483 9.748 9.378 8.805 7.381 2.048 4.135 1.21E-06 7.849096 
HIST1H4C 12.907 14.060 13.937 13.573 12.775 13.717 14.040 13.215 13.292 11.462 2.040 4.112 2.15E-07 9.025872 
CDT1 8.819 9.484 8.604 8.428 8.411 8.574 8.428 7.441 7.971 6.441 2.021 4.059 2.46E-07 8.928118 
OS9 10.685 11.258 10.894 10.560 12.670 7.378 10.466 8.006 10.735 8.294 2.001 4.003 0.007074 3.124248 
MCM2 9.644 9.367 9.874 9.716 8.537 9.106 9.276 7.944 8.568 7.114 2.001 4.002 4.25E-06 7.056522 
LOC731049 11.307 12.378 11.952 11.673 10.583 11.464 12.154 11.227 11.060 9.534 1.999 3.996 3.01E-06 7.269147 
TMEM51 9.696 10.049 9.484 10.166 11.301 9.434 10.008 8.938 9.393 7.833 1.997 3.992 4.52E-05 5.693548 
CCNF 8.087 10.185 9.511 10.515 9.839 9.273 9.527 8.802 9.014 7.428 1.989 3.969 2.49E-05 6.024545 
STMN1 9.124 9.357 9.081 8.567 8.852 8.840 9.254 7.628 8.360 6.799 1.985 3.959 1.19E-06 7.859257 
HBEGF 7.992 8.495 9.064 9.869 9.889 10.573 9.374 8.612 8.007 7.119 1.978 3.940 0.00085 4.168348 
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APPENDIX C. TOP 50 DIFFERENTIALLY EXPRESSED GENES IN VITRO AND IN VIVO FOLLOWING 
SAR405838 TREATMENT. 
Top up-regulated 
in vitro in vivo 
Gene Fold Change Gene Fold Change 
GDF15 16.2129 PADI4 23.8301 
LOC100008589 9.9671 LCE1B 16.2649 
C18ORF56 9.7888 MYBPHL 15.0798 
CLCA2 9.6741 BTG2 9.7775 
MDM2 5.5876 RN5S9 8.6088 
MGC42367 5.4459 GADD45A 8.0443 
BTG2 5.3475 PHLDA3 7.4409 
PRAGMIN 5.2925 CLCA2 7.3535 
C7ORF10 5.0681 EFCAB7 6.9302 
SESN1 4.9502 FUCA1 6.5052 
EFCAB7 4.8842 TXNIP 5.6006 
CDH10 4.8820 SLC2A5 5.1532 
TP53INP1 4.7794 LCE1C 4.9808 
C2ORF55 4.5492 LCE1A 4.8335 
AKR1B10 4.3901 HOOK1 4.7078 
SPATA18 4.1305 KIAA1324 4.1808 
LOC729989 4.1040 SESN2 3.8978 
CDKN1A 3.8017 MR1 3.7296 
HMOX1 3.5960 C1ORF68 3.6732 
GADD45A 3.5772 ATF3 3.6688 
RDH10 3.5767 RNPEP 3.5194 
SNORD3D 3.3887 SYNC1 3.4818 
ACTA2 3.3438 OVGP1 3.3910 
RRM2B 3.2410 DHRS3 3.2688 
HIST2H2BE 3.1726 C1ORF183 3.2535 
Top down-regulated 
in vitro in vivo 
Gene Fold Change Gene Fold Change 
RAB3IP -1.3343 PAQR4 -6.35542 
LOC100129362 -1.3519 HSPA8 -6.19031 
UBE2N -1.3671 HIST1H4C -6.07239 
LSM3 -1.4068 EMG1 -5.29068 
C7ORF44 -1.4088 LOC399988 -5.11464 
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GSG2 -1.4129 MCM6 -4.75124 
NRM -1.4147 GINS2 -4.54509 
WDR67 -1.4180 TMEM126A -4.37410 
ORC3L -1.4211 DCTPP1 -4.47037 
NONO -1.4223 MRPL17 -4.34799 
LRRC8C -1.4232 ARMCX2 -4.32155 
APLN -1.4233 TM4SF1 -4.29947 
CXORF57 -1.4237 COMMD7 -4.23540 
C1ORF93 -1.4241 LOC493869 -4.14157 
C6ORF125 -1.4258 USP13 -4.06063 
MTF2 -1.4284 METTL1 -4.04629 
PTBP1 -1.4298 REEP1 -4.04095 
SHPK -1.4351 MCM2 -3.87347 
HNRNPA2B1 -1.4377 TWIST1 -3.77542 
CDCA7L -1.4381 FAM136A -3.84662 
SFRS7 -1.4391 ATIC -3.82031 
C1ORF24 -1.4393 LOC552889 -3.81067 
POLE -1.4417 HS.213541 -3.82384 
CCDC18 -1.4481 MT1X -3.75534 
MRPS11 -1.4492 TST -3.73768 
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APPENDIX D. THE HEPATOCYTE GROWTH FACTOR RECEPTOR AS A POTENTIAL 
THERAPEUTIC TARGET FOR DEDIFFERENTIATED LIPOSARCOMA.  
 
Manuscript briefly mentioned throughout this dissertation, which involved a small 
project investigating the receptor tyrosine kinase, Met, in dedifferentiated liposarcoma as a 
therapeutic target. For reference once published, the manuscript is titled: The hepatocyte 
growth factor receptor as a potential therapeutic target for dedifferentiated 
liposarcoma.  
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APPENDIX E.  SAR405838: A NOVEL AND POTENT INHIBITOR OF THE MDM2:P53 AXIS FOR 
THE TREATMENT OF DEDIFFERENTIATED LIPOSARCOMA 
 
Manuscript in preparation for submission and involves the data discussed throughout 
this dissertation. For reference once published, the manuscript is titled: SAR405838: a novel 
and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated 
liposarcoma. The following authors were involved in this manuscript: 
 
Kate Lynn Bill, Jeanine Garnett, Isabelle Meaux, XiaoYen Ma, Chad J. Creighton, David 
Pollock, Theresa Nguyen, Svetlana Bolshakov, Cedric Barriere, Alexander J. Lazar, Dina Lev, 
Raphael E Pollock.  
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